Original Article
Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
N Engl J Med 2005; 353:238-248July 21, 2005DOI: 10.1056/NEJMoa043545
- Abstract
Background
Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined.
Methods
We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined.
Results
After four weeks of treatment, the median level of low-density lipoprotein cholesterol was reduced by 42 percent among patients receiving atorvastatin, and among those receiving placebo it was reduced by 1.3 percent. During a median follow-up period of four years, 469 patients (37 percent) reached the primary end point, of whom 226 were assigned to atorvastatin and 243 to placebo (relative risk, 0.92; 95 percent confidence interval, 0.77 to 1.10; P=0.37). Atorvastatin had no significant effect on the individual components of the primary end point, except that the relative risk of fatal stroke among those receiving the drug was 2.03 (95 percent confidence interval, 1.05 to 3.93; P=0.04). Atorvastatin reduced the rate of all cardiac events combined (relative risk, 0.82; 95 percent confidence interval, 0.68 to 0.99; P=0.03, nominally significant) but not all cerebrovascular events combined (relative risk, 1.12; 95 percent confidence interval, 0.81 to 1.55; P=0.49) or total mortality (relative risk, 0.93; 95 percent confidence interval, 0.79 to 1.08; P=0.33).
Conclusions
Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
Media in This Article
Figure 1
Numbers of Patients Who Entered the Study, Were Assigned to a Study Group, and Completed the Protocol.Figure 2
Median Level of Low-Density Lipoprotein (LDL) Cholesterol from Baseline to the End of the Study.Article Activity
- Article
Primary and secondary prevention trials, including those involving persons with diabetes mellitus, have documented substantial cardiovascular benefit from the administration of statins.1,2 The recent Collaborative Atorvastatin Diabetes Study (CARDS) reported a decrease in deaths from cardiovascular causes among persons with type 2 diabetes mellitus in the absence of marked renal insufficiency.3 There are no prospective data on the effects of statins in patients with end-stage renal disease with type 2 diabetes mellitus who are receiving hemodialysis, although type 2 diabetes is the most common diagnosis among patients at excessive risk of cardiovascular events4 whose condition requires hemodialysis in both Germany5 and the United States.6 Abnormalities in serum lipid levels that are associated with renal disease rank high among the factors implicated in accelerated atherosclerosis.7 However, not all the observational data on patients receiving hemodialysis link dyslipidemia with reduced rates of survival; indeed, opposite trends have been noted.8 An observational retrospective analysis of patients receiving hemodialysis, the U.S. Renal Data System Morbidity and Mortality Study, Wave 2,9 reported that the risk of death from cardiovascular causes was decreased by 36 percent among patients receiving statins, as compared with those who did not receive statins. There has been concern about the side effects of statins in patients receiving hemodialysis,10 but data from small cohorts appeared to be reassuring.11 The present investigator-initiated, prospective, randomized, placebo-controlled study of patients with type 2 diabetes mellitus receiving hemodialysis was designed to answer these questions.
Methods
Study Design
Subjects with type 2 diabetes mellitus 18 to 80 years of age who had been receiving maintenance hemodialysis for less than two years were enrolled at 178 centers in Germany. Exclusion criteria included levels of fasting serum low-density lipoprotein (LDL) cholesterol of less than 80 mg per deciliter (2.1 mmol per liter) or more than 190 mg per deciliter (4.9 mmol per liter), triglyceride levels greater than 1000 mg per deciliter (11.3 mmol per liter); liver-function values more than three times the upper limit of normal or equal to those in patients with symptomatic hepatobiliary cholestatic disease; hematopoietic disease or systemic disease unrelated to end-stage renal disease; vascular intervention, congestive heart failure, or myocardial infarction within the three months preceding the period of enrollment; unsuccessful kidney transplantation; and hypertension resistant to therapy (i.e., systolic blood pressure continuously greater than 200 mm Hg or diastolic blood pressure greater than 110 mm Hg). On enrollment, lipid-lowering medications were discontinued, and patients received placebo during the four-week run-in phase of the study. Thereafter, eligible patients were randomly assigned to double-blind treatment with either atorvastatin at a dose of 20 mg once daily or matching placebo. Data were recorded at four weeks and then every six months. The protocol was approved by the ethics committee at the coordinating center and the 29 regional institutional review boards. Specifically, the ethical implications of the inclusion of a placebo group — that is, of not providing lipid-lowering medications to those randomly assigned to the control group — were taken into account and considered acceptable. Written informed consent was obtained from all patients.
Academic investigators led, managed, and coordinated the study. The principal investigators wrote the protocol and prepared the manuscript. The data were monitored and collected by two contract research organizations supported by Pfizer, one of which (Datamap) holds the data. A university-based, independent statistician performed the statistical analyses. The plan for the statistical analysis was completed before the database was locked and unblinded.
A computer-generated randomization code was prepared by a central Pfizer unit that was independent of local study personnel. Medication was prepackaged on the basis of a block size of four subjects at each center. Each consecutive subject was given the next consecutive randomization number, and eligible patients were assigned in a 1:1 ratio to receive the study drug or placebo. Lipid levels measured after randomization were not released to the clinical sites. If LDL cholesterol levels fell below 50 mg per deciliter (1.3 mmol per liter), the dose of atorvastatin was reduced to 10 mg per day. To maintain blinding, a randomly selected subject from the placebo group received an identical dose reduction. One person in the central laboratory who had access to the randomization code controlled the changes in dose. After a patient reached a primary end point, the study drug could be replaced by treatment with an active statin. Details of the study design have been described previously.12,13
End Points
The study end points and serious adverse events were continuously monitored and reported to the contract research organization. Every end point was adjudicated by three members of the end-point committee, on the basis of predefined criteria that are part of the study protocol. All analyses of primary and secondary end points were based on the classification by the end-point committee that was agreed on by consensus or majority vote. All committee members were blinded to the treatment assignments until August 13, 2004. The primary end point was a composite of death from cardiac causes, fatal stroke, nonfatal myocardial infarction, or nonfatal stroke, whichever occurred first. Only one event per subject was included in the analysis. Myocardial infarction was diagnosed when two of the following three criteria were met: typical symptoms; elevated levels of cardiac enzymes (i.e., a level of creatine kinase MB above 5 percent of the total level of creatine kinase, a level of lactic dehydrogenase 1.5 times the upper limit of normal, or a level of troponin T greater than 2 ng per milliliter); or diagnostic changes on the electrocardiogram. A resting electrocardiogram was recorded every six months and evaluated by independent cardiologists from the electrocardiographic monitoring board, according to the Minnesota classification system for the electrocardiogram (codes 1-1-1 through 9-2 for QRS-complex, ST-segment, or T-wave changes). An electrocardiogram that documented silent myocardial infarction was considered evidence of a primary end point.
Stroke was defined as a neurologic deficit lasting longer than 24 hours. Computed tomographic or magnetic resonance imaging of the brain was recommended and available in all but 16 cases. Death from cardiac causes comprised fatal myocardial infarction (death within 28 days after a myocardial infarction), sudden death, death due to congestive heart failure, death due to coronary heart disease during or within 28 days after an intervention, and all other deaths ascribed to coronary heart disease. Patients who died unexpectedly and did not present with a potassium level greater than 7.5 mmol per liter before the start of the three most recent sessions of hemodialysis were considered to have had sudden death from cardiac causes.
Secondary end points included death from all causes, all cardiac events combined, and all cerebrovascular events combined. Death from any cause other than cardiac disease or cerebrovascular disease was treated as a competing risk.
A central laboratory performed all the analyses. LDL cholesterol was measured directly by agarose-gel electrophoresis with subsequent enzymatic staining for cholesterol with the use of the rapid electrophoresis system (Helena Diagnostika). This method produces more accurate measurements of LDL cholesterol than ultracentrifugation and precipitation combined in samples with elevated triglyceride concentrations.14
Statistical Analysis
The study was designed to have 90 percent power to detect a 27 percent reduction in the incidence of the composite primary end point at an alpha level of 0.05 in a two-sided test, adjusted for one preplanned interim analysis according to an alpha-spending function based on the O'Brien–Fleming method, yielding a nominal level of significance for the final analysis of 0.045.15 The alpha-spending function would have allowed for additional interim analyses, if necessary. For the study to have this level of power, at least 424 primary end points had to occur (event-driven analysis), requiring the randomization of at least 1200 patients. This calculation was based on observational studies.16,17 The results were assessed in an intention-to-treat analysis. The primary end points were evaluated according to time-to-event analysis. Death from other causes was treated as a competing event, and for patients who died from other causes, follow-up was censored as of the date of death.18 Times to an event for patients without a primary end point or competing event were treated as censored and were calculated as the time from randomization to the date of the last contact.
Cumulative incidence and Kaplan–Meier curves were used only to show the survival curves within the treatment groups and to calculate the corresponding survival probabilities. The Cox proportional-hazards model was used to estimate the multivariate relative risks of the primary and secondary end points with corresponding 95 percent confidence intervals. Adjustments were made for sex, age, and baseline status with respect to coronary heart disease. Unless otherwise stated, the baseline lipid and safety laboratory value was defined as the last value measured during the run-in period. The baseline data were analyzed with the use of standard descriptive statistics.
Results
Patients
A total of 1255 subjects were randomly assigned to double-blind treatment with either atorvastatin (619) or placebo (636) between March 1998 and October 2002 and were followed until their final visit in March 2004 (Figure 1Figure 1
Numbers of Patients Who Entered the Study, Were Assigned to a Study Group, and Completed the Protocol.). The two groups of patients were well matched with respect to baseline characteristics and concomitant therapy (Table 1Table 1
Baseline Characteristics of Patients in the Placebo and Atorvastatin Groups.). Nineteen percent of the patients had taken statins before entering the study. The mean length of follow-up was 3.96 years in the atorvastatin group and 3.91 years in the placebo group (median, 4.0 and 4.08 years, respectively).Lipid Levels
At randomization, the median level of LDL cholesterol was 121 mg per deciliter (3.13 mmol per liter) in the atorvastatin group and 125 mg per deciliter (3.23 mmol per liter) in the placebo group. After four weeks, in the atorvastatin group, the median level of LDL cholesterol was 72 mg per deciliter (1.86 mmol per liter; median change from baseline, –42 percent). In the placebo group, the level of LDL cholesterol remained essentially unchanged (120 mg per deciliter [3.10 mmol per liter]; median change from baseline, –1.3 percent) (Figure 2Figure 2
Median Level of Low-Density Lipoprotein (LDL) Cholesterol from Baseline to the End of the Study.).Primary Outcomes
The cumulative incidence of the primary end point was 12.6 percent at one year and 31.9 percent at three years in the atorvastatin group, as compared with 11.2 percent and 30.5 percent, respectively, in the placebo group (Figure 3Figure 3
Estimated Cumulative Incidence of the Composite Primary End Point.). The relative risk reduction afforded by active treatment, as compared with placebo, was 8 percent (hazard ratio, 0.92; 95 percent confidence interval, 0.77 to 1.10; P=0.37). A similar number of patients died from cardiac causes in the two groups (20 percent in the atorvastatin group and 23 percent in the placebo group; relative risk, 0.81; 95 percent confidence interval, 0.64 to 1.03; P=0.08). Eleven percent (70) of the patients in the atorvastatin group had a nonfatal myocardial infarction, as compared with 12 percent (79) of those in the placebo group (relative risk, 0.88; 95 percent confidence interval, 0.64 to 1.21; P=0.42). More patients (27) died of stroke in the atorvastatin group than in the placebo group (13; relative risk, 2.03; 95 percent confidence interval, 1.05 to 3.93; P=0.04). Nonfatal stroke was distributed equally in the two groups (33 patients in the atorvastatin group and 32 patients in the placebo group; relative risk, 1.04; 95 percent confidence interval, 0.64 to 1.69; P=0.89) (Table 2Table 2
Rates of Primary and Secondary End Points.).Secondary Outcomes
Death from all causes was similar in the two groups (48 percent in the atorvastatin group, as compared with 50 percent in the placebo group; relative risk, 0.93; 95 percent confidence interval, 0.79 to 1.08; P=0.33). Of nominal significance, the risk of all cardiac events combined was reduced by 18 percent in the atorvastatin group, with a total event rate of 33 percent, as compared with 39 percent in the placebo group (relative risk, 0.82; 95 percent confidence interval, 0.68 to 0.99; P=0.03) (Table 2). This result was driven mainly by differences in the rates of coronary-artery bypass grafting and percutaneous transluminal coronary angioplasty. The incidence of all cerebrovascular events combined in the atorvastatin group was not different from that in the placebo group (relative risk, 1.12; 95 percent confidence interval, 0.81 to 1.55; P=0.49) (Table 2).
Adherence, Tolerability, and Adverse Events
The mean (±SD) duration of exposure to placebo was 27.2±17.9 months (range, 0.03 to 70.2), and to atorvastatin, 28.5±18.6 months (range, 0.07 to 69.9). In the placebo group, 82 percent of patients took the study medication without interruption, and in the atorvastatin group, 80 percent of patients did so. The average number of days that treatment was interrupted was 12±36 in the placebo group and 13±40 in the atorvastatin group. During treatment, the dose of atorvastatin or matching placebo was halved when administered to 190 patients (15 percent). During the study, 98 patients in the placebo group (15 percent) began nonstudy statins, as compared with 10 percent of those in the atorvastatin group. The proportion of patients who continued to receive the study drug at one and two years, expressed as a percentage of those who remained alive and free of a primary event, was 74 percent (459 patients) and 51 percent (317 patients), respectively, in the atorvastatin group and 74 percent (469 patients) and 48 percent (303 patients), respectively, in the placebo group.
Patients receiving hemodialysis generally have many adverse and serious adverse events (Table 3Table 3
Adverse Events.), but no cases of rhabdomyolysis or severe liver disease were detected in either group. The study medication was discontinued by the investigators in one patient receiving placebo because of a report of myalgia in combination with elevated creatine kinase levels.Discussion
We examined the value of lowering the level of LDL cholesterol in patients receiving hemodialysis who have type 2 diabetes mellitus, among whom the average annual incidence of myocardial infarction or death from coronary heart disease is 8.2 percent. This incidence rate exceeds the average annual rates of major coronary events that were reported in the placebo group of the Scandinavian Simvastatin Survival Study (6.6 percent) and is the highest rate of cardiovascular events in a long-term prospective trial of statin therapy.19 Atorvastatin (20 mg daily) lowered LDL cholesterol levels by 42 percent, to 72 mg per deciliter, which is close to the target value of 70 mg per deciliter (1.81 mmol per liter) recommended by the Third Adult Treatment Panel of the National Cholesterol Education Program for persons at very high risk of cardiovascular disease. Despite the high rate of cardiovascular events and the pronounced LDL cholesterol–lowering activity of atorvastatin, a significant reduction in the incidence of the composite primary end point was not achieved.
Of nominal significance, more cases of fatal stroke occurred in the atorvastatin group (27) than in the placebo group (13). This finding is unexplained and could be a chance finding, particularly in view of the data from CARDS, which indicate that atorvastatin lowers the incidence of stroke.3 That study reported a relative risk for stroke of 0.52 (95 percent confidence interval, 0.31 to 0.89) in persons with type 2 diabetes mellitus who were taking atorvastatin. The rate of fatal and nonfatal stroke decreased from 2.8 to 1.5 percent (39 vs. 21 patients), whereas in the present study, it increased from 7.0 to 9.7 percent (44 vs. 59 patients).
The complete absence of a stroke benefit and the increase in fatal strokes contribute considerably to the finding that the treatment effect on the primary end point was less than predicted. A possible reason for the unexpected results with regard to the primary end point might be related to the LDL cholesterol concentration at baseline. In general, the absolute risk reduction attained by lowering LDL cholesterol by a given percentage is less when pretreatment concentrations are low than when they are high.20 The baseline levels of LDL cholesterol among patients in our study were, on average, above the target (126 mg per deciliter [3.25 mmol per liter]). Given the log-linear relation between LDL cholesterol and coronary heart disease, reducing levels of LDL cholesterol by 40 percent from a starting level of 125 mg per deciliter would result in an approximate relative risk reduction of 30 percent or more.20 This estimate is empirically supported by the results of CARDS3 and the British Heart Protection Study21 and is very close to our initial assumption of a risk reduction of 27 percent.
Since we did not fully achieve this benefit, we speculate that the pathogenesis of vascular events in patients with diabetes mellitus who are receiving hemodialysis may, at least in part, be different from that in patients without end-stage renal disease. Subgroup analyses showed no difference in outcome for any LDL cholesterol level or patients with and patients without cardiovascular disease. Interestingly, there was a continuous decrease in LDL cholesterol levels over time among patients in both groups. Some malnutrition cannot be ruled out during the course of the study, although there was no decrease in the body-mass index.
The extremely high rate of death from cardiovascular causes among patients receiving dialysis22 is explained by more than the traditional coronary risk factors. Apart from the presence of many aggravating coexisting factors, such as inappropriate left ventricular hypertrophy, cardiac fibrosis, cardiac microvessel disease,23 and sympathetic overactivity, among others, there are also indications that atherosclerosis itself is promoted by risk factors other than the traditional cardiovascular risk factors.24,25 The most plausible explanation for the absence of a significant effect on mortality from cardiac causes and cardiac end points in this study is the presence of additional pathogenetic pathways in cardiovascular disease. The dose of atorvastatin in the present study was 20 mg, which is lower than the high dose used in a recent study by LaRosa et al.26 in which intensive lipid-lowering therapy with atorvastatin at a dose of 80 mg per day was more effective than a dose of 10 mg per day in patients with stable coronary heart disease. However, whether such an advantage would accrue if patients with type 2 diabetes who were receiving dialysis were given a higher dose of atorvastatin is unknown.
Several important conclusions can be drawn from this study. First, we showed that it is difficult to rely on uncontrolled observational studies that show substantial advantages of statins in the treatment of patients receiving hemodialysis.9,27 Second, and more important, is the conclusion that the benefit of atorvastatin is limited when intervention with statins is postponed until patients have reached end-stage renal disease. Subgroup analyses of major statin-intervention trials documented a cardiovascular benefit in patients with chronic kidney disease (stages 1, 2, and 3 according to the classification of the National Kidney Foundation).28,29 According to CARDS, lowering LDL cholesterol levels early during the clinical course of type 2 diabetes mellitus is of benefit.3 Third, there was no excess of serious adverse events; specifically, no cases of rhabdomyolysis occurred, but we found a nominally significant increase in fatal stroke.
We conclude that in persons with type 2 diabetes mellitus who are receiving maintenance hemodialysis and have LDL cholesterol values between 80 and 190 mg per deciliter, routine treatment with a statin to reduce the primary composite end point of death from cardiac causes, myocardial infarction, and stroke is not warranted. The initiation of lipid-lowering therapy in patients with type 2 diabetes mellitus who already have end-stage renal disease may come too late to translate into consistent improvement of the cardiovascular outcome.
Supported by Pfizer. The committee members and investigators did not receive remuneration for conducting the study, except for reimbursement of costs to participate in scientific meetings.
Dr. Wanner reports having received consulting fees and lecture fees from Genzyme; Dr. März, consulting fees, lecture fees, a research grant and stock options from Pfizer; and Dr. Mann, lecture fees from Aventis, Roche, and Janssen Cilag. Dr. Ritz is a member of the safety board of a trial sponsored by AstraZeneca and reports having received consulting fees from the company.
We are indebted to the German Association for Clinical Nephrology (K.-W. Kühn, chair) and the Association of German Nephrology Centers (H. Kütemeyer, chair).
Source Information
From the Department of Medicine, Division of Nephrology, University of Würzburg, Würzburg, Germany (C.W., V.K.); the Clinical Institute of Medical and Chemical Laboratory Diagnostics, University General Hospital, Graz, Austria (W.M.); the Department of Medical Biometrics and Statistics, University Hospital of Freiburg, Freiburg, Germany (M.O.); Schwabing General Hospital, Munich, Germany (J.F.E.M.); Clinical Research Department, Pfizer, Karlsruhe, Germany (G.R.); and the Department of Medicine, University of Heidelberg, Heidelberg, Germany (E.R.).
Address reprint requests to Dr. Wanner at the Department of Medicine, Division of Nephrology, University Hospital, Josef-Schneider-Str. 2, D-97080 Würzburg, Germany, or at wanner_c@medizin.uni-wuerzburg.de.
Investigators and research coordinators participating in this study are listed in the Appendix.
Appendix
The following investigators and research coordinators participated in the study known as the 4D Study (a complete list is available at www.uni-wuerzburg.de/nephrologie): Steering committee: C. Wanner, E. Ritz. Clinical coordinator: V. Krane. Medical end-point monitors: Z. Ülger, F. Swoboda. Data and safety monitoring committee: M. Wehling (chair), E. Keller (deceased), M. Schumacher, T. Eschenhagen. Event committee: J. Mann (chair), J. Bommer, P. Schanzenbächer, P. Schollmeyer, M. Schartl. Electrocardiography monitoring board: F. Heinrich, H. Mörl. Biometric and statistical analysis: University of Freiburg, M. Olschewski. Central laboratory (lipid and safety core laboratory): University of Freiburg, W. März. Contract research organization: Kendle, Munich, S. Reichmuth (Project manager); Datamap, Freiburg, J. Lilienthal. Sponsor: Pfizer, Karlsruhe, G. Ruf, B. Rauer (Project manager).
- References
References
1
Cheung BM ,Lauder IJ ,Lau CP ,Kumana CR . Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57:640-651
CrossRef | Web of Science | Medline2
Armitage J ,Bowman L . Cardiovascular outcomes among participants with diabetes in the recent large statin trials. Curr Opin Lipidol 2004;15:439-446
CrossRef | Web of Science | Medline3
Colhoun HM ,Betteridge DJ ,Durrington PN , et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696
CrossRef | Web of Science | Medline4
Schwenger V ,Hofmann A ,Kalifeh N , et al. Uremic patients -- late referral, early death. Dtsch Med Wochenschr 2003;128:1216-1220
CrossRef | Web of Science | Medline5
Koch M ,Thomas B ,Tschope W ,Ritz E . Survival and predictors of death in dialysed diabetic patients. Diabetologia 1993;36:1113-1117
CrossRef | Web of Science | Medline6
Renal Data System. USRDS 2003 annual data report: atlas of end-stage renal disease in the United States. Bethesda, Md.: National Institute of Diabetes and Digestive and Kidney Disease, 2003. (Accessed June 27, 2005, at http://www.usrds.org.)
7
Prichard SS . Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003;14:Suppl 4:S315-S320
CrossRef | Web of Science | Medline8
Iseki K ,Yamazato M ,Tozawa M ,Takishita S . Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002;61:1887-1893
CrossRef | Web of Science | Medline9
Seliger SL ,Weiss NS ,Gillen DL , et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002;61:297-304
CrossRef | Web of Science | Medline10
Baigent C ,Burbury K ,Wheeler D . Premature cardiovascular disease in chronic renal failure. Lancet 2000;356:147-152
CrossRef | Web of Science | Medline11
Lins RL ,Matthys KE ,Verpooten GA , et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant 2003;18:967-976
CrossRef | Web of Science | Medline12
Wanner C ,Krane V ,Ruf G ,Marz W ,Ritz E . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Kidney Int Suppl 1999;71:S222-S226
CrossRef | Medline13
Wanner C ,Krane V ,Marz W , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D Study): demographic and baseline characteristics. Kidney Blood Press Res 2004;27:259-266
CrossRef | Web of Science | Medline14
Nauck M ,Winkler K ,Marz W ,Wieland H . Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem 1995;41:1761-1767
Web of Science | Medline15
O'Brien PC ,Fleming TR . A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
CrossRef | Web of Science | Medline16
Tschope W ,Koch M ,Thomas B ,Ritz E . Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis: results of a prospective study. Nephron 1993;64:354-358
CrossRef | Medline17
Koch M ,Kuthuhn B ,Trenkwalder E , et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997;8:1889-1898
Web of Science | Medline18
Schulgen G ,Olschewski M ,Krane V ,Wanner C ,Ruf G ,Schumacher M . Sample sizes for clinical trials with time-to-event endpoints and competing risks. Contemp Clin Trials 2005;26:386-396
CrossRef | Web of Science | Medline19
Scandinavian Simvastatin Survival Study Group
CrossRef | Web of Science | Medline20
Grundy SM ,Cleeman JI ,Merz CNB , et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239[Erratum, Circulation 2004;110:763.]
CrossRef | Web of Science | Medline21
Heart Protection Study Collaborative Group
CrossRef | Web of Science | Medline22
Foley RN ,Parfrey PS ,Sarnak MJ . Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:Suppl 3:S112-S119
CrossRef | Web of Science | Medline23
Amann K ,Breitbach M ,Ritz E ,Mall G . Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998;9:1018-1022
Web of Science | Medline24
Takayama F ,Aoyama I ,Tsukushi S , et al. Immunohistochemical detection of imidazolone and N(epsilon)-(carboxymethyl) lysine in aortas of hemodialysis patients. Cell Mol Biol 1998;44:1101-1109
Web of Science | Medline25
Himmelfarb J ,Stenvinkel P ,Ikizler TA ,Hakim RM . The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-1538
CrossRef | Web of Science | Medline26
LaRosa JC ,Grundy SM ,Waters DD , et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435
Free Full Text | Web of Science | Medline27
Mason NA ,Bailie GR ,Satayathum S , et al. HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005;45:119-126
CrossRef | Web of Science | Medline28
Tonelli M ,Isles C ,Curhan GC , et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557-1563
CrossRef | Web of Science | Medline29
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:Suppl 1:S1-S266
CrossRef | Web of Science | Medline
- Citing Articles (892)
Citing Articles
1
Rizwana Batool, Masood Sadiq Butt, Muhammad Tauseef Sultan, Farhan Saeed, Rabia Naz. (2015) Protein–Energy Malnutrition: A Risk Factor for Various Ailments. Critical Reviews in Food Science and Nutrition 55:2, 242-253
CrossRef2
Isidro B. Salusky, Katherine Wesseling-Perry. The Parathyroids in Renal Disease. In: The Parathyroids. Elsevier, 2015:641-651.
CrossRef3
Patrick S. Parfrey, Brendan J. Barrett. Cardiovascular Disease and Chronic Kidney Disease. In: Chronic Renal Disease. Elsevier, 2015:181-198.
CrossRef4
Anne M. Murray, Stephen Seliger, John C. Stendahl. Neurologic Complications of Chronic Kidney Disease. In: Chronic Renal Disease. Elsevier, 2015:249-265.
CrossRef5
Christoph Wanner. Dyslipidemia and Chronic Kidney Disease. In: Chronic Renal Disease. Elsevier, 2015:706-710.
CrossRef6
Ashte’ K. Collins, Mark E. Rosenberg, Paul L. Kimmel. Clinical Assessment and Management of Chronic Kidney Disease Across its Stages. In: Chronic Renal Disease. Elsevier, 2015:43-54.
CrossRef7
Mark Shipeng Yu, David A. Folt, Christopher A. Drummond, Steven T. Haller, Emily L. Cooper, Pamela Brewster, Kaleigh L. Evans, Christopher J. Cooper. (2014) Endovascular Versus Medical Therapy for Atherosclerotic Renovascular Disease. Current Atherosclerosis Reports 16:12,
CrossRef8
David Charytan. (2014) Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease. Current Opinion in Nephrology and Hypertension 23:6, 578-585
CrossRef9
Suetonia C Palmer, Giovanni FM Strippoli, Jonathan C Craig. (2014) KHA-CARI commentary on the KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Nephrology 19:11, 663-666
CrossRef10
Alberto Martínez-Castelao, José L. Górriz, Jordi Bover, Julián Segura-de la Morena, Jesús Cebollada, Javier Escalada, Enric Esmatjes, Lorenzo Fácila, Javier Gamarra, Silvia Gràcia, Julio Hernández-Moreno, José L. Llisterri-Caro, Pilar Mazón, Rosario Montañés, Francisco Morales-Olivas, Manuel Muñoz-Torres, Pedro de Pablos-Velasco, Ana de Santiago, Marta Sánchez-Celaya, Carmen Suárez, Salvador Tranche. (2014) Documento de consenso para la detección y manejo de la enfermedad renal crónica. Endocrinología y Nutrición 61:9, e25-e43
CrossRef11
Theodoros I. Kassimatis, David J.A. Goldsmith. (2014) Statins in chronic kidney disease and kidney transplantation. Pharmacological Research 88, 62-73
CrossRef12
Nicola Ferri, Alberto Corsini. (2014) Clinical evidence of statin therapy in non-dyslipidemic disorders. Pharmacological Research 88, 20-30
CrossRef13
Alberto Martínez-Castelao, José L. Górriz, Jordi Bover, Julián Segura-de la Morena, Jesús Cebollada, Javier Escalada, Enric Esmatjes, Lorenzo Fácila, Javier Gamarra, Silvia Gràcia, Julio Hernández-Moreno, José L. Llisterri-Caro, Pilar Mazón, Rosario Montañés, Francisco Morales-Olivas, Manuel Muñoz-Torres, Pedro de Pablos-Velasco, Ana de Santiago, Marta Sánchez-Celaya, Carmen Suárez, Salvador Tranche. (2014) Documento de consenso para la detección y manejo de la enfermedad renal crónica. SEMERGEN - Medicina de Familia
CrossRef14
Alberto Martínez-Castelao, José L. Górriz, Jordi Bover, Julián Segura-de la Morena, Jesús Cebollada, Javier Escalada, Enric Esmatjes, Lorenzo Fácila, Javier Gamarra, Silvia Gràcia, Julio Hernández-Moreno, José L. Llisterri-Caro, Pilar Mazón, Rosario Montañés, Francisco Morales-Olivas, Manuel Muñoz-Torres, Pedro de Pablos-Velasco, Ana de Santiago, Marta Sánchez-Celaya, Carmen Suárez, Salvador Tranche. (2014) Documento de consenso para la detección y manejo de la enfermedad renal crónica. Hipertensión y Riesgo Vascular
CrossRef15
Alberto Martínez-Castelao, José L. Górriz, Jordi Bover, Julián Segura-de la Morena, Jesús Cebollada, Javier Escalada, Enric Esmatjes, Lorenzo Fácila, Javier Gamarra, Silvia Gràcia, Julio Hernández-Moreno, José L. Llisterri-Caro, Pilar Mazón, Rosario Montañés, Francisco Morales-Olivas, Manuel Muñoz-Torres, Pedro de Pablos-Velasco, Ana de Santiago, Marta Sánchez-Celaya, Carmen Suárez, Salvador Tranche. (2014) Documento de consenso para la detección y manejo de la enfermedad renal crónica. Atención Primaria
CrossRef16
Yoshiyuki Morishita, Akihiko Numata, Atushi Miki, Mari Okada, Kenichi Ishibashi, Fumi Takemoto, Yasuhiro Ando, Shigeaki Muto, Eiji Kusano. (2014) Medication-prescribing patterns of primary care physicians in chronic kidney disease. Clinical and Experimental Nephrology 18:5, 690-696
CrossRef17
Peter F. Wilson. Statins. In: Wiley StatsRef: Statistics Reference Online. John Wiley & Sons, Ltd, 2014.
CrossRef18
G. M. Lucas, M. J. Ross, P. G. Stock, M. G. Shlipak, C. M. Wyatt, S. K. Gupta, M. G. Atta, K. K. Wools-Kaloustian, P. A. Pham, L. A. Bruggeman, J. L. Lennox, P. E. Ray, R. C. Kalayjian. (2014) Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases
CrossRef19
Stein Ivar Hallan. (2014) Cardiovascular Disease Prevention in CKD. American Journal of Kidney Diseases 64:3, 326-328
CrossRef20
Junichi Tazaki, Takeshi Morimoto, Ryuzo Sakata, Hitoshi Okabayashi, Fumio Yamazaki, Noboru Nishiwaki, Kazuaki Mitsudo, Takeshi Kimura. (2014) Impact of statin therapy on patients with coronary heart disease and aortic aneurysm or dissection. Journal of Vascular Surgery 60:3, 604-612.e2
CrossRef21
K. Jameson, S. Jick, K. W. Hagberg, B. Ambegaonkar, A. Giles, D. O'Donoghue. (2014) Prevalence and management of chronic kidney disease in primary care patients in the UK. International Journal of Clinical Practice 68:9, 1110-1121
CrossRef22
Alberico L. Catapano, Michel Farnier, JoAnne M. Foody, Peter P. Toth, Joanne E. Tomassini, Philippe Brudi, Andrew M. Tershakovec. (2014) Combination therapy in Dyslipidemia: Where are we now?. Atherosclerosis
CrossRef23
Peter P. Toth, George Thanassoulis, Ken Williams, Curt D. Furberg, Allan Sniderman. (2014) The Risk-Benefit Paradigm versus the Causal Exposure Paradigm: LDL as a Primary Cause of Vascular Disease. Journal of Clinical Lipidology
CrossRef24
S. C. Palmer, J. C. Craig, A. Jones, G. Higgins, N. Willis, G. F. M. Strippoli. (2014) Celebrating 20 years of evidence from the Cochrane Collaboration: what has been the impact of systematic reviews on nephrology?. Nephrology Dialysis Transplantation
CrossRef25
Rita S. Suri, Lakshman Gunaratnam. (2014) Dialysis Recovery Time: More Than Just Another Serum Albumin. American Journal of Kidney Diseases 64:1, 7-9
CrossRef26
Roger Rear, Pascal Meier, Robert M. Bell. (2014) Implications of Kidney Disease in the Cardiac Patient. Interventional Cardiology Clinics 3:3, 317-331
CrossRef27
Michael S. Kostapanos, Christos V. Rizos, Moses S. Elisaf. (2014) Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases. Drug Safety 37:7, 481-500
CrossRef28
Itsuki Nagata, Amane Ike, Hiroaki Nishikawa, Bo Zhang, Makoto Sugihara, Ken Mori, Atsushi Iwata, Akira Kawamura, Kazuyuki Shirai, Yoshinari Uehara, Masahiro Ogawa, Shin-ichiro Miura, Keijiro Saku. (2014) Associations between lipid profiles and MACE in hemodialysis patients with percutaneous coronary intervention: From the FU-Registry. Journal of Cardiology
CrossRef29
William Herrington, Richard Haynes, Natalie Staplin, Jonathan Emberson, Colin Baigent, Martin Landray. (2014) Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. Seminars in Dialysisn/a-n/a
CrossRef30
Pamela B. Morris, Christie M. Ballantyne, Kim K. Birtcher, Steven P. Dunn, Elaine M. Urbina. (2014) Review of Clinical Practice Guidelines for the Management of LDL-Related Risk. Journal of the American College of Cardiology 64:2, 196-206
CrossRef31
Guillaume Jean. (2014) Une autre histoire du sevelamer. Néphrologie & Thérapeutique
CrossRef32
Marta Kalousová, Tomáš Zima, Vera Krane, Winfried März, Christoph Wanner, Vladimír Tesař, Christiane Drechsler. (2014) Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients. Atherosclerosis
CrossRef33
Neil J. Stone, Jennifer G. Robinson, Alice H. Lichtenstein, C. Noel Bairey Merz, Conrad B. Blum, Robert H. Eckel, Anne C. Goldberg, David Gordon, Daniel Levy, Donald M. Lloyd-Jones, Patrick McBride, J. Sanford Schwartz, Susan T. Shero, Sidney C. Smith, Karol Watson, Peter W.F. Wilson. (2014) 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Journal of the American College of Cardiology 63:25, 2889-2934
CrossRef34
S. V. Badve, S. C. Palmer, D. W. Johnson, G. F. M. Strippoli. (2014) A nephrology guide to reading and using systematic reviews of randomized trials. Nephrology Dialysis Transplantation
CrossRef35
M. Pauriah, D. H. J. Elder, S. Ogston, A. Y. S. Noman, A. Majeed, J. C. Wyatt, A.-M. Choy, T. M. MacDonald, A. D. Struthers, C. C. Lang. (2014) High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study. Heart 100:11, 867-872
CrossRef36
Cynthia Herrick, Marina Litvin, Anne Carol Goldberg. (2014) Lipid lowering in liver and chronic kidney disease. Best Practice & Research Clinical Endocrinology & Metabolism 28:3, 339-352
CrossRef37
Virginia McCoy Hass. (2014) Updated management of chronic kidney disease in patients with diabetes. Journal of the American Academy of Physician Assistants 27:6, 17-22
CrossRef38
A. Olyaei. (2014) Statins do not improve cardiovascular outcomes for dialysis patients. Evidence-Based Medicine 19:3, 89-89
CrossRef39
Christoph Wanner, Marcello Tonelli, Alan Cass, Amit X Garg, Hallvard Holdaas, Alan G Jardine, Lixin Jiang, Florian Kronenberg, Rulan S Parekh, Tetsuo Shoji, Robert J Walker. (2014) KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney International 85:6, 1303-1309
CrossRef40
Lin Wang, Wenjie Tian, Zaid Uwais, Guangyong Li, Huixi Li, Ruili Guan, Zhezhu Gao, Zhongcheng Xin. (2014) AGE-Breaker ALT-711 Plus Insulin Could Restore Erectile Function in Streptozocin-Induced Type 1 Diabetic Rats. The Journal of Sexual Medicine 11:6, 1452-1462
CrossRef41
Jagannath H. Saikumar, Csaba P. Kovesdy. (2014) What is the Role of Lipid Measurements in End-Stage Renal Disease?. Seminars in Dialysisn/a-n/a
CrossRef42
Meredith C. Foster, Andreea M. Rawlings, Elizabeth Marrett, David Neff, Morgan E. Grams, Bertram L. Kasiske, Kerry Willis, Lesley A. Inker, Josef Coresh, Elizabeth Selvin. (2014) Potential Effects of Reclassifying CKD as a Coronary Heart Disease Risk Equivalent in the US Population. American Journal of Kidney Diseases 63:5, 753-760
CrossRef43
Aidar R. Gosmanov, Barry M. Wall, Elvira O. Gosmanova. (2014) Diagnosis and Treatment of Diabetic Kidney Disease. The American Journal of the Medical Sciences 347:5, 406-413
CrossRef44
Ragnar Pálsson, Uptal D. Patel. (2014) Cardiovascular Complications of Diabetic Kidney Disease. Advances in Chronic Kidney Disease 21:3, 273-280
CrossRef45
Hideki Ishii, Toyoaki Murohara. (2014) Can lipid profiles predict clinical outcomes in hemodialysis patients with ischemic heart disease?. Journal of Cardiology
CrossRef46
Alberto Ortiz, Adrian Covic, Danilo Fliser, Denis Fouque, David Goldsmith, Mehmet Kanbay, Francesca Mallamaci, Ziad A Massy, Patrick Rossignol, Raymond Vanholder, Andrzej Wiecek, Carmine Zoccali, Gérard M London. (2014) Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. The Lancet 383:9931, 1831-1843
CrossRef47
Mark E Molitch, Amanda I Adler, Allan Flyvbjerg, Robert G Nelson, Wing-Yee So, Christoph Wanner, Bertram L Kasiske, David C Wheeler, Dick de Zeeuw, Carl E Mogensen. (2014) Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney International
CrossRef48
Bertram Kasiske, Takao Saito. (2014) The kidney and lipids: preface. Clinical and Experimental Nephrology
CrossRef49
Ioannis Tentzeris, Miklos Rohla, Rudolf Jarai, Serdar Farhan, Matthias K. Freynhofer, Gerhard Unger, Michael Nürnberg, Alexander Geppert, Emil Wessely, Johann Wojta, Kurt Huber. (2014) Influence of High-Dose Highly Efficient Statins on Short-Term Mortality in Patients Undergoing Percutaneous Coronary Intervention With Stenting for Acute Coronary Syndromes. The American Journal of Cardiology 113:7, 1099-1104
CrossRef50
Mark K. Elliott, Jennifer A. McCaughan, Damian G. Fogarty. (2014) Do patients with chronic kidney disease get optimal cardiovascular risk reduction?. Current Opinion in Nephrology and Hypertension1
CrossRef51
Sripal Bangalore, Rana Fayyad, G. Kees Hovingh, Rachel Laskey, Liffert Vogt, David A. DeMicco, David D. Waters. (2014) Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials. The American Journal of Cardiology
CrossRef52
Harsha V. Ganga, Hanna B. Slim, Paul D. Thompson. (2014) A systematic review of statin-induced muscle problems in clinical trials. American Heart Journal
CrossRef53
Adriana M. Hung, Chutatip Limkunakul, Jenny S. Placido, Edward D. Siew, Charles D. Ellis, Ayumi Shintani, Talat Alp Ikizler. (2014) Administration of IL-1ra improves adiponectin levels in chronic hemodialysis patients. Journal of Nephrology
CrossRef54
Guenther Silbernagel, Iris Baumgartner, Christoph Wanner, Winfried März. (2014) Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease. Journal of Renal Nutrition 24:2, 65-71
CrossRef55
M. Bonthuis, K. J. van Stralen, K. J. Jager, S. Baiko, T. Jahnukainen, G. F. Laube, L. Podracka, T. Seeman, K. Tyerman, T. Ulinski, J. W. Groothoff, F. Schaefer, E. Verrina. (2014) Dyslipidaemia in children on renal replacement therapy. Nephrology Dialysis Transplantation 29:3, 594-603
CrossRef56
Hiroaki Watabe, Akira Sato, Tomoya Hoshi, Noriyuki Takeyasu, Daisuke Abe, Daiki Akiyama, Yuki Kakefuda, Hidetaka Nishina, Yuichi Noguchi, Kazutaka Aonuma. (2014) Association of contrast-induced acute kidney injury with long-term cardiovascular events in acute coronary syndrome patients with chronic kidney disease undergoing emergent percutaneous coronary intervention. International Journal of Cardiology
CrossRef57
H. Moradi, E. Streja, M. L. Kashyap, N. D. Vaziri, G. C. Fonarow, K. Kalantar-Zadeh. (2014) Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrology Dialysis Transplantation
CrossRef58
Ambreen Gul, Dana Miskulin, Jennifer Gassman, Antonia Harford, Bruce Horowitz, Joline Chen, Susan Paine, Edward Bedrick, John W. Kusek, Mark Unruh, Philip Zager. (2014) Design of the Blood Pressure Goals in Dialysis Pilot Study. The American Journal of the Medical Sciences 347:2, 125-130
CrossRef59
F. Hammer, V. Krane, S. Stork, C. Roser, K. Hofmann, N. Pollak, B. Allolio, C. Wanner. (2014) Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrology Dialysis Transplantation 29:2, 400-405
CrossRef60
Jian-Min Wang, Jia-Jun Zhou, Qian Zheng, Hua Gan, Hang Wang. (2014) Dialysis Method Alters the Expression of MicroRNA-33a and Its Target Genes ABCA1, ABCG1 in THP-1 Macrophages. Therapeutic Apheresis and Dialysis 18:1, 44-50
CrossRef61
Bertram Pitt, Patrick Rossignol. (2014) Mineralocorticoid Receptor Antagonists in Patients With End-Stage Renal Disease on Chronic Hemodialysis. Journal of the American College of Cardiology 63:6, 537-538
CrossRef62
Tarun W. Dasari, David J. Cohen, Neal S. Kleiman, Michelle J. Keyes, Chen-Hsing Yen, Elias B. Hanna, Jorge F. Saucedo. (2014) Statin Therapy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry). The American Journal of Cardiology 113:4, 621-625
CrossRef63
Kunitoshi Iseki. (2014) Epidemiology of dyslipidemia in chronic kidney disease. Clinical and Experimental Nephrology
CrossRef64
Marcello Tonelli. (2014) The Roads Less Traveled? Diverging Research and Clinical Priorities for Dialysis Patients and Those With Less Severe CKD. American Journal of Kidney Diseases 63:1, 124
CrossRef65
Georges Khoueiry, Mokhtar Abdallah, Faisal Saiful, Nidal Abi Rafeh, Muhammad Raza, Tariq Bhat, Suzanne El-Sayegh, Kamyar Kalantar-Zadeh, James Lafferty. (2014) High-density lipoprotein in uremic patients: metabolism, impairment, and therapy. International Urology and Nephrology 46:1, 27-39
CrossRef66
Rika Jimbo, Tatsuo Shimosawa. (2014) Cardiovascular Risk Factors and Chronic Kidney Disease—FGF23: A Key Molecule in the Cardiovascular Disease. International Journal of Hypertension 2014, 1-9
CrossRef67
(2014) An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. Journal of Clinical Lipidology 8:1, 29-60
CrossRef68
Baris Afsar, Kultigin Turkmen, Adrian Covic, Mehmet Kanbay. (2014) An Update on Coronary Artery Disease and Chronic Kidney Disease. International Journal of Nephrology 2014, 1-9
CrossRef69
Young-Ki Lee, Jieun Oh. (2014) Hemodialysis. Korean Journal of Medicine 86:2, 131
CrossRef70
Tamio Teramoto, Jun Sasaki, Shun Ishibashi, Sadatoshi Birou, Hiroyuki Daida, Seitaro Dohi, Genshi Egusa, Takafumi Hiro, Kazuhiko Hirobe, Mami Iida, Shinji Kihara, Makoto Kinoshita, Chizuko Maruyama, Takao Ohta, Tomonori Okamura, Shizuya Yamashita, Masayuki Yokode, Koutaro Yokote. (2014) Chronic Kidney Disease. Journal of Atherosclerosis and Thrombosis 21:3, 173-174
CrossRef71
Matthew I. Tomey, Jonathan A. Winston. (2014) Cardiovascular Pathophysiology in Chronic Kidney Disease: Opportunities to Transition from Disease to Health. Annals of Global Health 80:1, 69-76
CrossRef72
Marcello Bertoluci, Augusto Pimazoni-Netto, Antonio Pires, Antonio Pesaro, Beatriz D Schaan, Bruno Caramelli, Carisi Polanczyk, Carlos Vicente Júnior, Danielle M Gualandro, Domingos Malerbi, Emilio Moriguchi, Flavio Antonio Borelli, João Eduardo Salles, José Júnior, Luis Rohde, Luis H Canani, Luiz Antonio Cesar, Marcos Tambascia, Maria Zanella, Miguel Gus, Rafael Scheffel, Raul dos Santos. (2014) Diabetes and cardiovascular disease: from evidence to clinical practice – position statement 2014 of Brazilian Diabetes Society. Diabetology & Metabolic Syndrome 6:1, 58
CrossRef73
Michelle C Mann, Derek V Exner, Brenda R Hemmelgarn, David A Hanley, Tanvir C Turin, Jennifer M MacRae, Sofia B Ahmed. (2014) The VITAH Trial Vitamin D supplementation and cardiac autonomic tone in hemodialysis: a blinded, randomized controlled trial. BMC Nephrology 15:1, 129
CrossRef74
Mingxin Li, Jing Xin, Ding-Wei Kuang, Un-I Kuok, Chiu-Leong Li, Kin Cheung, Weng-In Lio. (2014) Risk Factors of Arterial Damage Assessed by ABI and baPWV among Hemodialysis Patients in Macao. Advances in Nephrology 2014, 1-6
CrossRef75
Darren Green, James P. Ritchie, Nik Abidin, David I. New, Philip A. Kalra. (2013) The association of ECG and echocardiographic abnormalities with sudden cardiac death in a dialysis patient cohort. Journal of Nephrology
CrossRef76
Vasil Peev, Ali Nayer, Gabriel Contreras. (2013) Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease. Current Opinion in Lipidology1
CrossRef77
Mayoor V. Prabhu, B.H. Santosh Pai, Sreedhar Reddy, Parul Kodan. (2013) Cardiovascular disease in peritoneal dialysis: A review. Clinical Queries: Nephrology
CrossRef78
Christiane Drechsler, Andreas Schneider, Lena Gutjahr-Lengsfeld, Matthias Kroiss, Juan Jesús Carrero, Vera Krane, Bruno Allolio, Christoph Wanner, Martin Fassnacht. (2013) Thyroid Function, Cardiovascular Events, and Mortality in Diabetic Hemodialysis Patients. American Journal of Kidney Diseases
CrossRef79
DIMITRIOS POULIKAKOS, DEBASISH BANERJEE, MAREK MALIK. (2013) Risk of Sudden Cardiac Death in Chronic Kidney Disease. Journal of Cardiovascular Electrophysiologyn/a-n/a
CrossRef80
Jaakko Helve, Reijo Sund, Mikko Haapio, Per-Henrik Groop, Carola Grönhagen-Riska, Patrik Finne. (2013) Medication among patients with type 1 diabetes and predialytic renal disease. Diabetes Research and Clinical Practice
CrossRef81
Sharon M. Moe, Ravi Thadhani. (2013) What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?. Current Opinion in Nephrology and Hypertension 22:6, 651-655
CrossRef82
Maciej Banach, . (2013) Statins in patients with chronic kidney disease – an attempt at recommendations. Current Medical Research and Opinion 29:11, 1419-1422
CrossRef83
(2013) Chapter 2: Pharmacological cholesterol-lowering treatment in adults. Kidney International Supplements 3:3, 271-279
CrossRef84
Alfonso M. Cueto-Manzano, Juan R. Ángel-Zúñiga, Gabina Ornelas-Carrillo, E. Rojas-Campos, Héctor R. Martínez-Ramírez, Laura Cortés-Sanabria. (2013) Anti-Inflammatory Interventions in End-Stage Renal Disease: A Randomized, Double-Blinded, Controlled and Crossover Clinical Trial on the Use of Pravastatin in Continuous Ambulatory Peritoneal Dialysis. Archives of Medical Research
CrossRef85
Ricardo Gómez-Huelgas, Alberto Martínez-Castelao, Sara Artola, José Luis Górriz, Edelmiro Menéndez. (2013) Tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica. Medicina Clínica
CrossRef86
Dimitrios Poulikakos, Debasish Banerjee, Marek Malik. (2013) Major arrhythmic events and T wave morphology descriptors in hemodialyzed patients. Journal of Electrocardiology
CrossRef87
Christoph Wanner, Kai-Renke Schmidt, Vera Krane. (2013) Results of the 4D study: ten years of follow-up?. Clinical and Experimental Nephrology
CrossRef88
N. Chen, X. Wu, X. Ding, C. Mei, P. Fu, G. Jiang, X. Li, J. Chen, B. Liu, Y. La, F. Hou, Z. Ni, J. Fu, C. Xing, X. Yu, C. Huang, L. Zuo, L. Wang, J. Hunter, M. Dillon, M. Plone, J. Neylan. (2013) Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study. Nephrology Dialysis Transplantation
CrossRef89
L. Redahan, B. Brady, A. Smyth, S. Higgins, C. Wall. (2013) The use of palliative care services amongst end-stage kidney disease patients in an Irish tertiary referral centre. Clinical Kidney Journal
CrossRef90
Chin-Chou Huang, Wan-Leong Chan, Yu-Chun Chen, Tzeng-Ji Chen, Chia-Min Chung, Po-Hsun Huang, Shing-Jong Lin, Jaw-Wen Chen, Hsin-Bang Leu. (2013) The beneficial effects of statins in patients undergoing hemodialysis. International Journal of Cardiology 168:4, 4155-4159
CrossRef91
Christos Rammos, Ulrike B. Hendgen-Cotta, Julia Sobierajski, Sarah Adamczyk, Gerd R. Hetzel, Werner Kleophas, Frank Dellanna, Malte Kelm, Tienush Rassaf. (2013) Macrophage migration inhibitory factor is associated with vascular dysfunction in patients with end-stage renal disease. International Journal of Cardiology 168:6, 5249-5256
CrossRef92
Suma Vupputuri, Teresa M. Kimes, Michael O. Calloway, Jennifer B. Christian, David Bruhn, Alan A. Martin, Gregory A. Nichols. (2013) The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. Journal of Diabetes and its Complications
CrossRef93
Tetsuo Shoji. (2013) Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients. Clinical and Experimental Nephrology
CrossRef94
Suetonia C Palmer, Sankar D Navaneethan, Jonathan C Craig, David W Johnson, Vlado Perkovic, Sagar U Nigwekar, Jorgen Hegbrant, Giovanni FM Strippoli, Giovanni FM Strippoli. HMG CoA reductase inhibitors (statins) for dialysis patients. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2013.
CrossRef95
Catherine M. Shanahan. (2013) Mechanisms of vascular calcification in CKD—evidence for premature ageing?. Nature Reviews Nephrology 9:11, 661-670
CrossRef96
Suguru Yamamoto, Valentina Kon. (2013) Chronic kidney disease induced dysfunction of high density lipoprotein. Clinical and Experimental Nephrology
CrossRef97
Ziad A Massy, Dick de Zeeuw. (2013) LDL cholesterol in CKD—to treat or not to treat?. Kidney International 84:3, 451-456
CrossRef98
C. P. Kovesdy, L. D. Quarles. (2013) Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrology Dialysis Transplantation 28:9, 2228-2236
CrossRef99
Tanja Hojs Fabjan, Radovan Hojs. (2013) Stroke and renal dysfunction. European Journal of Internal Medicine
CrossRef100
A. Olyaei, J. L. Steffl, J. MacLaughlan, M. Trabolsi, S. P. Quadri, I. Abbasi, E. Lerma. (2013) HMG-CoA Reductase Inhibitors in Chronic Kidney Disease. American Journal of Cardiovascular Drugs
CrossRef101
Nosratola D. Vaziri. (2013) Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. Clinical and Experimental Nephrology
CrossRef102
J. A. Beckman, F. Paneni, F. Cosentino, M. A. Creager. (2013) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. European Heart Journal 34:31, 2444-2452
CrossRef103
Kunitoshi Iseki. (2013) Nephrology for the people: Presidential Address at the 42nd Regional Meeting of the Japanese Society of Nephrology in Okinawa 2012. Clinical and Experimental Nephrology 17:4, 480-487
CrossRef104
Mark R. Kahn, Michael J. Robbins, Michael C. Kim, Valentin Fuster. (2013) The role of fibrates in chronic kidney disease and diabetes mellitus. Nature Reviews Cardiology 10:9, 547-547
CrossRef105
Pierre Delanaye, Jean-Marie Krzesinski, Etienne Cavalier. (2013) EVOLVE : entre déception et optimisme. Néphrologie & Thérapeutique 9:4, 241-245
CrossRef106
Charles Chazot, Guillaume Jean. (2013) The dynamics of prognostic indicators: toward earlier identification of dialysis patients with a high risk of dying. Kidney International 84:1, 19-21
CrossRef107
V. S. Stel, F. W. Dekker, C. Zoccali, K. J. Jager. (2013) Instrumental variable analysis. Nephrology Dialysis Transplantation 28:7, 1694-1699
CrossRef108
F. Locatelli, N. Dimkovic, G. Spasovski. (2013) Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrology Dialysis Transplantation 28:7, 1874-1888
CrossRef109
Jane Stock. (2013) HDL function and cardiovascular risk: Debate continues…. Atherosclerosis 229:1, 38-41
CrossRef110
W. Hou, J. Lv, V. Perkovic, L. Yang, N. Zhao, M. J. Jardine, A. Cass, H. Zhang, H. Wang. (2013) Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. European Heart Journal 34:24, 1807-1817
CrossRef111
C. Wanner. (2013) Chronic kidney disease and statin therapy: to treat or not to treat?. European Heart Journal 34:24, 1772-1774
CrossRef112
David K. Hooper, Jason C. Williams, Adam C. Carle, Sandra Amaral, Deepa H. Chand, Maria E. Ferris, Hiren P. Patel, Christoph Licht, Gina-Marie Barletta, Veronica Zitterman, Mark Mitsnefes, Uptal D. Patel. (2013) The quality of cardiovascular disease care for adolescents with kidney disease: a Midwest Pediatric Nephrology Consortium study. Pediatric Nephrology 28:6, 939-949
CrossRef113
Marcin Barylski, Shekoufeh Nikfar, Dimitri P. Mikhailidis, Peter P. Toth, Pooneh Salari, Kausik K. Ray, Michael J. Pencina, Manfredi Rizzo, Jacek Rysz, Mohammad Abdollahi, Stephen J. Nicholls, Maciej Banach. (2013) Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—A meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacological Research 72, 35-44
CrossRef114
Allon N Friedman, Zhangsheng Yu, Rebeka Tabbey, Cheryl Denski, Hector Tamez, Julia Wenger, Ravi Thadhani, Yong Li, Bruce A Watkins. (2013) Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. Kidney International 83:6, 1130-1135
CrossRef115
Adeera Levin, William Lancashire, Robert G Fassett. (2013) Targets, trends, excesses, and deficiencies: refocusing clinical investigation to improve patient outcomes. Kidney International 83:6, 1001-1009
CrossRef116
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette K. Wenger, R. Scott Wright. (2013) 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 61:23, e179-e347
CrossRef117
K. Iseki, H. Arima, K. Kohagura, I. Komiya, S. Ueda, K. Tokuyama, Y. Shiohira, H. Uehara, S. Toma, , N. Tomiyama, H. Arima, S. Chinen, K. Tokashiki, A. Hirano-Nakasone, C. Nohara, S. Ueda, S. Ueda, K. Kohagura, S. Toma, T. Tana, A. Higa, M. Yamazato, Y. Ishida, K. Tokuyama, N. Nagayoshi, S. Miyagi, T. Asato, R. Kobayashi, Y. Shiohira, T. Yonaha, Y. Uezu, N. Kuwae, S. Nakasato, Y. Oshiro, K. Nashiro, T. Asato, H. Katsuren, H. Kagawa, K. Naika-Geka, T. Higa, M. Ikema, K. Akamine, M. Nishihira, M. Jahana, C. Imai, T. Yonaha, M. Ikemura, M. Uechi, M. Yamazato, K. Yoshihara, M. Arakaki, K. Iha, H. Afuso, S. Kiyuna, K. Shiroma, T. Miyara, M. Itokazu, T. Naka, S. Naka, E. Yamaguchi, Y. Uechi, T. Kowatari, H. Yamada, S. Yoshi, H. Sunagawa, M. Tozawa, M. Uechi, M. Adaniya, H. Afuso, H. Uehara, H. Miyazato, C. Sakuda, T. Taminato, H. Uchima, Y. Nakasone, T. Funakoshi, M. Nakazato, N. Nagata, S. Miyazato, H. Katsuren, T. Miyagi, H. Hirano, K. Iwashiro, T. Sunagawa, H. Yoshida, Y. Oshiro, T. Shimabukuro, T. Oura, H. Henzan, I. Kyan, S. Maeshiro, T. Wake, S. Tagawa, T. Inoue, T. Tokashiki, H. Ishii, S. Miyagi, S. Takishita, S. Saito, K. Shimizu, Y. Ohya, F. Barzi. (2013) Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrology Dialysis Transplantation 28:6, 1579-1589
CrossRef118
Valentina Kon, T. Alp Ikizler, Sergio Fazio. (2013) Importance of high-density lipoprotein quality. Current Opinion in Nephrology and Hypertension 22:3, 259-265
CrossRef119
Dragana Nikolic, Shekoufeh Nikfar, Pooneh Salari, Manfredi Rizzo, Kausik K. Ray, Michael J. Pencina, Dimitri P. Mikhailidis, Peter P. Toth, Stephen J. Nicholls, Jacek Rysz, Mohammad Abdollahi, Maciej Banach, . (2013) Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion 29:5, 435-451
CrossRef120
Karthiek R. Narala, Sohail Hassan, Thomas A. LaLonde, Peter A. McCullough. (2013) Management of Coronary Atherosclerosis and Acute Coronary Syndromes in Patients With Chronic Kidney Disease. Current Problems in Cardiology 38:5, 165-206
CrossRef121
P. M. Ridker, J. J. P. Kastelein, J. Genest, W. Koenig. (2013) C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care. European Heart Journal 34:17, 1258-1261
CrossRef122
Mario Bonomini, Lorenzo Di Liberato, Goffredo Del Rosso, Antonio Stingone, Giancarlo Marinangeli, Agostino Consoli, Silvio Bertoli, Amedeo De Vecchi, Emanuele Bosi, Roberto Russo, Roberto Corciulo, Loreto Gesualdo, Francesco Giorgino, Paolo Cerasoli, Augusto Di Castelnuovo, Maria Pia Monaco, Ty Shockley, Claudia Rossi, Arduino Arduini. (2013) Effect of an l-Carnitine–Containing Peritoneal Dialysate on Insulin Sensitivity in Patients Treated With CAPD: A 4-Month, Prospective, Multicenter Randomized Trial. American Journal of Kidney Diseases
CrossRef123
Yuya Matsue, Makoto Suzuki, Wataru Nagahori, Masakazu Ohno, Akihiko Matsumura, Yuji Hashimoto. (2013) Beta-blocker prevents sudden cardiac death in patients with hemodialysis. International Journal of Cardiology 165:3, 519-522
CrossRef124
Jürgen Floege, Georg Schlieper. (2013) Chronic kidney disease: How effective and safe are antiplatelet agents in CKD?. Nature Reviews Nephrology 9:6, 314-316
CrossRef125
H. Gohlke, C. Albus, G. Bönner, H. Darius, S. Eckert, C. Gohlke-Bärwolf, D. Gysan, H. Hahmann, M. Halle, R. Hambrecht, P. Mathes, H.-G. Predel, G. Sauer †, C. Schacky, G. Schuler, J. Siegrist, J. Thiery, D. Tschöpe, H. Völler, A. Wirth. (2013) Empfehlungen der Projektgruppe Prävention der DGK zur risikoadjustierten Prävention von Herz- und Kreislauferkrankungen. Der Kardiologe 7:2, 141-156
CrossRef126
Staci Valley, Julie Wright-Nunes. (2013) Management Considerations for the Hospitalist Caring for Patients with End-Stage Renal Disease. Hospital Medicine Clinics 2:2, e209-e226
CrossRef127
Mark D. Alscher, Udo Sechtem. (2013) Das kardiorenale Syndrom verstehen und behandeln. CME 10:4, 65-72
CrossRef128
Eun-Hee Jang, Yong-Moon Park, Joon Hur, Mee-Kyoung Kim, Seung-Hyun Ko, Ki-Hyun Baek, Ki-Ho Song, Kwang-Woo Lee, Hyuk-Sang Kwon. (2013) Higher levels of small dense low-density lipoprotein (LDL) are associated with cardiac autonomic neuropathy in patients with Type 2 diabetes. Diabetic Medicinen/a-n/a
CrossRef129
Bruce K. Birmingham, Suzanne K. Swan, Tom Puchalski, Pat Mitchell, Connie Azumaya, Julie Zalikowski, Yi Wang. (2013) Pharmacokinetic and Pharmacodynamic Profile of Rosuvastatin in Patients with End-Stage Renal Disease on Chronic Haemodialysis. Clinical Drug Investigation 33:4, 233-241
CrossRef130
Wendy L. St. Peter, Eric D. Weinhandl, Michael F. Flessner. (2013) Sitagliptin—Another Option for Managing Type 2 Diabetes in Dialysis Patients?. American Journal of Kidney Diseases 61:4, 532-535
CrossRef131
C.P.M.S. Oliveira, C.R. Kappel, E.R. Siqueira, V.M.R. Lima, J.T. Stefano, M.T. Michalczuk, S.S. Marini, H.V. Barbeiro, F.G. Soriano, F.J. Carrilho, L.M.M.B. Pereira, M.R. Alvares-da-Silva. (2013) Effects of Hepatitis C virus on cardiovascular risk in infected patients: A comparative study. International Journal of Cardiology 164:2, 221-226
CrossRef132
Sudarshan Balla, Maen B Nusair, Martin A Alpert. (2013) Risk factors for atherosclerosis in patients with chronic kidney disease: recognition and management. Current Opinion in Pharmacology 13:2, 192-199
CrossRef133
A. H. Berg, C. Drechsler, J. Wenger, R. Buccafusca, T. Hod, S. Kalim, W. Ramma, S. M. Parikh, H. Steen, D. J. Friedman, J. Danziger, C. Wanner, R. Thadhani, S. A. Karumanchi. (2013) Carbamylation of Serum Albumin as a Risk Factor for Mortality in Patients with Kidney Failure. Science Translational Medicine 5:175, 175ra29-175ra29
CrossRef134
Nael Hawwa, Martin J. Schreiber, W. H. Wilson Tang. (2013) Pharmacologic Management of Chronic Reno-Cardiac Syndrome. Current Heart Failure Reports 10:1, 54-62
CrossRef135
L. Regazzoni, L. Del Vecchio, A. Altomare, K.-J. Yeum, D. Cusi, F. Locatelli, M. Carini, G. Aldini. (2013) Human serum albumin cysteinylation is increased in end stage renal disease patients and reduced by hemodialysis: mass spectrometry studies. Free Radical Research 47:3, 172-180
CrossRef136
Christopher T Chan, Adrian Covic, Jonathan C Craig, Andrew Davenport, Bertram L Kasiske, Martin K Kuhlmann, Nathan W Levin, Philip K T Li, Francesco Locatelli, Michael V Rocco, David C Wheeler. (2013) Novel techniques and innovation in blood purification: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney International 83:3, 359-371
CrossRef137
Katherine Wesseling-Perry, Isidro B. Salusky. (2013) Chronic Kidney Disease: Mineral and Bone Disorder in Children. Seminars in Nephrology 33:2, 169-179
CrossRef138
Kevin F. Erickson, Sohan Japa, Douglas K. Owens, Glenn M. Chertow, Alan M. Garber, Jeremy D. Goldhaber-Fiebert. (2013) Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease. Journal of the American College of Cardiology 61:12, 1250-1258
CrossRef139
Joost Besseling, Julian Capelleveen, John J. P. Kastelein, G. Kees Hovingh. (2013) LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?. Drugs 73:4, 293-301
CrossRef140
Bertram L. Kasiske, David C. Wheeler. (2013) The Management of Dyslipidemia in CKD: New Analyses of an Expanding Dataset. American Journal of Kidney Diseases 61:3, 371-374
CrossRef141
Hidehiro Kaneko, Junji Yajima, Yuji Oikawa, Shingo Tanaka, Daisuke Fukamachi, Shinya Suzuki, Koichi Sagara, Takayuki Otsuka, Shunsuke Matsuno, Ryuichi Funada, Hiroto Kano, Tokuhisa Uejima, Akira Koike, Kazuyuki Nagashima, Hajime Kirigaya, Hitoshi Sawada, Tadanori Aizawa, Takeshi Yamashita. (2013) Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. Heart and Vessels
CrossRef142
Mark R. Kahn, Michael J. Robbins, Michael C. Kim, Valentin Fuster. (2013) Management of cardiovascular disease in patients with kidney disease. Nature Reviews Cardiology 10:5, 261-273
CrossRef143
C. Drechsler, E. Ritz, A. Tomaschitz, S. Pilz, S. Schonfeld, K. Blouin, M. Bidlingmaier, F. Hammer, V. Krane, W. Marz, B. Allolio, M. Fassnacht, C. Wanner. (2013) Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. European Heart Journal 34:8, 578-587
CrossRef144
Min Jun, Meg J. Jardine, Nicholas Gray, Rosemary Masterson, Peter G. Kerr, John W.M. Agar, Carmel M. Hawley, Carolyn van Eps, Alan Cass, Martin Gallagher, Vlado Perkovic. (2013) Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home. American Journal of Kidney Diseases 61:2, 247-253
CrossRef145
Tzu-Hsien Tsai, Kuo-Ho Yeh, Cheuk-Kwan Sun, Cheng-Hsu Yang, Shyh-Ming Chen, Chi-Ling Hang, Chien-Jen Chen, Sheng-Ying Chung, Yung-Lung Chen, Chiung-Jen Wu, Hsuen-Wen Chang, Hon-Kan Yip. (2013) Estimated Glomerular Filtration Rate as a Useful Predictor of Mortality in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. The American Journal of the Medical Sciences 345:2, 104-111
CrossRef146
Alberico Catapano, Peter P Toth, Joanne E Tomassini, Andrew M Tershakovec. (2013) The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. Clinical Lipidology 8:1, 13-41
CrossRef147
Arjan J. Kwakernaak, Gilles Lambert, Maartje C.J. Slagman, Femke Waanders, Gozewijn D. Laverman, Francine Petrides, Bert D. Dikkeschei, Gerjan Navis, Robin P.F. Dullaart. (2013) Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment. Atherosclerosis 226:2, 459-465
CrossRef148
S. Sharma, K. Farrington, R. Kozarski, C. Christopoulos, M. Niespialowska-Steuden, D. Moffat, D. A. Gorog. (2013) Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. European Heart Journal 34:5, 354-363
CrossRef149
Muriel Ghosn, Fuad N. Ziyadeh. Treatment of the Patient with End-Stage Diabetic Nephropathy. In: Diabetes and Kidney Disease. Wiley-Blackwell, 2013:215-231.
CrossRef150
Christoph Wanner. Statin Therapy in Patients with Diabetic Nephropathy. In: Diabetes and Kidney Disease. Wiley-Blackwell, 2013:101-115.
CrossRef151
Neil J. Stone. Drugs for Elevated Low-Density Lipoprotein Cholesterol. In: Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. Elsevier, 2013:421-433.
CrossRef152
Pranav S. Garimella, Daniel E. Weiner, Mark J. Sarnak. Prevention and Management of Cardiovascular Disease in Kidney Disease and Kidney Failure. In: Nutritional Management of Renal Disease. Elsevier, 2013:123-135.
CrossRef153
Nosratola D. Vaziri. Altered Lipid Metabolism and Serum Lipids in Kidney Disease and Kidney Failure. In: Nutritional Management of Renal Disease. Elsevier, 2013:31-48.
CrossRef154
R. Hajhosseiny, K. Khavandi, D. J. Goldsmith. (2013) Cardiovascular disease in chronic kidney disease: untying the Gordian knot. International Journal of Clinical Practice 67:1, 14-31
CrossRef155
Csaba Kovesdy, Kamyar Kalantar-Zadeh. Protein-Energy Wasting as a Risk Factor of Morbidity and Mortality in Chronic Kidney Disease. In: Nutritional Management of Renal Disease. Elsevier, 2013:171-195.
CrossRef156
(2013) Chapter 5: Referral to specialists and models of care. Kidney International Supplements 3:1, 112-119
CrossRef157
(2013) Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney International Supplements 3:1, 91-111
CrossRef158
Willibald Hochholzer, Robert P. Giugliano. (2013) Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?. Current Atherosclerosis Reports 15:1,
CrossRef159
Rod Passman. (2013) Prevention of Sudden Cardiac Death in Dialysis Patients: Drugs, Defibrillators or What Else. Blood Purification 35:1-3, 49-54
CrossRef160
Elaine Ku, Vito Campese. (2013) Is Lipid Management Effective for All Stages of CKD?. Blood Purification 35:1-3, 26-30
CrossRef161
Nosratola D. Vaziri, Keith C. Norris. (2013) Reasons for the Lack of Salutary Effects of Cholesterol-Lowering Interventions in End-Stage Renal Disease Populations. Blood Purification 35:1-3, 31-36
CrossRef162
Andreas Schneider, Alan G. Jardine, Markus P. Schneider, Hallvard Holdaas, Ingar Holme, Bengt C. Fellstroem, Faiez Zannad, Roland E. Schmieder. (2013) Determinants of Cardiovascular Risk in Haemodialysis Patients: Post hoc Analyses of the AURORA Study. American Journal of Nephrology 37:2, 144-151
CrossRef163
Michel de Lorgeril, Patricia Salen, Pascal Defaye, Mikael Rabaeus. (2013) Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?. BMC Medicine 11:1, 5
CrossRef164
Andreas Schneider, Markus P Schneider, Hubert Scharnagl, Alan G Jardine, Christoph Wanner, Christiane Drechsler. (2013) Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes. BMC Nephrology 14:1, 67
CrossRef165
Jean-Philippe Lafrance, Elham Rahme, Sameena Iqbal, Martine Leblanc, Vincent Pichette, Naoual Elftouh, Michel Vallée. (2013) Magnitude of discordance between registry data and death certificate when evaluating leading causes of death in dialysis patients. BMC Medical Research Methodology 13:1, 51
CrossRef166
Sang Yup Lim. (2013) Role of Statins in Coronary Artery Disease. Chonnam Medical Journal 49:1, 1
CrossRef167
Steven Grangé, Mélanie Hanoy, Frank Le Roy, Dominique Guerrot, Michel Godin. (2013) Monitoring of hemodialysis quality-of-care indicators: why is it important?. BMC Nephrology 14:1, 109
CrossRef168
Andreas Kuznik, Jack Mardekian, Lisa Tarasenko. (2013) Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010. BMC Nephrology 14:1, 132
CrossRef169
Jung Tak Park, Hyung Jung Oh, Shin-Wook Kang. (2013) Cardiovascular disease in end-stage renal disease. Journal of the Korean Medical Association 56:7, 576
CrossRef170
Joanna Dunlop, Alain Vandal, Janak de Zoysa, Ruvin Gabriel, Imad Haloob, Christopher Hood, Philip Matheson, David Owen Ross McGregor, Kannaiyan Rabindranath, David Semple, Mark Marshall. (2013) Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass. BMC Nephrology 14:1, 149
CrossRef171
Daisuke Koya, Vito M Campese. (2013) Statin Use in Patients with Diabetes and Kidney Disease: The Japanese Experience. Journal of Atherosclerosis and Thrombosis 20:5, 407-424
CrossRef172
(2013) Nihon Toseki Igakkai Zasshi 46:3, 352-355
CrossRef173
L. Darryl Quarles. Management of Calcium and Bone Disease in Renal Patients. In: Seldin and Giebisch's The Kidney. Elsevier, 2013:3073-3086.
CrossRef174
William F Keane, Joanne E Tomassini, David R Neff. (2013) Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis. Journal of Atherosclerosis and Thrombosis 20:2, 123-133
CrossRef175
Eiichiro Kanda, Masumi Ai, Asami Iwamoto, Mitsuyo Okazaki, Yoshitaka Maeda, Sei Sasaki, Masayuki Yoshida. (2013) Relationship between Icodextrin use and decreased level of small low-density lipoprotein cholesterol fractioned by high-performance gel permeation chromatography. BMC Nephrology 14:1, 234
CrossRef176
Jwa-Kyung Kim, Young Rim Song, Min Gang Kim, Hyung Jik Kim, Sung Gyun Kim. (2013) Clinical significance of subclinical carotid atherosclerosis and its relationship with echocardiographic parameters in non-diabetic chronic kidney disease patients. BMC Cardiovascular Disorders 13:1, 96
CrossRef177
Darren Green, James P. Ritchie, Philip A. Kalra. (2013) Meta-Analysis of Lipid-Lowering Therapy in Maintenance Dialysis Patients. Nephron Clinical Practice 124:3-4, 209-217
CrossRef178
Michiel G. H. Betjes, Willem Weimar, Nicolle H. R. Litjens. (2013) Circulating CD4+CD28null T Cells May Increase the Risk of an Atherosclerotic Vascular Event Shortly after Kidney Transplantation. Journal of Transplantation 2013, 1-8
CrossRef179
Driss Elkabbaj, Abdelali Bahadi, Yahia Cherrah, Mourad Errasfa, Rachid Eljaoudi. (2013) Impact of Improving Quality of Dialysis Fluid on Oxidative Stress and Lipid Profile in Hemodialysis Patients. ISRN Nephrology 2013, 1-5
CrossRef180
The EVOLVE Trial Investigators. (2012) Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. New England Journal of Medicine 367:26, 2482-2494
Free Full Text181
Stephen P Adams, Michael Tsang, James M Wright, Stephen P Adams. Lipid lowering efficacy of atorvastatin. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012.
CrossRef182
Elaine M Beller, Rashmi Balaram, Talvika Kooblal, Benita Thurairajah, Christine Sammartino, Yan T Lai, Elaine M Beller. Dietary interventions for lowering cholesterol in dialysis patients. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012.
CrossRef183
Shideh Pouria. Chronic Kidney Disease. In: Advancing Medicine with Food and Nutrients, Second Edition. CRC Press, 2012:467-480.
CrossRef184
Usama Elewa, Maria Dolores Sanchez-Niño, Catalina Martin-Cleary, Beatriz Fernandez-Fernandez, Jesus Egido, Alberto Ortiz. (2012) Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled. International Urology and Nephrology 44:6, 1731-1744
CrossRef185
Masahiro Natsuaki, Yutaka Furukawa, Takeshi Morimoto, Ryuzo Sakata, Takeshi Kimura. (2012) Renal Function and Effect of Statin Therapy on Cardiovascular Outcomes in Patients Undergoing Coronary Revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). The American Journal of Cardiology 110:11, 1568-1577
CrossRef186
Folgerdiena M. de Vries, Petra Denig, Koen B. Pouwels, Maarten J. Postma, Eelko Hak. (2012) Primary Prevention of Major Cardiovascular and Cerebrovascular Events with Statins in Diabetic Patients. Drugs 72:18, 2365-2373
CrossRef187
Christopher D. Owens. (2012) Statins and other agents for vascular inflammation. Journal of Vascular Surgery 56:6, 1799-1806
CrossRef188
Philip W. Connelly, G. V. Prasad. (2012) Adiponectin in renal disease – a review of the evidence as a risk factor for cardiovascular and all-cause mortality. Critical Reviews in Clinical Laboratory Sciences 49:5-6, 218-231
CrossRef189
Scott M. Grundy. (2012) Treatment Targets in the Management of Dyslipidemias: Which Targets in Whom?. Current Cardiology Reports 14:6, 692-700
CrossRef190
(2012) Chapter 1: Introduction. Kidney International Supplements 2:5, 343-346
CrossRef191
Kelli King-Morris, T. Alp Ikizler. (2012) Insulin Resistance in Patients Undergoing Peritoneal Dialysis: Can We Improve It?. Cardiovascular Drugs and Therapy 26:6, 441-443
CrossRef192
Alper Azak, Bülent Huddam, Kürşad Öneç, Gülay Koçak, Fatih Dede, Deniz Aylı, Murat Duranay. (2012) Contribution of High Flux Membranes to the Therapy of Uremia-Associated Dyslipidemia. Therapeutic Apheresis and Dialysis 16:6, 595-599
CrossRef193
(2012) Chapter 3: Blood pressure management in CKD ND patients without diabetes mellitus. Kidney International Supplements 2:5, 357-362
CrossRef194
Niina Matikainen, Marja-Riitta Taskinen. (2012) Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes. Current Cardiology Reports 14:6, 721-731
CrossRef195
R. Kramann, J. Floege, M. Ketteler, N. Marx, V. M. Brandenburg. (2012) Medical options to fight mortality in end-stage renal disease: a review of the literature. Nephrology Dialysis Transplantation 27:12, 4298-4307
CrossRef196
B. Kollerits, V. Krane, C. Drechsler, C. Lamina, W. März, E. Ritz, C. Wanner, F. Kronenberg, . (2012) Apolipoprotein A-IV concentrations and clinical outcomes in haemodialysis patients with type 2 diabetes mellitus - a post hoc analysis of the 4D Study. Journal of Internal Medicine 272:6, 592-600
CrossRef197
Suguru Yamamoto, Patricia G. Yancey, T. Alp Ikizler, W. Gray Jerome, Ryohei Kaseda, Brian Cox, Aihua Bian, Ayumi Shintani, Agnes B. Fogo, MacRae F. Linton, Sergio Fazio, Valentina Kon. (2012) Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis. Journal of the American College of Cardiology 60:23, 2372-2379
CrossRef198
Anna Tomaszuk-Kazberuk, Marcin Kozuch, Jolanta Malyszko, Hanna Bachorzewska-Gajewska, Slawomir Dobrzycki, Wlodzimierz J. Musial. (2012) Pharmacologic Treatment in Dialysis Patients Hospitalized for Cardiovascular Reasons: Do We Follow the Guidelines?. Renal Failure1-8
CrossRef199
Betti Schaefer, Elke Wühl. (2012) Educational Paper: Progression in chronic kidney disease and prevention strategies. European Journal of Pediatrics 171:11, 1579-1588
CrossRef200
Aitor Arias Fernández, Artemio Álvarez Cosmea, Ana isabel Barrio Alonso, Luis Díaz González, Ana Laura Rivero Pérez. (2012) Colesterol de las lipoproteínas de baja densidad <70mg/dl en la enfermedad renal crónica. ¿Ficción o realidad?. Clínica e Investigación en Arteriosclerosis 24:6, 284-288
CrossRef201
James B. Wetmore, Jonathan D. Mahnken, Purna Mukhopadhyay, Qingjiang Hou, Edward F. Ellerbeck, Sally K. Rigler, John A. Spertus, Theresa I. Shireman. (2012) Geographic Variation in HMG-CoA Reductase Inhibitor Use in Dialysis Patients. Journal of General Internal Medicine 27:11, 1475-1483
CrossRef202
J.-K. Lee, H.-H. Lin, C.-T. Tsai, J.-J. Chen, C.-C. Kuo, Y.-C. Lien, J.-W. Lin, J.-W. Huang, S.-W. Hwang, J.-J. Hwang, C.-D. Tseng, F.-T. Chiang, J.-J. Chen, C.-K. Wu. (2012) Differential association of proinflammatory cytokines with left ventricular diastolic dysfunction in subjects with and without continuous ambulatory peritoneal dialysis. Nutrition, Metabolism and Cardiovascular Diseases 22:11, 974-980
CrossRef203
Robert A. DeAngelis, Edimara S. Reis, Daniel Ricklin, John D. Lambris. (2012) Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology 217:11, 1097-1105
CrossRef204
Yelena Slinin, Areef Ishani, Thomas Rector, Patrick Fitzgerald, Roderick MacDonald, James Tacklind, Indulis Rutks, Timothy J. Wilt. (2012) Management of Hyperglycemia, Dyslipidemia, and Albuminuria in Patients With Diabetes and CKD: A Systematic Review for a KDOQI Clinical Practice Guideline. American Journal of Kidney Diseases 60:5, 747-769
CrossRef205
(2012) KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. American Journal of Kidney Diseases 60:5, 850-886
CrossRef206
Hallvard Holdaas, Alan Jardine. (2012) Chronic kidney disease: Do patients with CKD benefit from lipid-lowering therapy?. Nature Reviews Nephrology 8:12, 684-685
CrossRef207
Min Jun, Vinod Venkataraman, Mona Razavian, Bruce Cooper, Sophia Zoungas, Toshiharu Ninomiya, Angela C Webster, Vlado Perkovic, Vlado Perkovic. Antioxidants for chronic kidney disease. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012.
CrossRef208
Agata Kujawa-Szewieczek, Andrzej Więcek, Grzegorz Piecha. (2012) The lipid story in chronic kidney disease: a long story with a happy end?. International Urology and Nephrology
CrossRef209
Myles Wolf. (2012) Update on fibroblast growth factor 23 in chronic kidney disease. Kidney International 82:7, 737-747
CrossRef210
C. Zoccali. (2012) Pulmonary hypertension in dialysis patients: a prevalent, risky but still uncharacterized disorder. Nephrology Dialysis Transplantation 27:10, 3674-3677
CrossRef211
Kazuhiko Tsuruya, Hideki Hirakata. (2012) Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis. Therapeutic Apheresis and Dialysis 16:5, 384-386
CrossRef212
Hideki Hirakata, Kosaku Nitta, Masaaki Inaba, Tetsuo Shoji, Hideki Fujii, Shuzo Kobayashi, Kaoru Tabei, Nobuhiko Joki, Hiroki Hase, Masato Nishimura, Shigeyuki Ozaki, Yuji Ikari, Yoshitaka Kumada, Kazuhiko Tsuruya, Shouichi Fujimoto, Tohru Inoue, Hiroyoshi Yokoi, Sumio Hirata, Kazuaki Shimamoto, Kiyotaka Kugiyama, Takashi Akiba, Kunitoshi Iseki, Yoshiharu Tsubakihara, Tadashi Tomo, Tadao Akizawa. (2012) Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis. Therapeutic Apheresis and Dialysis 16:5, 387-435
CrossRef213
Yoshihisa Echida, Tetsuya Ogawa, Kuniaki Otsuka, Yoshitaka Ando, Kosaku Nitta. (2012) Serum non-high-density lipoprotein cholesterol (non-HDL-C) levels and cardiovascular mortality in chronic hemodialysis patients. Clinical and Experimental Nephrology 16:5, 767-772
CrossRef214
Dimitrios Kirmizis, Aikaterini Papagianni, Fani Dogrammatzi, Anna-Maria Belechri, Efstathios Alexopoulos, Georgios Efstratiadis, Dimitrios Memmos. (2012) The Effects of Vitamin E-Coated Membrane Dialyzer Compared to Simvastatin in Patients on Chronic Hemodialysis. Renal Failure 34:9, 1135-1139
CrossRef215
Pranav S. Garimella, Peter D. Hart, Ann O'Hare, Stephanie DeLoach, Charles A. Herzog, Alan T. Hirsch. (2012) Peripheral Artery Disease and CKD: A Focus on Peripheral Artery Disease as a Critical Component of CKD Care. American Journal of Kidney Diseases 60:4, 641-654
CrossRef216
M. K. de Bie, M. G. Koopman, A. Gaasbeek, F. W. Dekker, A. C. Maan, C. A. Swenne, R. W. Scherptong, P. F. van Dessel, A. A. Wilde, M. J. Schalij, T. J. Rabelink, J. W. Jukema. (2012) Incremental prognostic value of an abnormal baseline spatial QRS-T angle in chronic dialysis patients. Europace
CrossRef217
Suetonia C Palmer, Kannaiyan S Rabindranath, Jonathan C Craig, Paul J Roderick, Francesco Locatelli, Giovanni FM Strippoli, Giovanni FM Strippoli. High-flux versus low-flux membranes for end-stage kidney disease. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012.
CrossRef218
Darren Green, Rosica Panayotova, James P. Ritchie, Edmond O’Riordan, John McDonald. (2012) LIPID-LOWERING THERAPY IN CHRONIC KIDNEY DISEASE: IS THERE A ROLE FOR EZETIMIBE?. Journal of Renal Care 38:3, 138-146
CrossRef219
TSUYOSHI NOZUE, SHINGO YAMAMOTO, SHINICHI TOHYAMA, KAZUKI FUKUI, SHIGEO UMEZAWA, YUKO ONISHI, TOMOYUKI KUNISHIMA, KIYOSHI HIBI, MITSUYASU TERASHIMA, ICHIRO MICHISHITA, . (2012) Impacts of estimated glomerular filtration rate on coronary atherosclerosis and plaque composition before and during statin therapy in patients with normal to mild renal dysfunction: Subanalysis of the TRUTH study. Nephrology 17:7, 628-635
CrossRef220
Keiji Kono, Hideki Fujii, Kentaro Nakai, Shunsuke Goto, Junya Shite, Ken-ichi Hirata, Masafumi Fukagawa, Shinichi Nishi. (2012) Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease. Kidney International 82:3, 344-351
CrossRef221
Cristina Karohl, Paolo Raggi. (2012) Approach to Cardiovascular Disease Prevention in Patients With Chronic Kidney Disease. Current Treatment Options in Cardiovascular Medicine 14:4, 391-413
CrossRef222
Kosaku Nitta. (2012) Clinical assessment and management of dyslipidemia in patients with chronic kidney disease. Clinical and Experimental Nephrology 16:4, 522-529
CrossRef223
G. H. Heine, S. Seiler, D. Fliser. (2012) FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrology Dialysis Transplantation 27:8, 3072-3081
CrossRef224
My Svensson, Alan Jardine, Bengt Fellström, Hallvard Holdaas. (2012) Prevention of cardiovascular disease after renal transplantation. Current Opinion in Organ Transplantation 17:4, 393-400
CrossRef225
V. Bongard, J. Dallongeville, D. Arveiler, J.-B. Ruidavets, D. Cottel, A. Wagner, J. Ferrières. (2012) Estimation et caractérisation de l’insuffisance rénale chronique en France. Annales de Cardiologie et d'Angéiologie 61:4, 239-244
CrossRef226
Hirotaka Komaba, Kensuke Moriwaki, Shunsuke Goto, Shunsuke Yamada, Masatomo Taniguchi, Takatoshi Kakuta, Isao Kamae, Masafumi Fukagawa. (2012) Cost-Effectiveness of Cinacalcet Hydrochloride for Hemodialysis Patients With Severe Secondary Hyperparathyroidism in Japan. American Journal of Kidney Diseases 60:2, 262-271
CrossRef227
(2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet 380:9841, 581-590
CrossRef228
Kristen L. Jablonski, Michel Chonchol. (2012) Cardiovascular disease: Should statin therapy be expanded in patients with CKD?. Nature Reviews Nephrology 8:8, 440-441
CrossRef229
Kosmas I. Paraskevas, Anthony S. Wierzbicki, Dimitri P. Mikhailidis. (2012) Statins and noncardiac vascular disease. Current Opinion in Cardiology 27:4, 392-397
CrossRef230
Mark Jenkins, David Goldsmith. (2012) Statins and kidney disease. Current Opinion in Cardiology 27:4, 429-440
CrossRef231
K. Rahimi, W. Majoni, A. Merhi, J. Emberson. (2012) Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials. European Heart Journal 33:13, 1571-1581
CrossRef232
T. Bejan-Angoulvant, C. Bergerot, L. Juillard, A. Mezergues, E. Morelon, C. Pouteil-Noble, X. Andre-Fouet, D. Angoulvant. (2012) Myocardial microvascular disease and major adverse cardiovascular events in patients with end-stage renal disease: rationale and design of the MICROCARD study. Nephrology Dialysis Transplantation 27:7, 2886-2891
CrossRef233
Theodoros Eleftheriadis, Georgia Antoniadi, Vassilios Liakopoulos, Georgios Pissas, Spyridon Arampatzis, Theodora Sparopoulou, Grammati Galaktidou, Ioannis Stefanidis. (2012) Perilipin-1 in Hemodialyzed Patients: Association With History of Coronary Heart Disease and Lipid Profile. Therapeutic Apheresis and Dialysisno-no
CrossRef234
Karl Winkler, Michael M. Hoffmann, Vera Krane, Christiane Drechsler, Christoph Wanner, . (2012) Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis. European Journal of Clinical Investigation 42:7, 693-701
CrossRef235
Csaba P. Kovesdy, Kamyar Kalantar-Zadeh. (2012) Accuracy and Limitations of the Diagnosis of Malnutrition in Dialysis Patients. Seminars in Dialysis 25:4, 423-427
CrossRef236
Jai Prakash. (2012) Management of dyslipidemia in CKD, dialysis and renal transplant recipient. Clinical Queries: Nephrology
CrossRef237
G. M. Chertow, R. Correa-Rotter, G. A. Block, T. B. Drueke, J. Floege, W. G. Goodman, C. A. Herzog, Y. Kubo, G. M. London, K. W. Mahaffey, T.-C. Mix, S. M. Moe, D. C. Wheeler, P. S. Parfrey. (2012) Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrology Dialysis Transplantation 27:7, 2872-2879
CrossRef238
Krista L. Lentine, Salvatore P. Costa, Matthew R. Weir, John F. Robb, Lee A. Fleisher, Bertram L. Kasiske, Robert L. Carithers, Michael Ragosta, Kline Bolton, Andrew D. Auerbach, Kim A. Eagle. (2012) Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates. Journal of the American College of Cardiology
CrossRef239
Sheila A Doggrell. (2012) The ezetimibe controversy – can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?. Expert Opinion on Pharmacotherapy 13:10, 1469-1480
CrossRef240
Tanuj Bhatia, Aditya Kapoor. (2012) Chronic kidney disease and its adverse cardiovascular associations. Clinical Queries: Nephrology
CrossRef241
Eun Hui Bae, Sang Yup Lim, Kyung Hoon Cho, Joon Seok Choi, Chang Seong Kim, Jeong Woo Park, Seong Kwon Ma, Myung Ho Jeong, Soo Wan Kim. (2012) GFR and Cardiovascular Outcomes After Acute Myocardial Infarction: Results From the Korea Acute Myocardial Infarction Registry. American Journal of Kidney Diseases 59:6, 795-802
CrossRef242
Diane L. Frankenfield, Eric D. Weinhandl, Christopher A. Powers, Benjamin L. Howell, Charles A. Herzog, Wendy L. St. Peter. (2012) Utilization and Costs of Cardiovascular Disease Medications in Dialysis Patients in Medicare Part D. American Journal of Kidney Diseases 59:5, 670-681
CrossRef243
Filitsa H. Bender. (2012) Avoiding Harm in Peritoneal Dialysis Patients. Advances in Chronic Kidney Disease 19:3, 171-178
CrossRef244
Sang Yup Lim, Eun Hui Bae, Joon Seok Choi, Chang Seong Kim, Jeong Woo Park, Seong Kwon Ma, Myung Ho Jeong, Soo Wan Kim. (2012) Effect on Short- and Long-Term Major Adverse Cardiac Events of Statin Treatment in Patients With Acute Myocardial Infarction and Renal Dysfunction. The American Journal of Cardiology 109:10, 1425-1430
CrossRef245
Fran Kittell. Diabetes Management. In: Nutrition Therapy for Chronic Kidney Disease. CRC Press, 2012:197-212.
CrossRef246
Anurag Gupta. (2012) Hemodialysis in diabetics end-stage renal disease. Clinical Queries: Nephrology 1:2, 163-165
CrossRef247
Jai Prakash. (2012) Dyslipidemia in diabetic kidney disease. Clinical Queries: Nephrology 1:2, 115-118
CrossRef248
Sudeep Kumar, Nagaraja Moorthy. (2012) Pre-transplant cardiac evaluation and management of diabetic kidney disease patients before transplant. Clinical Queries: Nephrology 1:2, 151-156
CrossRef249
Mark R. Marshall, Joanna L. Dunlop. (2012) Are Dialysate Sodium Levels Too High?. Seminars in Dialysisno-no
CrossRef250
Mohit Turagam, Poonam Velagapudi. (2012) The SHARP trial: Lessons learnt; answers and more questions!. International Journal of Cardiology 156:1, e6
CrossRef251
Rüya Mutluay, Ceyla Konca Degertekin, Fatih Poyraz, Mahmut İlker Yılmaz, Cem Yücel, Murat Turfan, Yusuf Tavil, Ülver Derici, Turgay Arınsoy, Şükrü Sindel. (2012) Dialysis Type May Predict Carotid Intima Media Thickness and Plaque Presence in End-Stage Renal Disease Patients. Advances in Therapy
CrossRef252
Gunnar H. Heine, Alberto Ortiz, Ziad A. Massy, Bengt Lindholm, Andrzej Wiecek, Alberto Martínez-Castelao, Adrian Covic, David Goldsmith, Gültekin Süleymanlar, Gérard M. London, Gianfranco Parati, Rosa Sicari, Carmine Zoccali, Danilo Fliser. (2012) Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nature Reviews Nephrology 8:6, 362-369
CrossRef253
Michelle M. O’Shaughnessy, David W. Lappin, Donal N. Reddan. (2012) Sudden Cardiac Death in Dialysis: Do Current Guidelines for Implantable Cardioverter Defibrillator Therapy Apply to Patients with End-stage Kidney Disease?. Seminars in Dialysisno-no
CrossRef254
W. Kleophas. (2012) Individuelle Therapieziele bei Diabetes und Dialyse. Der Diabetologe 8:2, 117-122
CrossRef255
Claudine T. Jurkovitz, Daniel Elliott, Suying Li, Georges Saab, Andrew S. Bomback, Keith C. Norris, Shu-Cheng Chen, Peter A. McCullough, Adam T. Whaley-Connell. (2012) Physician Utilization, Risk-Factor Control, and CKD Progression Among Participants in the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases 59:3, S24-S33
CrossRef256
Murray Epstein, Nosratola D. Vaziri. (2012) Statins in the management of dyslipidemia associated with chronic kidney disease. Nature Reviews Nephrology 8:4, 214-223
CrossRef257
Ashish Upadhyay, Daniel E. Weiner. (2012) Lipid-Lowering Therapy in Individuals With CKD: Lessons Learned From SHARP. American Journal of Kidney Diseases 59:2, 170-173
CrossRef258
Albert Power, Kakit Chan, Seema K. Singh, David Taube, Neill Duncan. (2012) Appraising Stroke Risk in Maintenance Hemodialysis Patients: A Large Single-Center Cohort Study. American Journal of Kidney Diseases 59:2, 249-257
CrossRef259
(2012) Journal Club. Kidney International 81:4, 334-335
CrossRef260
Jeff S Coombes, Robert G Fassett. (2012) Antioxidant therapy in hemodialysis patients: a systematic review. Kidney International 81:3, 233-246
CrossRef261
M.D. Alscher, U. Sechtem. (2012) Kardiorenales Syndrom. Der Internist
CrossRef262
Luis Rodríguez Padial, Francisco Ridocci Soriano. (2012) Eficacia bioquímica y beneficio clínico de la doble inhibición con ezetimiba y simvastatina. Revista Española de Cardiología Suplementos 12, 2-7
CrossRef263
Paul M Ridker, Peter Libby. Risk Markers for Atherothrombotic Disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier, 2012:914-934.
CrossRef264
Chien-Te Lee, Yueh-Ting Lee, Hwee-Yeong Ng, Terry Ting-Yu Chiou, Cheng-I Cheng, Chien-Chun Kuo, Chien-Hsing Wu, Po-Jui Chi, Wen-Chin Lee. (2012) Lack of modulatory effect of simvastatin on indoxyl sulfate-induced activation of cultured endothelial cells. Life Sciences 90:1-2, 47-53
CrossRef265
Hiskias G Keizer. (2012) The “Mevalonate hypothesis”: a cholesterol-independent alternative for the etiology of atherosclerosis. Lipids in Health and Disease 11:1, 149
CrossRef266
David A. Goldfarb, Emilio D. Poggio. Etiology, Pathogenesis, and Management of Renal Failure. In: Campbell-Walsh Urology. Elsevier, 2012:1193-1225.e6.
CrossRef267
Jane Y. Yeun, Daniel B. Ornt, Thomas A. Depner. Hemodialysis. In: Brenner and Rector's The Kidney. Elsevier, 2012:2294-2346.
CrossRef268
Patrick H. Pun, John P. Middleton. (2012) Sudden Cardiac Death in Hemodialysis Patients: A Comprehensive Care Approach to Reduce Risk. Blood Purification 33:1-3, 183-189
CrossRef269
Yuri Tanaka, Nobuhiko Joki, Hiroki Hase, Masaki Iwasaki, Masato Ikeda, Ryoichi Ando, Toshio Shinoda, Daijo Inaguma, Toshifumi Sakaguchi, Yasuhiro Komatsu, Fumihiko Koiwa, Toshihiko Yamaka, Takashi Shigematsu. (2012) Effect of erythropoietin-stimulating agent on uremic inflammation. Journal of Inflammation 9:1, 17
CrossRef270
Jae-Geun Lee, Sung Joo Koh, So Yeon Yoo, Jung Re Yu, Sang Ah Lee, Gwanpyo Koh, Daeho Lee. (2012) Characteristics of Subjects with Very Low Serum Low-Density Lipoprotein Cholesterol and the Risk for Intracerebral Hemorrhage. The Korean Journal of Internal Medicine 27:3, 317
CrossRef271
Yoshiki Nishizawa, Hidenori Koyama, Masaaki Inaba. (2012) AGEs and Cardiovascular Diseases in Patients With End-Stage Renal Diseases. Journal of Renal Nutrition 22:1, 128-133
CrossRef272
P.P. Toth. (2012) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Yearbook of Endocrinology 2012, 68-71
CrossRef273
Chun Soo Lim. (2012) Medical therapy in patients with chronic kidney disease. Journal of Korean Medical Association 55:4, 381
CrossRef274
David C. Wheeler, Richard Haynes, Martin J. Landray, Colin Baigent. Cardiovascular Aspects of Kidney Disease. In: Brenner and Rector's The Kidney. Elsevier, 2012:2059-2080.
CrossRef275
Khurram Nasir, Leslee J. Shaw, Matthew J. Budoff, Paul M. Ridker, Jessica M. Peña. (2012) Coronary Artery Calcium Scanning Should be Used for Primary Prevention. JACC: Cardiovascular Imaging 5:1, 111-118
CrossRef276
Ron Wald, Andrew T Yan, Jeffrey Perl, Depeng Jiang, M Sandra Donnelly, Howard Leong-Poi, Philip A McFarlane, Jordan J Weinstein, Marc B Goldstein. (2012) Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysis. BMC Nephrology 13:1, 3
CrossRef277
Eugene O. Apostolov, Alexei G. Basnakian, Ercan Ok, Sudhir V. Shah. (2012) Carbamylated Low-Density Lipoprotein: Nontraditional Risk Factor for Cardiovascular Events in Patients With Chronic Kidney Disease. Journal of Renal Nutrition 22:1, 134-138
CrossRef278
Rory F. McQuillan, Christopher T. Chan. (2012) The Intuitive Case for β-blockers in Patients with ESRD. Seminars in Dialysis 25:1, 15-21
CrossRef279
Csaba P. Kovesdy, Kamyar Kalantar-Zadeh. (2012) Observational Studies Versus Randomized Controlled Trials: Avenues to Causal Inference in Nephrology. Advances in Chronic Kidney Disease 19:1, 11-18
CrossRef280
Damian G. Fogarty, Maarten W. Taal. A Stepped Care Approach to the Management of Chronic Kidney Disease. In: Brenner and Rector's The Kidney. Elsevier, 2012:2205-2239.
CrossRef281
Jacques Genest, Peter Libby. Lipoprotein Disorders and Cardiovascular Disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier, 2012:975-995.
CrossRef282
Manjula Kurella Tamura. Neurologic Aspects of Kidney Disease. In: Brenner and Rector's The Kidney. Elsevier, 2012:2138-2155.
CrossRef283
James B. Wetmore, Jonathan D. Mahnken, Sally K. Rigler, Edward F. Ellerbeck, Purna Mukhopadhyay, Qingjiang Hou, Theresa I. Shireman. (2012) Association of Race with Cumulative Exposure to Statins in Dialysis. American Journal of Nephrology 36:1, 90-96
CrossRef284
Cassandra D. Benge, Brandon Markley, Michael Shawn McFarland. (2012) Role of Aggressive LDL Reduction in Patients With Coronary Heart Disease. Southern Medical Journal 105:1, 48-55
CrossRef285
Adriana Izquierdo, Gema Medina-Gómez. (2012) Papel de la lipotoxicidad en el desarrollo de la lesión renal en el síndrome metabólico y el envejecimiento. Diálisis y Trasplante
CrossRef286
Andrew A. House. (2012) Cardio-Renal Syndrome Type 4: Epidemiology, Pathophysiology and Treatment. Seminars in Nephrology 32:1, 40-48
CrossRef287
Yongxia Wu, Yan Wang, Chuankai An, Zhe Dong, Hui Liu, Yun Zhang, Mingxiang Zhang, Fengshuang An. (2012) Effects of Rosuvastatin and Atorvastatin on Renal Function. Circulation Journal 76:5, 1259-1266
CrossRef288
Joshua A. Samuels, Donald A. Molony. (2012) Randomized Controlled Trials in Nephrology: State of the Evidence and Critiquing the Evidence. Advances in Chronic Kidney Disease 19:1, 40-46
CrossRef289
Chi-yuan Hsu. Epidemiology of Kidney Disease. In: Brenner and Rector's The Kidney. Elsevier, 2012:728-741.
CrossRef290
Alberto Cordero, Iñaki Lekuona, Enrique Galve, Pilar Mazón. (2012) Novedades en hipertensión arterial y diabetes mellitus. Revista Española de Cardiología 65, 12-23
CrossRef291
San Jung, Seok-Beom Kwon, Sung-Hee Hwang, Jung Woo Noh, Young-Ki Lee. (2012) Ischemic Stroke among the Patients with End-Stage Renal Disease Who Were Undergoing Maintenance Dialysis. Yonsei Medical Journal 53:5, 894
CrossRef292
Andrej Rasch, Matthias Perleth, Gero Langer, Joerg J. Meerpohl, Gerald Gartlehner, Angela Kaminski-Hartenthaler, Holger J. Schünemann. (2012) GRADE Leitlinien: 8. Einschätzung der Qualität der Evidenz – Indirektheit. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 106:10, 745-753
CrossRef293
Tetsuo Shoji, Takaaki Abe, Hiroshi Matsuo, Genshi Egusa, Yoshimitsu Yamasaki, Naoki Kashihara, Kohji Shirai, Atsunori Kashiwagi. (2012) Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis. Journal of Atherosclerosis and Thrombosis 19:4, 299-315
CrossRef294
Katherine Wesseling Perry, Isidro B. Salusky. Chronic Kidney Disease Mineral and Bone Disorder. In: Pediatric Bone. Elsevier, 2012:795-820.
CrossRef295
Peter A. McCullough. Interface Between Renal Disease and Cardiovascular Illness. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier, 2012:1934-1948.
CrossRef296
M. Vircoulon, C. Combe. (2012) Conséquences cardiaques de l’insuffisance rénale chronique. EMC - Néphrologie 9:1, 1-14
CrossRef297
Michael P. Delaney, Christopher P. Price, Edmund J. Lamb. Kidney Disease. In: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier, 2012:1523-1607.
CrossRef298
Iñaki Lekuona Goya, Miren Morillas Bueno. (2012) Tratamiento de las dislipemias en situaciones especiales. Revista Española de Cardiología Suplementos 12, 26-32
CrossRef299
Shigeru Otsubo, Yasuko Yabuki, Miwa Ishihara, Masayo Takasaki, Syuitsu Ueda, Hisayuki Sugimoto, Yuriko Otsubo, Kosaku Nitta. (2012) Effect of cilostazol on lipid profile in hemodialysis patients. Nihon Toseki Igakkai Zasshi 45:7, 567-570
CrossRef300
Anabela Malho Guedes, Pedro Leão Neves. (2012) Statins for Renal Patients: A Fiddler on the Roof?. International Journal of Nephrology 2012, 1-7
CrossRef301
Yehuda Handelsman, Vivian Fonseca, Julio Rosenstock. (2012) Is combination therapy an effective way of reaching lipid goals in Type 2 diabetes mellitus?. Expert Review of Clinical Pharmacology 5:1, 43-54
CrossRef302
Andrew S Levey, Josef Coresh. (2012) Chronic kidney disease. The Lancet 379:9811, 165-180
CrossRef303
Navdeep Tangri, Shani Shastri, Hocine Tighiouart, Gerald J. Beck, Alfred K. Cheung, Garabed Eknoyan, Mark J. Sarnak. (2011) β-Blockers for Prevention of Sudden Cardiac Death in Patients on Hemodialysis: A Propensity Score Analysis of the HEMO Study. American Journal of Kidney Diseases 58:6, 939-945
CrossRef304
J. E. Lee, K.-H. Oh, K. H. Choi, S. B. Kim, Y.-S. Kim, J.-Y. Do, Y.-L. Kim, D. J. Kim. (2011) Statin therapy is associated with improved survival in incident peritoneal dialysis patients: propensity-matched comparison. Nephrology Dialysis Transplantation 26:12, 4090-4094
CrossRef305
Gordon H. Guyatt, Andrew D. Oxman, Regina Kunz, James Woodcock, Jan Brozek, Mark Helfand, Pablo Alonso-Coello, Yngve Falck-Ytter, Roman Jaeschke, Gunn Vist, Elie A. Akl, Piet N. Post, Susan Norris, Joerg Meerpohl, Vijay K. Shukla, Mona Nasser, Holger J. Schünemann. (2011) GRADE guidelines: 8. Rating the quality of evidence—indirectness. Journal of Clinical Epidemiology 64:12, 1303-1310
CrossRef306
Emma Burnhope, Darren Green, Philip A Kalra, Paul R Kalra. (2011) Current developments in lipid-lowering therapy for the patient with chronic kidney disease. Clinical Lipidology 6:6, 693-702
CrossRef307
Michael M. Hoffmann, Winfried März, Bernd Genser, Christiane Drechsler, Christoph Wanner. (2011) Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: The 4D study. Atherosclerosis 219:2, 659-662
CrossRef308
C.-C. Wu, H.-H. Liou, P.-F. Su, M.-Y. Chang, H.-H. Wang, M.-J. Chen, S.-Y. Hung. (2011) Abdominal obesity is the most significant metabolic syndrome component predictive of cardiovascular events in chronic hemodialysis patients. Nephrology Dialysis Transplantation 26:11, 3689-3695
CrossRef309
Tetsu Miyamoto, Juan J. Carrero, Peter Stenvinkel. (2011) Inflammation as a risk factor and target for therapy in chronic kidney disease. Current Opinion in Nephrology and Hypertension 20:6, 662-668
CrossRef310
Alberto Ortiz, Ziad A. Massy, Danilo Fliser, Bengt Lindholm, Andrzej Wiecek, Alberto Martínez-Castelao, Adrian Covic, David Goldsmith, Gültekin Süleymanlar, Gérard M. London, Carmine Zoccali. (2011) Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nature Reviews Nephrology 8:3, 141-150
CrossRef311
Kalani L. Raphael, Alfred K. Cheung. (2011) Implications of the Frequent Hemodialysis Network-Daily Trial. Seminars in Dialysisno-no
CrossRef312
Luigi Padeletti, Lisa Innocenti, Alessandro Paoletti Perini, Edoardo Gronda. (2011) Arrhythmic complication in cardiorenal syndrome. Heart Failure Reviews 16:6, 569-573
CrossRef313
Eugene P. Rhee, Ravi Thadhani. (2011) New insights into uremia-induced alterations in metabolic pathways. Current Opinion in Nephrology and Hypertension 20:6, 593-598
CrossRef314
Kevin E Chan, T Alp Ikizler, Jorge L Gamboa, Chang Yu, Raymond M Hakim, Nancy J Brown. (2011) Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney International 80:9, 978-985
CrossRef315
S. H. Han, E. W. Kang, S.-J. Yoon, H. S. Yoon, H. C. Lee, T. H. Yoo, K. H. Choi, D.-S. Han, S.-W. Kang. (2011) Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis. Nephrology Dialysis Transplantation 26:11, 3722-3728
CrossRef316
Stephen J Nicholls, Kiyoko Uno, Yu Kataoka. (2011) Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. Expert Review of Cardiovascular Therapy 9:11, 1383-1390
CrossRef317
S Susan Hedayati, Venkata Yalamanchili, Fredric O Finkelstein. (2011) A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. Kidney International
CrossRef318
Juliana C.N. Chan, Siew Pheng Chan, Chaicharn Deerochanawong, Ruby T. Go, Kok-Onn Lee, Ronald Ching-Wan Ma, Chang-Yu Pan, Wayne H-H. Sheu, Philip Barter. (2011) Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don’t know. Diabetes Research and Clinical Practice 94:1, 1-13
CrossRef319
Brett W. Stephens, Aleksandra M. De Golovine, Risheng Xu, Donald A. Molony. (2011) How the latest evidence from clinical research informs patient care. Dialysis & Transplantation 40:10, 467-470
CrossRef320
M. Chmielewski, M. Verduijn, C. Drechsler, B. Lindholm, P. Stenvinkel, B. Rutkowski, E. W. Boeschoten, R. T. Krediet, F. W. Dekker. (2011) Low cholesterol in dialysis patients--causal factor for mortality or an effect of confounding?. Nephrology Dialysis Transplantation 26:10, 3325-3331
CrossRef321
Joseph Menzin, Lisa M. Lines, Daniel E. Weiner, Peter J. Neumann, Christine Nichols, Lauren Rodriguez, Irene Agodoa, Tracy Mayne. (2011) A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease. PharmacoEconomics 29:10, 839-861
CrossRef322
Christiane Drechsler, Diana C. Grootendorst, Stefan Pilz, Andreas Tomaschitz, Vera Krane, Friedo Dekker, Winfried März, Eberhard Ritz, Christoph Wanner. (2011) Wasting and Sudden Cardiac Death in Hemodialysis Patients: A Post Hoc Analysis of 4D (Die Deutsche Diabetes Dialyse Studie). American Journal of Kidney Diseases 58:4, 599-607
CrossRef323
Stuart M. Sprague. (2011) Impact of CKD on Coronary Artery Calcifications. American Journal of Kidney Diseases 58:4, 503-505
CrossRef324
(2011) Journal Club. Kidney International 80:7, 690-691
CrossRef325
Hitinder S. Gurm, Joel M. Gore, Frederick A. Anderson, Allison Wyman, Keith A.A. Fox, P. Gabriel Steg, Kim A. Eagle. (2011) Comparison of Acute Coronary Syndrome in Patients Receiving Versus Not Receiving Chronic Dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). The American Journal of Cardiology
CrossRef326
Jaime García de Tena, Laura Abejón, David Bernal, Estefanía Águila, Manuel Rodríguez-Zapata. (2011) Benefits of lowering cholesterol in chronic kidney disease. The Lancet 378:9800, 1376
CrossRef327
Jeppe Hagstrup Christensen, Erik Berg Schmidt, My Svensson. (2011) n-3 polyunsaturated fatty acids, lipids and lipoproteins in end-stage renal disease. Clinical Lipidology 6:5, 563-576
CrossRef328
M. Alberton, P. Wu, E. Druyts, M. Briel, E. J. Mills. (2011) Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM
CrossRef329
Suetonia C. Palmer, Giovanni F. M. Strippoli. (2011) Cardiovascular diseases: Lipid-lowering in CKD—at the SHARP end of the evidence?. Nature Reviews Nephrology 7:11, 609-611
CrossRef330
A. S. Wierzbicki. (2011) The ezetimibe Jonah: the trials and tribulations of an unlucky drug. International Journal of Clinical Practiceno-no
CrossRef331
Inger Karin Lægreid, Knut Aasarød, Marit Jordhøy. (2011) End-stage renal disease and recruitment to randomized trials: Why is it so difficult? Results from a survey among Norwegian nephrologists. Scandinavian Journal of Urology and Nephrology 45:4, 285-289
CrossRef332
Sundararaman Swaminathan, Sudhir V Shah. (2011) Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease. Kidney International 80:5, 453-463
CrossRef333
Charles A Herzog, Richard W Asinger, Alan K Berger, David M Charytan, Javier Díez, Robert G Hart, Kai-Uwe Eckardt, Bertram L Kasiske, Peter A McCullough, Rod S Passman, Stephanie S DeLoach, Patrick H Pun, Eberhard Ritz. (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International 80:6, 572-586
CrossRef334
Tara I. Chang, Glenn M. Chertow. (2011) Chronic Kidney Disease and Cardiovascular Therapeutics. Journal of the American College of Cardiology 58:11, 1162-1164
CrossRef335
Sunil V. Badve, Matthew A. Roberts, Carmel M. Hawley, Alan Cass, Amit X. Garg, Henry Krum, Andrew Tonkin, Vlado Perkovic. (2011) Effects of Beta-Adrenergic Antagonists in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology 58:11, 1152-1161
CrossRef336
G.B. John Mancini, Steven Baker, Jean Bergeron, David Fitchett, Jiri Frohlich, Jacques Genest, Milan Gupta, Robert A. Hegele, Dominic Ng, Janet Pope. (2011) Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference. Canadian Journal of Cardiology 27:5, 635-662
CrossRef337
A. Kitchlu, K. Clemens, T. Gomes, D. G. Hackam, D. N. Juurlink, M. Mamdani, M. Manno, M. J. Oliver, R. R. Quinn, R. S. Suri, R. Wald, A. T. Yan, A. X. Garg. (2011) Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada. Nephrology Dialysis Transplantation
CrossRef338
P.-O. Attman, O. Samuelsson, P. Alaupovic. (2011) The effect of decreasing renal function on lipoprotein profiles. Nephrology Dialysis Transplantation 26:8, 2572-2575
CrossRef339
Fabio Fabbian, Alfredo Giorgi, Marco Pala, Ruana Tiseo, Roberto Manfredini, Francesco Portaluppi. (2011) Evidence-based statin prescription for cardiovascular protection in renal impairment. Clinical and Experimental Nephrology 15:4, 456-463
CrossRef340
Keith R. Solomon, Michael R. Freeman. (2011) The Complex Interplay Between Cholesterol and Prostate Malignancy. Urologic Clinics of North America 38:3, 243-259
CrossRef341
Scott E. Liebman, Steven P. Lamontagne, Li-Shan Huang, Susan Messing, David A. Bushinsky. (2011) Smoking in Dialysis Patients: A Systematic Review and Meta-analysis of Mortality and Cardiovascular Morbidity. American Journal of Kidney Diseases 58:2, 257-265
CrossRef342
Vinod K. Bansal. (2011) Sudden Cardiac Death & Dialysis: Target Risk Factors. Nephrology Times 4:8, 3-5
CrossRef343
Sergio Martinez-Hervas, Rafael Carmena, Juan F Ascaso. (2011) Significance of LDL-C lowering therapy in diabetic patients. Clinical Lipidology 6:4, 389-399
CrossRef344
C. Drechsler, A. Meinitzer, S. Pilz, V. Krane, A. Tomaschitz, E. Ritz, W. Marz, C. Wanner. (2011) Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients. European Journal of Heart Failure 13:8, 852-859
CrossRef345
, , Z. Reiner, A. L. Catapano, G. De Backer, I. Graham, M.-R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P. P. Filardi, G. Riccardi, R. F. Storey, D. Wood, , J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, R. Hobbs, A. Hoes, P. Kearney, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, D. Reviewers:, C. Funck-Brentano, D. Poldermans, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G. F. Guida, S. Gulec, Y. Henkin, K. Huber, Y. A. Kesaniemi, J. Lekakis, A. J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, M. E. Wittekoek, J. L. Zamorano. (2011) ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 32:14, 1769-1818
CrossRef346
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217, 1-44
CrossRef347
Mehmet KOC, Cengiz DOGAN, Turgay ARINSOY, Zeki TONBUL, Deniz AYLI, Mustafa CIRIT, Mehmet Sukru SEVER, Mehmet Emin YILMAZ, Abdulkadir UNSAL, Gultekin SULEYMANLAR, Ercan OK, Ali BASCI, Alaatin YILDIZ. (2011) Statin use is associated with lower inflammation and erythropoietin responsiveness index in hemodialysis patients. Hemodialysis International 15:3, 366-373
CrossRef348
T. Miyamoto, A. Rashid Qureshi, T. Yamamoto, A. Nakashima, B. Lindholm, P. Stenvinkel, A. Alvestrand, J. Axelsson. (2011) Postprandial metabolic response to a fat- and carbohydrate-rich meal in patients with chronic kidney disease. Nephrology Dialysis Transplantation 26:7, 2231-2237
CrossRef349
Matthew A. Roberts, Kevan R. Polkinghorne, Stephen P. McDonald, Francesco L. Ierino. (2011) Secular Trends in Cardiovascular Mortality Rates of Patients Receiving Dialysis Compared With the General Population. American Journal of Kidney Diseases 58:1, 64-72
CrossRef350
Mark J. Sarnak, Robert N. Foley. (2011) Cardiovascular Mortality in the General Population Versus Dialysis: A Glass Half Full or Empty?. American Journal of Kidney Diseases 58:1, 4-6
CrossRef351
W. Virgil Brown, George Bakris, Edgar Lerma, Glenn Chertow. (2011) Assessment and management of vascular disease risk in patients with chronic kidney disease. Journal of Clinical Lipidology 5:4, 251-260
CrossRef352
Charlie Tomson, Pippa Bailey. (2011) Management of chronic kidney disease. Medicine 39:7, 407-413
CrossRef353
S. Agewall. (2011) The large clinical statin trials. International Journal of Cardiology 150:1, 108-111
CrossRef354
Patrick Mark, Alan Jardine. (2011) Cardiovascular complications of chronic renal disease. Medicine 39:7, 421-424
CrossRef355
DJ Blom. (2011) Secondary dyslipidaemia. South African Family Practice 53:4, 317-323
CrossRef356
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217:1, 3-46
CrossRef357
Adeera Levin, Paul E. Stevens. (2011) Early detection of CKD: the benefits, limitations and effects on prognosis. Nature Reviews Nephrology 7:8, 446-457
CrossRef358
Paolo C. Colombo, Anjali Ganda, Jeffrey Lin, Duygu Onat, Ante Harxhi, Julia E. Iyasere, Nir Uriel, Gad Cotter. (2011) Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Failure Reviews
CrossRef359
Debasish Banerjee, Alejandro Recio-Mayoral, Nihil Chitalia, Juan-Carlos Kaski. (2011) Insulin Resistance, Inflammation, and Vascular Disease in Nondiabetic Predialysis Chronic Kidney Disease Patients. Clinical Cardiology 34:6, 360-365
CrossRef360
Kitty J Jager, Bengt Lindholm, David Goldsmith, Danilo Fliser, Andrzej Wiecek, Gultekin Suleymanlar, Alberto Ortiz, Ziad Massy, Alberto Martinez-Castelao, Rajiv Agarwal, Peter J Blankestijn, Adrian Covic, Gerard London, Carmine Zoccali, Friedo W Dekker. (2011) Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?. Kidney International Supplements 1:1, 21-23
CrossRef361
Angela Yee-Moon WANG. (2011) Cardiovascular risk in diabetic end-stage renal disease patients. Journal of Diabetes 3:2, 119-131
CrossRef362
Michel Chonchol, Jessica Kendrick, Giovanni Targher. (2011) Extra-skeletal effects of vitamin D deficiency in chronic kidney disease. Annals of Medicine 43:4, 273-282
CrossRef363
Darren Green, Paul R. Roberts, David I. New, Philip A. Kalra. (2011) Sudden Cardiac Death in Hemodialysis Patients: An In-Depth Review. American Journal of Kidney Diseases 57:6, 921-929
CrossRef364
Werner Ribitsch, Alexander R Rosenkranz. (2011) Prehypertension and prechronic kidney disease: fact or fiction?. Expert Review of Cardiovascular Therapy 9:6, 651-653
CrossRef365
Kathryn K Stevens, Alan G Jardine. (2011) SHARP: a stab in the right direction in chronic kidney disease. The Lancet 377:9784, 2153-2154
CrossRef366
Colin Baigent, Martin J Landray, Christina Reith, Jonathan Emberson, David C Wheeler, Charles Tomson, Christoph Wanner, Vera Krane, Alan Cass, Jonathan Craig, Bruce Neal, Lixin Jiang, Lai Seong Hooi, Adeera Levin, Lawrence Agodoa, Mike Gaziano, Bertram Kasiske, Robert Walker, Ziad A Massy, Bo Feldt-Rasmussen, Udom Krairittichai, Vuddidhej Ophascharoensuk, Bengt Fellström, Hallvard Holdaas, Vladimir Tesar, Andrzej Wiecek, Diederick Grobbee, Dick de Zeeuw, Carola Grönhagen-Riska, Tanaji Dasgupta, David Lewis, William Herrington, Marion Mafham, William Majoni, Karl Wallendszus, Richard Grimm, Terje Pedersen, Jonathan Tobert, Jane Armitage, Alex Baxter, Christopher Bray, Yiping Chen, Zhengming Chen, Michael Hill, Carol Knott, Sarah Parish, David Simpson, Peter Sleight, Alan Young, Rory Collins. (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet 377:9784, 2181-2192
CrossRef367
Hisato Takagi, Takuya Umemoto. (2011) Reduction in coronary heart disease with atorvastatin independent of low-density lipoprotein cholesterol. International Journal of Cardiology 149:2, 267-269
CrossRef368
Kamyar Kalantar-Zadeh, Noël J. Cano, Klemens Budde, Charles Chazot, Csaba P. Kovesdy, Robert H. Mak, Rajnish Mehrotra, Dominic S. Raj, Ashwini R. Sehgal, Peter Stenvinkel, T. Alp Ikizler. (2011) Diets and enteral supplements for improving outcomes in chronic kidney disease. Nature Reviews Nephrology 7:7, 369-384
CrossRef369
Vera Krane, Christoph Wanner. (2011) Statins, inflammation and kidney disease. Nature Reviews Nephrology 7:7, 385-397
CrossRef370
K. M. Espe, J. Raila, A. Henze, V. Krane, F. J. Schweigert, B. Hocher, C. Wanner, C. Drechsler, . (2011) Impact of vitamin A on clinical outcomes in haemodialysis patients. Nephrology Dialysis Transplantation
CrossRef371
Bengt C Fellström. (2011) Cardioprotective role of statins in chronic kidney disease: do we have the answer?. Kidney International 79:9, 931-932
CrossRef372
Charles A. Herzog. (2011) Is There Something Special About Coronary Artery Disease in Dialysis Patients?. Seminars in Dialysis 24:3, 280-282
CrossRef373
W. Kleophas. (2011) Diabetes und Dialyse. Der Diabetologe 7:3, 201-212
CrossRef374
Paolo Cravedi, Giuseppe Remuzzi, Piero Ruggenenti. (2011) Targeting the Renin Angiotensin System in Dialysis Patients. Seminars in Dialysis 24:3, 290-297
CrossRef375
John P. Middleton. (2011) Predisposition to Arrhythmias: Electrolytes, Uremic Fibrosis, Other Factors. Seminars in Dialysis 24:3, 287-289
CrossRef376
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef377
D. John Betteridge. (2011) Lipid control in patients with diabetes mellitus. Nature Reviews Cardiology 8:5, 278-290
CrossRef378
Robert N. Foley. (2011) A Perfect Cardiomyopathic Storm. Seminars in Dialysis 24:3, 278-279
CrossRef379
Karolina Szummer, Pia Lundman, Stefan H Jacobson, Staffan Schön, Johan Lindbäck, Ulf Stenestrand, Lars Wallentin, Tomas Jernberg. (2011) Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. Kidney International 79:9, 997-1004
CrossRef380
Noémie Jourde-Chiche, Laetitia Dou, Claire Cerini, Françoise Dignat-George, Philippe Brunet. (2011) Vascular Incompetence in Dialysis Patients-Protein-Bound Uremic Toxins and Endothelial Dysfunction. Seminars in Dialysis 24:3, 327-337
CrossRef381
Thomas D. Nolin, Vikram Arya, Daniel S. Sitar, Marc Pfister. (2011) Optimizing Drug Development and Use in Patients With Kidney Disease. The Journal of Clinical Pharmacology 51:5, 628-630
CrossRef382
Erico Segovia. (2011) Síndrome cardio-renal: diagnóstico y tratamiento. Medwave
CrossRef383
Kjell Tullus. (2011) Dyslipidemia in children with CKD: should we treat with statins?. Pediatric Nephrology
CrossRef384
J. J. G. De Lima, L. H. W. Gowdak, F. J. de Paula, R. L. Arantes, L. A. M. Cesar, J. A. F. Ramires, E. M. Krieger. (2011) Unexplained sudden death in patients on the waiting list for renal transplantation. Nephrology Dialysis Transplantation 26:4, 1392-1396
CrossRef385
Maurizio Postorino, Carmen Marino, Giovanni Tripepi, Carmine Zoccali. (2011) Abdominal obesity modifies the risk of hypertriglyceridemia for all-cause and cardiovascular mortality in hemodialysis patients. Kidney International 79:7, 765-772
CrossRef386
A. L. M. de Francisco. (2011) Reply. Nephrology Dialysis Transplantation 26:4, 1443-1444
CrossRef387
Ali Olyaei, Edgar V. Lerma. (2011) Three strikes and statins out: A case against use of statins in dialysis patients for primary prevention. Dialysis & Transplantation 40:4, 148-151
CrossRef388
Albert POWER, Kakit CHAN, Ali HAYDAR, Mohamed HAMADY, Tom CAIRNS, David TAUBE, Neill DUNCAN. (2011) Intracranial arterial calcification is highly prevalent in hemodialysis patients but does not associate with acute ischemic stroke. Hemodialysis International 15:2, 256-263
CrossRef389
J. M. Lorenzen, S. David, A. Richter, K. de Groot, J. T. Kielstein, H. Haller, T. Thum, D. Fliser. (2011) TLR-4+ peripheral blood monocytes and cardiovascular events in patients with chronic kidney disease--a prospective follow-up study. Nephrology Dialysis Transplantation 26:4, 1421-1424
CrossRef390
D. S. H. Bell, F. Al Badarin, J. H. O’Keefe. (2011) Therapies for diabetic dyslipidaemia. Diabetes, Obesity and Metabolism 13:4, 313-325
CrossRef391
Vimal Ramjee, Terry A Jacobson. (2011) Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old. Clinical Lipidology 6:2, 131-136
CrossRef392
Harry R. Davis, Robert S. Lowe, David R. Neff. (2011) Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis 215:2, 266-278
CrossRef393
Sankar D Navaneethan, Jörgen Hegbrant, Giovanni FM Strippoli. (2011) Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Current Opinion in Nephrology and Hypertension 20:2, 146-152
CrossRef394
S. Bernardi, R. Candido, B. Toffoli, R. Carretta, B. Fabris. (2011) Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure. Nephrology Dialysis Transplantation 26:3, 832-838
CrossRef395
Pauline A. Swift, Peter A. Andrews. (2011) Medications to Reduce Cardiovascular Risk After Kidney Transplantation. Transplantation 91:5, 492-493
CrossRef396
Kosmas I. Paraskevas, Sotirios A. Koupidis, Alexandros A. Tzovaras, Achilleas Nikolaou, Dimitri P. Mikhailidis. (2011) Screening for peripheral artery disease in dialysis patients: an opportunity for early disease detection and timely initiation of appropriate therapeutic measures. International Urology and Nephrology 43:1, 143-145
CrossRef397
Pamela M. Katz, Aurora A. Mendelsohn, Shaun G. Goodman, Anatoly Langer, Hwee Teoh, Lawrence A. Leiter. (2011) Use of a Treatment Optimization Algorithm Involving Statin-Ezetimibe Combination Aids in Achievement of Guideline-Based Low-Density Lipoprotein Targets in Patients With Dyslipidemia at High Vascular Risk Guideline-Based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC). Canadian Journal of Cardiology 27:2, 138-145
CrossRef398
Lynda Szczech. (2011) CKD and CVD: No Need for a Turf War. Nephrology Times 4:3, 4-5
CrossRef399
P. Gourdy. (2011) Diabète de type 2 et insuffisance rénale : une situation à haut risque cardiovasculaire !. Médecine des Maladies Métaboliques 5, S31-S36
CrossRef400
Ariel Brautbar, Christie M. Ballantyne. (2011) Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nature Reviews Cardiology
CrossRef401
My Svensson, Kaj Anker Jørgensen, Jeppe Hagstrup Christensen. (2011) Omega-3 Polyunsaturated Fatty Acids and Clinical Trials. American Journal of Kidney Diseases 57:2, 352
CrossRef402
K. Amann, K. Benz. (2011) Statins--beyond lipids in CKD. Nephrology Dialysis Transplantation 26:2, 407-410
CrossRef403
E. J. Mills, P. WU, G. Chong, I. Ghement, S. Singh, E. A. Akl, O. Eyawo, G. Guyatt, O. Berwanger, M. Briel. (2011) Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJM 104:2, 109-124
CrossRef404
Abhishek Deshmukh, Jawahar L. Mehta. (2011) Statins and Renal Disease: Friend or Foe?. Current Atherosclerosis Reports 13:1, 57-63
CrossRef405
Jeffrey S. Berns. (2011) A SHARP Study, But With Blunted Conclusions : THE SHARP Study. Seminars in Dialysis 24:6, 684
CrossRef406
(2011) Nihon Toseki Igakkai Zasshi 44:5, 347-352
CrossRef407
Arthur Allignol, Martin Schumacher, Christoph Wanner, Christiane Drechsler, Jan Beyersmann. (2011) Understanding competing risks: a simulation point of view. BMC Medical Research Methodology 11:1, 86
CrossRef408
Hans-Henrik Parving, Michael Mauer, Paola Fioretto, Peter Rossing, Eberhard Ritz. Diabetic Nephropathy. In: Brenner and Rector's The Kidney. Elsevier, 2011:1411-1454.
CrossRef409
Timothy W. Meyer, Thomas H. Hostetter. The Pathophysiology of Uremia. In: Brenner and Rector's The Kidney. Elsevier, 2011:2000-2020.
CrossRef410
(2011) Nihon Toseki Igakkai Zasshi 44:5, 375-382
CrossRef411
Clay F. Semenkovich, Anne C. Goldberg, Ira J. Goldberg. Disorders of Lipid Metabolism. In: Williams Textbook of Endocrinology. Elsevier, 2011:1633-1674.
CrossRef412
Tetsuo Shoji. (2011) Nihon Toseki Igakkai Zasshi 44:12, 1136-1138
CrossRef413
Mark S. MacGregor, Maarten W. Taal. (2011) Renal Association Clinical Practice Guideline on Detection, Monitoring and Management of Patients with CKD. Nephron Clinical Practice 118:s1, c71-c100
CrossRef414
Joaquín Cardona, Enrique Rodilla, José María Pascual. (2011) Control de la dislipemia en grupos clínicos especiales: mujeres, ancianos, VIH, enfermedad renal crónica, pacientes con síndrome metabólico. Revista Española de Cardiología Suplementos 11, 36-41
CrossRef415
Vivencio Barrios Alonso, Carlos Escobar Cervantes. (2011) Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular. Revista Española de Cardiología Suplementos 11, 29-35
CrossRef416
David W. Johnson. (2011) Attempting to Build Solid Recommendations on a Shaky Evidence Base. Seminars in Dialysis 24:1, 22-24
CrossRef417
Stephen Holt, David Goldsmith. (2011) Renal Association Clinical Practice Guideline on Cardiovascular Disease in CKD. Nephron Clinical Practice 118:s1, c125-c144
CrossRef418
Denis Fouque, William E. Mitch. Dietary Approaches to Kidney Diseases. In: Brenner and Rector's The Kidney. Elsevier, 2011:2170-2204.
CrossRef419
Valentina Kon, MacRae F. Linton, Sergio Fazio. (2011) Atherosclerosis in chronic kidney disease: the role of macrophages. Nature Reviews Nephrology 7:1, 45-54
CrossRef420
(2011) Nihon Toseki Igakkai Zasshi 44:5, 353-357
CrossRef421
George A. Kaysen. (2011) New Insights Into Lipid Metabolism in Chronic Kidney Disease. Journal of Renal Nutrition 21:1, 120-123
CrossRef422
eljko Reiner, Alberico L. Catapano, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegr
CrossRef423
Rigas G. Kalaitzidis, Moses S. Elisaf. (2011) The Role of Statins in Chronic Kidney Disease. American Journal of Nephrology 34:3, 195-202
CrossRef424
Carolyn L van Eps, Leanne Jeffriess, Brian Haluska, Carmel M Hawley, Jeffrey Coombes, Aya Matsumoto, Janine K Jeffries, David W Johnson, Scott B Campbell, Nicole M Isbel, David W Mudge, Thomas Marwick. (2011) Cardiac and vascular structure and function parameters do not improve with alternate nightly home hemodialysis: An interventional cohort study. BMC Nephrology 12:1, 51
CrossRef425
Lucia Del Vecchio, Francesco Locatelli, Marina Carini. (2011) What We Know About Oxidative Stress in Patients with Chronic Kidney Disease on Dialysis-Clinical Effects, Potential Treatment, and Prevention. Seminars in Dialysis 24:1, 56-64
CrossRef426
Raymond Oliva, Tamar Polonsky, George L. Bakris. Advanced Risk Assessment in Patients with Kidney and Inflammatory Diseases. In: Preventive Cardiology: Companion to Braunwald's Heart Disease. Elsevier, 2011:64-68.
CrossRef427
Insuffisance Rénale et Vaisseaux. In: Traité de médecine vasculaire.. Elsevier, 2011:553-579.
CrossRef428
Panagiotis Pateinakis, Aikaterini Papagianni. (2011) Cardiorenal Syndrome Type 4—Cardiovascular Disease in Patients with Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management. International Journal of Nephrology 2011, 1-8
CrossRef429
Andrew A. House, Mikko Haapio, Johan Lassus, Rinaldo Bellomo, Claudio Ronco. (2011) Pharmacological Management of Cardiorenal Syndromes. International Journal of Nephrology 2011, 1-8
CrossRef430
Lisa M. Miller, Manish M. Sood, Amy R. Sood, Martina Reslerova, Paul Komenda, Claudio Rigatto, Joe Bueti. (2010) Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients. International Urology and Nephrology 42:4, 1007-1014
CrossRef431
Kosmas I. Paraskevas, Ioannis Kotsikoris, Sotirios A. Koupidis, Alexandros A. Tzovaras, Dimitri P. Mikhailidis. (2010) Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention. International Urology and Nephrology 42:4, 999-1006
CrossRef432
Tilman B. Drüeke, Ziad A. Massy. (2010) Atherosclerosis in CKD: differences from the general population. Nature Reviews Nephrology 6:12, 723-735
CrossRef433
Donald A. Molony, Brett W. Stephens. (2010) Nephrology Literature Watch. Dialysis & Transplantation 39:12, 538-540
CrossRef434
Roberto Scarpioni, Marco Ricardi, Luigi Melfa, Luciano Cristinelli. (2010) Dyslipidemia in Chronic Kidney Disease: Are Statins Still Indicated in Reduction Cardiovascular Risk in Patients on Dialysis Treatment?. Cardiovascular Therapeutics 28:6, 361-368
CrossRef435
José Álvaro Bonet Plá, Victoria Gosalbes Soler, Armando Berioz Heiland. (2010) Alteraciones metabólicas en la enfermedad renal crónica. FMC - Formación Médica Continuada en Atención Primaria 17:10, 647-655
CrossRef436
F. Yang, D. Chou, P. Schweitzer, S. Hanon. (2010) Warfarin in haemodialysis patients with atrial fibrillation: what benefit?. Europace 12:12, 1666-1672
CrossRef437
W Charles O'Neill, Koba A Lomashvili. (2010) Recent progress in the treatment of vascular calcification. Kidney International 78:12, 1232-1239
CrossRef438
S. Seiler, B. Reichart, D. Roth, E. Seibert, D. Fliser, G. H. Heine. (2010) FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrology Dialysis Transplantation 25:12, 3983-3989
CrossRef439
Himmelfarb , Jonathan , Ikizler , T. Alp , . (2010) Hemodialysis. New England Journal of Medicine 363:19, 1833-1845
Full Text440
Noriaki Kishimoto, Toshio Hayashi, Ichiro Sakuma, Hatsuyo Kano-Hayashi, Taku Tsunekawa, Masako Osawa, Kouichiro Ina, Akihisa Iguchi. (2010) A hydroxymethylglutaryl coenzyme a reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis. International Journal of Cardiology 145:1, 21-26
CrossRef441
SHARP Collaborative Group. (2010) Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal 160:5, 785-794.e10
CrossRef442
M. G. H. Betjes, E. E. A. de Wit, W. Weimar, N. H. R. Litjens. (2010) Circulating pro-inflammatory CD4posCD28null T cells are independently associated with cardiovascular disease in ESRD patients. Nephrology Dialysis Transplantation 25:11, 3640-3646
CrossRef443
Kevin E. Chan, Raymond Hakim. (2010) Association of digoxin with mortality in ESRD: Does the medical evidence still apply when the patient is on dialysis?. Dialysis & Transplantation 39:11, 468-469
CrossRef444
A. D. van Zuilen, P. J. Blankestijn, M. van Buren, M. A. G. J. ten Dam, K. A. H. Kaasjager, G. Ligtenberg, Y. W. J. Sijpkens, H. E. Sluiter, P. J. G. van de Ven, G. Vervoort, L.-J. Vleming, M. L. Bots, J. F. M. Wetzels, . (2010) Quality of care in patients with chronic kidney disease is determined by hospital specific factors. Nephrology Dialysis Transplantation 25:11, 3647-3654
CrossRef445
Kamyar Kalantar-Zadeh, Eliezer Golan, Tamy Shohat, Elani Streja, Keith C. Norris, Joel D. Kopple. (2010) Survival Disparities within American and Israeli Dialysis Populations: Learning from Similarities and Distinctions across Race and Ethnicity. Seminars in Dialysis 23:6, 586-594
CrossRef446
P. Stenvinkel. (2010) Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. Journal of Internal Medicine 268:5, 456-467
CrossRef447
Theodoros I. Kassimatis, Athanasios Agrafiotis. (2010) Chronic kidney disease: Implications of the AURORA and JUPITER results. Nature Reviews Nephrology 6:11, 636-637
CrossRef448
(2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet 376:9753, 1670-1681
CrossRef449
Andrew A. House, Mikko Haapio, Johan Lassus, Rinaldo Bellomo, Claudio Ronco. (2010) Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes. American Journal of Kidney Diseases 56:4, 759-773
CrossRef450
George Bakris, Joseph Vassalotti, Eberhard Ritz, Christoph Wanner, George Stergiou, Mark Molitch, Richard Nesto, George A Kaysen, James R Sowers. (2010) National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney International 78:8, 726-736
CrossRef451
A. Poli, A. Corsini. (2010) Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: Analysis of SEAS and JUPITER trials. European Journal of Internal Medicine 21:5, 372-373
CrossRef452
Arjun D. Sinha, Rajiv Agarwal. (2010) Should All Hypertensive Dialysis Patients Receive a Blocker of the Renin-Angiotensin System?. Current Hypertension Reports 12:5, 356-363
CrossRef453
C. Sanchez-Perales, E. Vazquez, M. J. Garcia-Cortes, J. Borrego, M. Polaina, C. P. Gutierrez, C. Lozano, A. Liebana. (2010) Ischaemic stroke in incident dialysis patients. Nephrology Dialysis Transplantation 25:10, 3343-3348
CrossRef454
Michal Chmielewski, Marion Verduijn, Friedo W. Dekker. (2010) ApoE genotype as risk factor in dialysis patients. Atherosclerosis 212:2, 695-696
CrossRef455
Peter P Toth, Alberico Catapano, Joanne E Tomassini, Andrew M Tershakovec. (2010) Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clinical Lipidology 5:5, 655-684
CrossRef456
C. Drechsler, S. Pilz, B. Obermayer-Pietsch, M. Verduijn, A. Tomaschitz, V. Krane, K. Espe, F. Dekker, V. Brandenburg, W. Marz, E. Ritz, C. Wanner. (2010) Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. European Heart Journal 31:18, 2253-2261
CrossRef457
Robert E. Cronin, Robert F. Reilly. (2010) Unfractionated Heparin for Hemodialysis: Still the Best Option. Seminars in Dialysis 23:5, 510-515
CrossRef458
Deeptankar DeMazumder, Rani K. Hasan, Roger S. Blumenthal, Erin D. Michos, Steven Jones. (2010) Should Statin Therapy Be Allocated on the Basis of Global Risk or on the Basis of Randomized Trial Evidence?. The American Journal of Cardiology 106:6, 905-909
CrossRef459
B. Coll, A. Betriu, M. Martinez-Alonso, M. Borras, L. Craver, M. L. Amoedo, M. {a. }P. Marco, F. Sarro, M. Junyent, J. M. Valdivielso, E. Fernandez. (2010) Cardiovascular risk factors underestimate atherosclerotic burden in chronic kidney disease: usefulness of non-invasive tests in cardiovascular assessment. Nephrology Dialysis Transplantation 25:9, 3017-3025
CrossRef460
Nosratola D. Vaziri. (2010) Lipotoxicity and Impaired High Density Lipoprotein-Mediated Reverse Cholesterol Transport in Chronic Kidney Disease. Journal of Renal Nutrition 20:5, S35-S43
CrossRef461
Juan J. Carrero, Peter Stenvinkel. (2010) Inflammation in End-Stage Renal Disease-What Have We Learned in 10 Years?. Seminars in Dialysis 23:5, 498-509
CrossRef462
Kosmas I. Paraskevas, Alexandros A. Tzovaras, Vassilios Stathopoulos, Dimitri P. Mikhailidis. (2010) Statin use in patients with chronic kidney disease stages 2–4: targeting beyond improved mortality rates. International Urology and Nephrology 42:3, 711-713
CrossRef463
Steven D. Weisbord, Anne Marie Shields, Maria K. Mor, Mary Ann Sevick, Marcia Homer, Janet Peternel, Patricia Porter, Bruce L. Rollman, Paul M. Palevsky, Robert M. Arnold, Michael J. Fine. (2010) Methodology of a randomized clinical trial of symptom management strategies in patients receiving chronic hemodialysis: The SMILE study. Contemporary Clinical Trials 31:5, 491-497
CrossRef464
Chris J Packard. (2010) Optimizing lipid-lowering therapy in the prevention of coronary heart disease. Expert Review of Clinical Pharmacology 3:5, 649-661
CrossRef465
John R Guyton. (2010) Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?. Current Opinion in Lipidology 21:4, 372-377
CrossRef466
J.L. Górriz Teruel, S. Beltrán Catalán. (2010) Cambios inducidos por la enfermedad renal crónica en los pacientes con diabetes. Avances en Diabetología 26:4, 235-241
CrossRef467
Theodoros I. Kassimatis, David J.A. Goldsmith. (2010) New Hope for Chronic Kidney Disease Patients After the JUPITER Trial. Journal of the American College of Cardiology 56:6, 529
CrossRef468
Dena E. Rifkin, Mark J. Sarnak. (2010) Chronic kidney disease: Absence of evidence or evidence of absence? ACS treatment in CKD. Nature Reviews Nephrology 6:8, 449-450
CrossRef469
Lorenzo Arnaboldi, Alberto Corsini. (2010) Do structural differences in statins correlate with clinical efficacy?. Current Opinion in Lipidology 21:4, 298-304
CrossRef470
Joel C Marrs, Joseph J Saseen. (2010) Effects of Lipid-Lowering Therapy on Reduction of Cardiovascular Events in Patients with End-Stage Renal Disease Requiring Hemodialysis. Pharmacotherapy 30:8, 823-829
CrossRef471
Raymond T. Krediet, Olga Balafa. (2010) Cardiovascular risk in the peritoneal dialysis patient. Nature Reviews Nephrology 6:8, 451-460
CrossRef472
Giovanni Tripepi, Francesco Mattace-Raso, Francesco Rapisarda, Benedetta Stancanelli, Lorenzo Malatino, Jacqueline Witteman, Carmine Zoccali, Francesca Mallamaci. (2010) Traditional and nontraditional risk factors as predictors of cerebrovascular events in patients with end stage renal disease. Journal of Hypertension1
CrossRef473
T. X. Pedersen, C. J. Binder, G. N. Fredrikson, J. Nilsson, S. Bro, L. B. Nielsen. (2010) The pro-inflammatory effect of uraemia overrules the anti-atherogenic potential of immunization with oxidized LDL in apoE-/- mice. Nephrology Dialysis Transplantation 25:8, 2486-2491
CrossRef474
Peter M. Nilsson, Adie Viljoen, Anthony S. Wierzbicki. Cardiovascular Risk Factors. In: Textbook of Diabetes. Wiley-Blackwell, 2010:657-683.
CrossRef475
Dena E. Rifkin, Wolfgang C. Winkelmayer. (2010) Medication Issues in Older Individuals With CKD. Advances in Chronic Kidney Disease 17:4, 320-328
CrossRef476
Allon N. Friedman. (2010) Omega-3 Fatty Acid Supplementation in Advanced Kidney Disease. Seminars in Dialysis 23:4, 396-400
CrossRef477
Sheila L. Stadler, Bharati Bhardwaja, Kari L. Olson, J. David Powers, Diane Lanese. (2010) An assessment of cholesterol goal attainment in patients with chronic kidney disease. Journal of Clinical Lipidology 4:4, 298-304
CrossRef478
Thiane Gama Axelsson, Gerd Faxén Irving, Jonas Axelsson. (2010) To Eat or Not to Eat: Dietary Fat in Uremia Is the Question. Seminars in Dialysis 23:4, 383-388
CrossRef479
D. Kiski, H. Reinecke. (2010) Herz und Niere. Der Internist 51:7, 850-856
CrossRef480
Ngan N Lam, Amit X Garg. (2010) The Authors Reply:. Kidney International 78:1, 112-112
CrossRef481
Eberhard Ritz, Christoph Wanner. (2010) Statins: do we definitely know whether they are completely inefficacious in ESRD?. Kidney International 78:1, 111-112
CrossRef482
Hidenori Koyama, Yoshiki Nishizawa. (2010) AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD?. European Journal of Clinical Investigation 40:7, 623-635
CrossRef483
F. Moreso, N. Calvo, J. Pascual, F. Anaya, C. Jimenez, D. del Castillo, J. Sanchez-Plumed, D. Seron. (2010) Early statin use is an independent predictor of long-term graft survival. Clinical Kidney Journal 3:suppl 2, ii26-ii31
CrossRef484
Anne-Emilie Declèves, Kumar Sharma. (2010) New pharmacological treatments for improving renal outcomes in diabetes. Nature Reviews Nephrology 6:6, 371-380
CrossRef485
Haseeb Jafri, Alawi A. Alsheikh-Ali, Richard H. Karas. (2010) Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy. Journal of the American College of Cardiology 55:25, 2846-2854
CrossRef486
P. A. McCullough, M. Haapio, S. Mankad, N. Zamperetti, B. Massie, R. Bellomo, T. Berl, S. D. Anker, I. Anand, N. Aspromonte, S. M. Bagshaw, I. Bobek, D. N. Cruz, L. Daliento, A. Davenport, H. Hillege, A. A. House, N. Katz, A. Maisel, A. Mebazaa, A. Palazzuoli, P. Ponikowski, F. Ronco, A. Shaw, G. Sheinfeld, S. Soni, G. Vescovo, P. Zanco, C. Ronco, T. Berl, . (2010) Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation 25:6, 1777-1784
CrossRef487
Rajan K. Patel, Alan G.M. Jardine, Patrick B. Mark, Anthony F. Cunningham, Tracey Steedman, Joanna R. Powell, Emily P. McQuarrie, Kathryn K. Stevens, Henry J. Dargie, Alan G. Jardine. (2010) Association of Left Atrial Volume With Mortality Among ESRD Patients With Left Ventricular Hypertrophy Referred for Kidney Transplantation. American Journal of Kidney Diseases 55:6, 1088-1096
CrossRef488
Bernd Krüger, Andreas Walberer, Jens Debler, Carsten A. Böger, Stefan Farkas, Stephan W. Reinhold, Aiman Obed, Hans Jürgen Schlitt, Michael Fischereder, Bernhard Banas, Bernhard K. Krämer. (2010) Is inflammation prior to renal transplantation predictive for cardiovascular and renal outcomes?. Atherosclerosis 210:2, 637-642
CrossRef489
Helen Eddington, Philip A. Kalra. (2010) THE ASSOCIATION OF CHRONIC KIDNEY DISEASE-MINERAL BONE DISORDER AND CARDIOVASCULAR RISK. Journal of Renal Care 36, 61-67
CrossRef490
David Lewis, Richard Haynes, Martin J. Landray. (2010) LIPIDS IN CHRONIC KIDNEY DISEASE. Journal of Renal Care 36, 27-33
CrossRef491
Katrin Uhlig. (2010) There Is No Practical Utility in Routinely Screening Dialysis Patients for Vascular Calcification. Seminars in Dialysis 23:3, 277-279
CrossRef492
Sabin Shurraw, Sumit R. Majumdar, Ravi Thadhani, Natasha Wiebe, Marcello Tonelli. (2010) Glycemic Control and the Risk of Death in 1,484 Patients Receiving Maintenance Hemodialysis. American Journal of Kidney Diseases 55:5, 875-884
CrossRef493
Nosratola D. Vaziri, Mohamad Navab, Alan M. Fogelman. (2010) HDL metabolism and activity in chronic kidney disease. Nature Reviews Nephrology 6:5, 287-296
CrossRef494
Mike Seddon, Nick Curzen. (2010) CORONARY REVASCULARISATION IN CHRONIC KIDNEY DISEASE PART 1: STABLE CORONARY ARTERY DISEASE. Journal of Renal Care 36, 106-117
CrossRef495
Irene M. Van Der Meer, Piero Ruggenenti, Giuseppe Remuzzi. (2010) THE DIABETIC CKD PATIENT-A MAJOR CARDIOVASCULAR CHALLENGE. Journal of Renal Care 36, 34-46
CrossRef496
Emily P. McQuarrie, Bengt C. Fellström, Hallvard Holdaas, Alan G. Jardine. (2010) CARDIOVASCULAR DISEASE IN RENAL TRANSPLANT RECIPIENTS. Journal of Renal Care 36, 136-145
CrossRef497
Min Jun, Celine Foote, Jicheng Lv, Bruce Neal, Anushka Patel, Stephen J Nicholls, Diederick E Grobbee, Alan Cass, John Chalmers, Vlado Perkovic. (2010) Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. The Lancet 375:9729, 1875-1884
CrossRef498
Robert M. Califf, Yuliya Lokhnygina, Christopher P. Cannon, Michael E. Stepanavage, Carolyn H. McCabe, Thomas A. Musliner, Richard C. Pasternak, Michael A. Blazing, Robert P. Giugliano, Robert A. Harrington, Eugene Braunwald. (2010) An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. American Heart Journal 159:5, 705-709
CrossRef499
Manish P. Ponda, Irina Barash, Jonathan E. Feig, Edward A. Fisher, Edward Y. Skolnik. (2010) Moderate kidney disease inhibits atherosclerosis regression. Atherosclerosis 210:1, 57-62
CrossRef500
Eugenie Pedagogos. (2010) Coronary artery, cerebrovascular and peripheral vascular disease. Nephrology 15, S19-S23
CrossRef501
(2010) Journal Club. Kidney International 77:7, 563-564
CrossRef502
Fiona E Mackie, Andrew R Rosenberg, Jason A Harmer, Gad Kainer, David S Celermajer. (2010) HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD) - a pilot study. Acta Paediatrica 99:3, 457-459
CrossRef503
Paul M. Ridker, Jean MacFadyen, Michael Cressman, Robert J. Glynn. (2010) Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein. Journal of the American College of Cardiology 55:12, 1266-1273
CrossRef504
Philipp Eller, Kathrin Eller, Anna M Wolf, Sebastian J Reinstadler, Andrea Tagwerker, Josef R Patsch, Gert Mayer, Alexander R Rosenkranz. (2010) Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis. Kidney International 77:5, 428-435
CrossRef505
C. Rinat, R. Becker-Cohen, A. Nir, S. Feinstein, D. Shemesh, N. Algur, E. Ben Shalom, B. Farber, Y. Frishberg. (2010) A comprehensive study of cardiovascular risk factors, cardiac function and vascular disease in children with chronic renal failure. Nephrology Dialysis Transplantation 25:3, 785-793
CrossRef506
Francesco Locatelli, Lucia Del Vecchio, Andrea Cavalli. (2010) How Can Prognosis for Diabetic ESRD Be Improved?. Seminars in Dialysis 23:2, 214-219
CrossRef507
Pedro L. Neves, Anabela Malho, Ana Cabrita, Ana Pinho, Alexandre Baptista, Elsa Morgado, Marília Faísca, Hermínio Carrasqueira, Ana P. Silva. (2010) Statins and vitamin D: a friendly association in pre-dialysis patients. International Urology and Nephrology 42:1, 173-179
CrossRef508
Radica Z. Alicic, Katherine R. Tuttle. (2010) Management of the Diabetic Patient with Advanced Chronic Kidney Disease. Seminars in Dialysis 23:2, 140-147
CrossRef509
Jan Galle. (2010) Das kardiorenale Syndrom. Medizinische Klinik 105:3, 142-149
CrossRef510
David Goldsmith, Adrian C. Covic. (2010) Jupiter or Aurora? Micro-inflammation and dyslipidaemia: twin targets for statin therapy in CKD. International Urology and Nephrology 42:1, 133-136
CrossRef511
Holger Schmid, Helmut Schiffl, Stephan R Lederer. (2010) Pharmacotherapy of end-stage renal disease. Expert Opinion on Pharmacotherapy 11:4, 597-613
CrossRef512
Tejas Patel, David M. Charytan. (2010) Cardiovascular Complications in Diabetic Kidney Disease. Seminars in Dialysis 23:2, 169-177
CrossRef513
F. Locatelli, N. Dimkovic, G. Pontoriero, G. Spasovski, S. Pljesa, S. Kostic, A. Manning, H. Sano, S. Nakajima. (2010) Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrology Dialysis Transplantation 25:2, 574-581
CrossRef514
C. A. Herzog. (2010) Kidney disease in cardiology. Nephrology Dialysis Transplantation 25:2, 356-360
CrossRef515
Anthony S. Wierzbicki, Adie Viljoen. (2010) Hyperlipidaemia in Paediatric Patients. Drug Safety 33:2, 115-125
CrossRef516
Michael J Gonyeau, Dayton W Yuen. (2010) A Clinical Review of Statins and Cancer: Helpful or Harmful?. Pharmacotherapy 30:2, 177-194
CrossRef517
Robert G. Fassett, Jeff S. Coombes, David Packham, Kenneth F. Fairley, Priscilla Kincaid-Smith. (2010) Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scandinavian Journal of Urology and Nephrology 44:1, 56-61
CrossRef518
(2010) Journal Club. Medizinische Klinik 105:2, 111-117
CrossRef519
Helmut Schiffl, Susanne M Lang. (2010) Effects of Dialysis Purity on Uremic Dyslipidemia. Therapeutic Apheresis and Dialysis 14:1, 5-11
CrossRef520
Ramanath Dukkipati, Kamyar Kalantar-Zadeh, Joel D. Kopple. (2010) Is There a Role for Intradialytic Parenteral Nutrition? A Review of the Evidence. American Journal of Kidney Diseases 55:2, 352-364
CrossRef521
Sabin Shurraw, Marcello Tonelli. (2010) AURORA: Is There a Role for Statin Therapy in Dialysis Patients?. American Journal of Kidney Diseases 55:2, 237-240
CrossRef522
M. de Lorgeril. (2010) Statines et diabète : mauvaise science ou mauvaise médecine ?. Médecine des Maladies Métaboliques 4:1, 79-81
CrossRef523
Abboud , Hanna , Henrich , William L. , . (2010) Stage IV Chronic Kidney Disease. New England Journal of Medicine 362:1, 56-65
Full Text524
Csaba P. Kovesdy, Kamyar Kalantar-Zadeh. Inflammation in Chronic Kidney Disease. In: Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier, 2010:183-197.
CrossRef525
Hidekuni INADERA, Tomohito HAMAZAKI. (2010) Cholesterol Controversy: Cutoff Point of Low-Density Lipoprotein Cholesterol Level in Guidelines by Japan Atherosclerosis Society. Nippon Eiseigaku Zasshi (Japanese Journal of Hygiene) 65:4, 506-515
CrossRef526
Marian Goicoechea, Soledad García de Vinuesa, Vicente Lahera, Victoria Cachofeiro, Úrsula Verdalles, José Luño. (2010) Papel de las estatinas en la enfermedad renal crónica (ERC). Clínica e Investigación en Arteriosclerosis 22:1, 17-24
CrossRef527
Robert R. Quinn, Nairne Scott-Douglas. (2010) Dialysis: Warfarin: safe in dialysis patients with atrial fibrillation?. Nature Reviews Nephrology 6:1, 17-18
CrossRef528
Stephen L Seliger. (2010) Comorbidity and confounding in end-stage renal disease. Kidney International 77:2, 83-85
CrossRef529
M. Ketteler, P.H. Biggar. (2010) Kardiorenales Syndrom. Der Nephrologe 5:1, 49-57
CrossRef530
Wolfgang C. Winkelmayer. Kidney Disease and Medications. In: Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier, 2010:208-217.
CrossRef531
S Ananth Karumanchi, Ravi Thadhani. (2010) Kidney complications: Why don't statins always work?. Nature Medicine 16:1, 38-40
CrossRef532
Nigel D. Toussaint, Grahame J. Elder, Peter G. Kerr. (2010) A Rational Guide to Reducing Fracture Risk in Dialysis Patients. Seminars in Dialysis 23:1, 43-54
CrossRef533
Michel de Lorgeri, Patricia Salen. (2010) Recent cholesterol-lowering drug trials: New data, new questions. Journal of Lipid Nutrition 19:1, 65-92
CrossRef534
Karl Winkler, Michael M. Hoffmann, Vera Krane, Winfried März, Christiane Drechsler, Christoph Wanner. (2010) Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus. Atherosclerosis 208:1, 197-202
CrossRef535
Donald A. Molony, Aleksandra Dyk, Mary Theresa Vu Hoang, Brett W. Stephens. (2010) Nephrology Literature Watch. Dialysis & Transplantation 39:1, 37-39
CrossRef536
Hiren P. Patel. (2010) Early Origins of Cardiovascular Disease in Pediatric Chronic Kidney Disease. Renal Failure 32:1, 1-9
CrossRef537
M P C Kao, D S C Ang, A Pall, A D Struthers. (2010) Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. Journal of Human Hypertension 24:1, 1-8
CrossRef538
Tariq Shafi, Josef Coresh. Chronic Kidney Disease. In: Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier, 2010:3-21.
CrossRef539
N.R. Robles, J.F. Macias. (2010) Cardiovascular Risk in Uremic Patients: Darkness after AURORA. Renal Failure 32:2, 269-272
CrossRef540
M. Klein. (2010) Results of a randomized controlled trial on statin use in dialysis patients had no influence on statin prescription. Yearbook of Medicine 2010, 254-255
CrossRef541
Daniel E. Weiner, Mark J. Sarnak. Cardiovascular Disease in Patients with Chronic Kidney Disease. In: Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier, 2010:128-144.
CrossRef542
Paola Fioretto, Paul M. Dodson, Dan Ziegler, Robert S. Rosenson. (2010) Residual microvascular risk in diabetes: unmet needs and future directions. Nature Reviews Endocrinology 6:1, 19-25
CrossRef543
Katherine R. Tuttle. Complications and Management of Chronic Kidney Disease. In: Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier, 2010:145-163.
CrossRef544
Matthew K. Abramowitz, Timothy W. Meyer, Thomas H. Hostetter. The Pathophysiology of Uremia. In: Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier, 2010:251-264.
CrossRef545
Lynda A. Szczech. (2010) Chronic kidney disease: Did 'renalism' skew the results of a negative study?. Nature Reviews Nephrology 6:1, 18-20
CrossRef546
Kerri Cavanaugh, T. Alp Ikizler. Chronic Renal Failure. In: Andreoli and Carpenter's Cecil Essentials of Medicine. Elsevier, 2010:369-379.
CrossRef547
Nadezda Koleganova, Grzegorz Piecha, Eberhard Ritz. (2010) Vasculotropic effects of calcimimetics. Current Opinion in Nephrology and Hypertension 19:1, 32-36
CrossRef548
M. Farnier. (2010) Dyslipidémies et risque cardiovasculaire : données des études de prévention cardiovasculaire. EMC - Endocrinologie - Nutrition 7:4, 1-13
CrossRef549
Manish M. Sood, Marisa Battistella, Charmaine E. Lok. (2009) Patterns of cardioprotective medication prescription in incident hemodialysis patients. International Urology and Nephrology 41:4, 1021-1027
CrossRef550
Sarah Seiler, Gunnar H Heine, Danilo Fliser. (2009) Clinical relevance of FGF-23 in chronic kidney disease. Kidney International 76, S34-S42
CrossRef551
Vincent M Brandenburg, Willi Jahnen-Dechent, Markus Ketteler. (2009) Sevelamer and the bone–vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation. Kidney International 76, S26-S33
CrossRef552
R. Fiedler, P. M. Jehle, B. Osten, O. Dorligschaw, M. Girndt. (2009) Clinical nutrition scores are superior for the prognosis of haemodialysis patients compared to lab markers and bioelectrical impedance. Nephrology Dialysis Transplantation 24:12, 3812-3817
CrossRef553
Ngan N Lam, Arsh K Jain, Dan G Hackam, Meaghan S Cuerden, Rita S Suri, Cindy Y Huo, Ping Li, William F Clark, Amit X Garg. (2009) Results of a randomized controlled trial on statin use in dialysis patients had no influence on statin prescription. Kidney International 76:11, 1172-1179
CrossRef554
M.D. Alscher. (2009) Herz und Niere. Der Kardiologe 3:6, 489-498
CrossRef555
D. Sander, K. Sander. (2009) Schlaganfall-Primärprävention bei Diabetespatienten. Der Diabetologe 5:8, 611-619
CrossRef556
Xiong Z. Ruan, Zac Varghese, John F. Moorhead. (2009) An update on the lipid nephrotoxicity hypothesis. Nature Reviews Nephrology 5:12, 713-721
CrossRef557
F. P. Hurst, R. T. Neff, R. M. Jindal, J. R. Roberts, K. L. Lentine, L. Y. Agodoa, K. C. Abbott. (2009) Incidence, predictors and associated outcomes of rhabdomyolysis after kidney transplantation. Nephrology Dialysis Transplantation 24:12, 3861-3866
CrossRef558
Devasmita Choudhury, Meryem Tuncel, Moshe Levi. (2009) Disorders of Lipid Metabolism and Chronic Kidney Disease in the Elderly. Seminars in Nephrology 29:6, 610-620
CrossRef559
Nosratola D. Vaziri. (2009) Causes of Dysregulation of Lipid Metabolism in Chronic Renal Failure. Seminars in Dialysis 22:6, 644-651
CrossRef560
John G.F. Cleland, John J.V. McMurray, John Kjekshus, Jan H. Cornel, Peter Dunselman, Cândida Fonseca, Åke Hjalmarson, Jerzy Korewicki, Magnus Lindberg, Naresh Ranjith, Dirk J. van Veldhuisen, Finn Waagstein, Hans Wedel, John Wikstrand. (2009) Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin. Journal of the American College of Cardiology 54:20, 1850-1859
CrossRef561
Helen M. Colhoun, D. John Betteridge, Paul N. Durrington, Graham A. Hitman, H. Andrew W. Neil, Shona J. Livingstone, Valentine Charlton-Menys, David A. DeMicco, John H. Fuller. (2009) Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases 54:5, 810-819
CrossRef562
A.-S. Bargnoux, A.-M. Dupuy, V. Garrigue, I. Jaussent, G. Gahide, S. Badiou, I. Szwarc, S. Deleuze, H. Vernhet, J.-P. Cristol, G. Mourad. (2009) Evolution of Coronary Artery Calcifications Following Kidney Transplantation: Relationship with Osteoprotegerin Levels. American Journal of Transplantation 9:11, 2571-2579
CrossRef563
Lori B. Daniels, Elizabeth Barrett-Connor. (2009) Can Natriuretic Peptides Help Identify Heart Failure Patients for Whom Statins Are Beneficial?. Journal of the American College of Cardiology 54:20, 1860-1861
CrossRef564
(2009) Journal Club. Kidney International 76:9, 923-924
CrossRef565
D E Weiner. (2009) Public Health Consequences of Chronic Kidney Disease. Clinical Pharmacology & Therapeutics 86:5, 566-569
CrossRef566
Jonathan Himmelfarb. (2009) Uremic Toxicity, Oxidative Stress, and Hemodialysis as Renal Replacement Therapy. Seminars in Dialysis 22:6, 636-643
CrossRef567
Vera Krane, Karl Winkler, Christiane Drechsler, Jürgen Lilienthal, Winfried März, Christoph Wanner. (2009) Association of LDL Cholesterol and Inflammation With Cardiovascular Events and Mortality in Hemodialysis Patients With Type 2 Diabetes Mellitus. American Journal of Kidney Diseases 54:5, 902-911
CrossRef568
Michael H. Davidson. (2009) AURORA and JUPITER trials: Recognizing the limitations and expanding the benefits of statin treatment. Current Cardiology Reports 11:6, 401-403
CrossRef569
Vivencio Barrios, Carlos Escobar. (2009) Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. Expert Review of Cardiovascular Therapy 7:11, 1317-1327
CrossRef570
Vlado Perkovic, Vinod Venkataraman, Bruce Cooper, Sophia Zoungas, Angela C Webster, Vlado Perkovic. Antioxidants for chronic kidney disease. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009.
CrossRef571
C. Drechsler, V. Krane, D. C. Grootendorst, E. Ritz, K. Winkler, W. Marz, F. Dekker, C. Wanner, . (2009) The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation 24:10, 3151-3157
CrossRef572
Jacques Genest, Ruth McPherson, Jiri Frohlich, Todd Anderson, Norm Campbell, André Carpentier, Patrick Couture, Robert Dufour, George Fodor, Gordon A. Francis, Steven Grover, Milan Gupta, Robert A. Hegele, David C. Lau, Lawrence Leiter, Gary F. Lewis, Eva Lonn, G.B. John Mancini, Dominic Ng, Glen J. Pearson, Allan Sniderman, James A. Stone, Ehud Ur. (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Canadian Journal of Cardiology 25:10, 567-579
CrossRef573
Dirk Sander, Mark T. Kearney. (2009) Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. Journal of Neurology 256:10, 1603-1619
CrossRef574
Tamara Isakova, Orlando M Gutiérrez, Myles Wolf. (2009) A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney International 76:7, 705-716
CrossRef575
Kentaro Nakai, Hirotaka Komaba, Masafumi Fukagawa. (2009) Management of Mineral and Bone Disorder in Chronic Kidney Disease: Quo Vadis?. Therapeutic Apheresis and Dialysis 13, S2-S6
CrossRef576
Stephen M. Sozio, Paige A. Armstrong, Josef Coresh, Bernard G. Jaar, Nancy E. Fink, Laura C. Plantinga, Neil R. Powe, Rulan S. Parekh. (2009) Cerebrovascular Disease Incidence, Characteristics, and Outcomes in Patients Initiating Dialysis: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. American Journal of Kidney Diseases 54:3, 468-477
CrossRef577
Sarina van der Zee, Usman Baber, Sammy Elmariah, Jonathan Winston, Valentin Fuster. (2009) Cardiovascular risk factors in patients with chronic kidney disease. Nature Reviews Cardiology 6:9, 580-589
CrossRef578
Christiane Drechsler, Vera Krane, Karl Winkler, Friedo W Dekker, Christoph Wanner. (2009) Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney International 76:5, 567-575
CrossRef579
Terje R. Pedersen. (2009) Lipid-lowering drugs and risk for cancer. Current Atherosclerosis Reports 11:5, 350-357
CrossRef580
Stephen L. Seliger. (2009) Stroke in ESRD: The Other Cardiovascular Disease. American Journal of Kidney Diseases 54:3, 403-405
CrossRef581
Lawrence A. Notaro, Mohammed H. Usman, James F. Burke, Aqeel Siddiqui, Keith R. Superdock, Michael D. Ezekowitz. (2009) Secondary Prevention in Concurrent Coronary Artery, Cerebrovascular, and Chronic Kidney Disease: Focus on Pharmacological Therapy. Cardiovascular Therapeutics 27:3, 199-215
CrossRef582
Jonathan Himmelfarb, Stuart J. Shankland. (2009) Creating Research Infrastructure and Functionality to Address Chronic Kidney Disease: The Kidney Research Institute. Seminars in Nephrology 29:5, 457-466
CrossRef583
Philip R. Liebson. (2009) ACTIVE A and AURORA. Preventive Cardiology 12:4, 205-208
CrossRef584
IOANNIS TSOUCHNIKAS, EVANGELIA DOUNOUSI, STAMATINA PAPAKONSTANTINOU, KYRIAKOS IOANNOU, APOSTOLOS KELESIDIS, NIKOLAOS KOTZADAMIS, KYRIAKI XANTHOPOULOU, DIMITRIOS TSAKIRIS. (2009) Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients. Nephrology 14:6, 560-564
CrossRef585
Carmine Zoccali. (2009) Dialysis: The sweetness of glitazones: randomized trials needed. Nature Reviews Nephrology 5:9, 497-498
CrossRef586
Raphael See, Robert N. Piana. (2009) Achieving optimum lipid-lowering goals in patients with vascular disease. Current Cardiovascular Risk Reports 3:5, 323-330
CrossRef587
Madhuri M. Vasudevan, Christie M. Ballantyne. (2009) Advances in Lipid Testing and Management in Patients with Diabetes Mellitus. Endocrine Practice 15:6, 641-652
CrossRef588
J. Floege. (2009) Reply. Nephrology Dialysis Transplantation 24:8, 2610-2611
CrossRef589
Per-Ola Attman, Ola Samuelsson. (2009) Dyslipidemia of kidney disease. Current Opinion in Lipidology 20:4, 293-299
CrossRef590
Kwang Kon Koh, Michael J. Quon. (2009) The importance of considering alternative or combination strategies for lowering LDL-C. International Journal of Cardiology 136:2, 115-119
CrossRef591
Anthony J. Joseph, Eli A. Friedman. (2009) Diabetic Nephropathy in the Elderly. Clinics in Geriatric Medicine 25:3, 373-389
CrossRef592
Harold A. Franch, William E. Mitch. (2009) Navigating Between the Scylla and Charybdis of Prescribing Dietary Protein for Chronic Kidney Diseases. Annual Review of Nutrition 29:1, 341-364
CrossRef593
Michal Chmielewski, Boleslaw Rutkowski, Bengt Lindholm. (2009) Mechanisms and clinical implications of lipid disorders in chronic kidney disease. Clinical Lipidology 4:4, 449-456
CrossRef594
Sankar D Navaneethan, Sagar U Nigwekar, Ashwini R Sehgal, Giovanni FM Strippoli, Sankar D Navaneethan. Aldosterone antagonists for preventing the progression of chronic kidney disease. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009.
CrossRef595
Sankar D Navaneethan, Sagar U Nigwekar, Vlado Perkovic, David W Johnson, Jonathan C Craig, Giovanni FM Strippoli, Sankar D Navaneethan. HMG CoA reductase inhibitors (statins) for dialysis patients. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009.
CrossRef596
(2009) Rosuvastatin in Patients Undergoing Hemodialysis. New England Journal of Medicine 361:1, 93-95
Free Full Text597
Joachim H. Ix, Glenn M. Chertow. (2009) Dialysis: Phosphorus binders and survival: need for randomized trials. Nature Reviews Nephrology 5:7, 368-370
CrossRef598
D. Benson Walker, Thanh Jennifer Walker, Terry A. Jacobson. (2009) Chronic kidney disease and statins: Improving cardiovascular outcomes. Current Atherosclerosis Reports 11:4, 301-308
CrossRef599
Ziad A. Massy, Peter Stenvinkel, Tilman B. Drueke. (2009) The Role of Oxidative Stress in Chronic Kidney Disease. Seminars in Dialysis 22:4, 405-408
CrossRef600
Raphaelle L. Dumaine, Gilles Montalescot, Ph. Gabriel Steg, E. Magnus Ohman, Kim Eagle, Deepak L. Bhatt. (2009) Renal function, atherothrombosis extent, and outcomes in high-risk patients. American Heart Journal 158:1, 141-148.e1
CrossRef601
M. K. de Bie, B. van Dam, A. Gaasbeek, M. van Buren, L. van Erven, J. J. Bax, M. J. Schalij, T. J. Rabelink, J. W. Jukema. (2009) The current status of interventions aiming at reducing sudden cardiac death in dialysis patients. European Heart Journal 30:13, 1559-1564
CrossRef602
Arezu Dezfuli, Deborah Scholl, Stanley M. Lindenfeld, Csaba P. Kovesdy, Kamyar Kalantar-Zadeh. (2009) Severity of Hypoalbuminemia Predicts Response to Intradialytic Parenteral Nutrition in Hemodialysis Patients. Journal of Renal Nutrition 19:4, 291-297
CrossRef603
Christoph Wanner, Christiane Drechsler, Vera Krane. (2009) C-Reactive Protein and Uremia. Seminars in Dialysis 22:4, 438-441
CrossRef604
Iren Szeki, Alastair Hutchison. (2009) Lanthanum carbonate for hyperphosphatemia in patients with advanced CKD and patients receiving dialysis. Expert Review of Endocrinology & Metabolism 4:4, 307-316
CrossRef605
STACEY O'SHEA, DAVID W JOHNSON. (2009) Review article: Addressing risk factors in chronic kidney disease mineral and bone disorder: Can we influence patient-level outcomes?. Nephrology 14:4, 416-427
CrossRef606
DENISE V O'SHAUGHNESSY, GRAHAME J ELDER. (2009) Review article: Patient-level outcomes: the missing link. Nephrology 14:4, 443-451
CrossRef607
Theodoros I. Kassimatis, Panagiotis A. Konstantinopoulos. (2009) The role of statins in chronic kidney disease (CKD): Friend or foe?. Pharmacology & Therapeutics 122:3, 312-323
CrossRef608
Victoria Cachofeiro, Vicente Lahera, Marian Goicochea, Soledad Garcia de Vinuesa, José Luño. (2009) Response to ‘Treatment with statins may be considered in ESRD patients for primary prevention of cardiovascular disease’. Kidney International 75:12, 1355-1355
CrossRef609
(2009) Journal Club. Kidney International 75:12, 1249-1250
CrossRef610
S. Methven, M. S. MacGregor. (2009) Clinical management of chronic kidney disease. Clinical Medicine 9:3, 269-272
CrossRef611
Vinod K. Bansal. (2009) Dyslipidemia in ESRD: Too Late to Treat?. Nephrology Times 2:6, 2
CrossRef612
John G.F. Cleland, Alison P. Coletta, Andrew L. Clark, Damien Cullington. (2009) Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA. European Journal of Heart Failure 11:6, 622-630
CrossRef613
C. John Sperati, Rulan S. Parekh, Yvette Berthier-Schaad, Bernard G. Jaar, Laura Plantinga, Nancy Fink, Neil R. Powe, Michael W. Smith, Josef Coresh, W.H. Linda Kao. (2009) Association of Single-Nucleotide Polymorphisms in JAK3, STAT4, and STAT6 With New Cardiovascular Events in Incident Dialysis Patients. American Journal of Kidney Diseases 53:5, 845-855
CrossRef614
David D. Waters. (2009) Clinical Insights From the Treating to New Targets Trial. Progress in Cardiovascular Diseases 51:6, 487-502
CrossRef615
S. van der Zee, V. Fuster. (2009) Enfermedades cardiovasculares y nefropatía crónica: del tratamiento al fomento de la salud. Medicina Clínica 132, 33-37
CrossRef616
Gianna Fabbri, Aldo Pietro Maggioni. (2009) Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. Advances in Therapy 26:5, 469-487
CrossRef617
H. Ishii, Y. Kumada, T. Toriyama, T. Aoyama, H. Takahashi, T. Amano, Y. Yasuda, Y. Yuzawa, S. Maruyama, S. Matsuo, T. Matsubara, T. Murohara. (2009) Aortic valvular calcification predicts restenosis after implantation of drug-eluting stents in patients on chronic haemodialysis. Nephrology Dialysis Transplantation 24:5, 1562-1567
CrossRef618
Suguru Yamamoto, Valentina Kon. (2009) Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Current Opinion in Nephrology and Hypertension 18:3, 181-188
CrossRef619
Michael J. Koren, Michael H. Davidson, Daniel J. Wilson, Rana S. Fayyad, Andrea Zuckerman, David P. Reed. (2009) Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD. American Journal of Kidney Diseases 53:5, 741-750
CrossRef620
Diana Rucker, Marcello Tonelli. (2009) Cardiovascular risk and management in chronic kidney disease. Nature Reviews Nephrology 5:5, 287-296
CrossRef621
Christoph Wanner. (2009) Statin Effects in CKD: Is There a “Point of No Return”?. American Journal of Kidney Diseases 53:5, 723-725
CrossRef622
Pierre Amarenco, Julien Labreuche. (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. The Lancet Neurology 8:5, 453-463
CrossRef623
Sankar D Navaneethan, Francesca Pansini, Vlado Perkovic, Carlo Manno, Fabio Pellegrini, David W Johnson, Jonathan C Craig, Giovanni FM Strippoli, Sankar D Navaneethan. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009.
CrossRef624
Strippoli , Giovanni F.M. , Craig , Jonathan C. , . (2009) Sunset for Statins after AURORA?. New England Journal of Medicine 360:14, 1455-1457
Full Text625
Fellström , Bengt C. , Jardine , Alan G. , Schmieder , Roland E. , Holdaas , Hallvard , Bannister , Kym , Beutler , Jaap , Chae , Dong-Wan , Chevaile , Alejandro , Cobbe , Stuart M. , Grönhagen-Riska , Carola , De Lima , José J. , Lins , Robert , Mayer , Gert , McMahon , Alan W. , Parving , Hans-Henrik , Remuzzi , Giuseppe , Samuelsson , Ola , Sonkodi , Sandor , Süleymanlar , Gultekin , Tsakiris , Dimitrios , Tesar , Vladimir , Todorov , Vasil , Wiecek , Andrzej , Wüthrich , Rudolf P. , Gottlow , Mattis , Johnsson , Eva , Zannad , Faiez , . (2009) Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. New England Journal of Medicine 360:14, 1395-1407
Free Full Text626
U.C. Hoppe, S. Nitschmann. (2009) Rosuvastatin bei Patienten mit chronischer Herzinsuffizienz. Der Internist 50:4, 501-502
CrossRef627
Kunitoshi Iseki, Kiyoyuki Tokuyama, Yoshiki Shiohira, Akira Higa, Hiroshi Hirano, Shigeki Toma, Kentaro Kohagura, Shinichiro Ueda. (2009) Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods. Clinical and Experimental Nephrology 13:2, 145-151
CrossRef628
Wilbert S. Aronow. (2009) Acute and Chronic Management of Atrial Fibrillation in Patients With Late-Stage CKD. American Journal of Kidney Diseases 53:4, 701-710
CrossRef629
Alexander Kapustin, Catherine M Shanahan. (2009) Targeting vascular calcification: softening-up a hard target. Current Opinion in Pharmacology 9:2, 84-89
CrossRef630
Terri Montague, Barbara Murphy. (2009) Lipid Management in Chronic Kidney Disease, Hemodialysis, and Transplantation. Endocrinology and Metabolism Clinics of North America 38:1, 223-234
CrossRef631
Sikander P Surana, Leonardo V Riella, Sai Ram Keithi-Reddy, David M Charytan, Ajay K Singh. (2009) Acute coronary syndrome in ESRD patients. Kidney International 75:5, 558-562
CrossRef632
Helen Eddington, Smeeta Sinha, Philip A. Kalra. (2009) VASCULAR CALCIFICATION IN CHRONIC KIDNEY DISEASE: A CLINICAL REVIEW. Journal of Renal Care 35, 45-50
CrossRef633
Hiddo J Lambers Heerspink, Toshiharu Ninomiya, Sophia Zoungas, Dick de Zeeuw, Diederick E Grobbee, Meg J Jardine, Martin Gallagher, Matthew A Roberts, Alan Cass, Bruce Neal, Vlado Perkovic. (2009) Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. The Lancet 373:9668, 1009-1015
CrossRef634
Allan Sosin. Chronic Kidney Disease. In: Food and Nutrients in Disease Management. CRC Press, 2009.
CrossRef635
Philippa J. Delahoy, Dianna J. Magliano, Kate Webb, Mendel Grobler, Danny Liew. (2009) The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clinical Therapeutics 31:2, 236-244
CrossRef636
Michal Chmielewski, Juan Jesus Carrero, Peter Stenvinkel, Bengt Lindholm. (2009) Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. Current Opinion in Lipidology 20:1, 3-9
CrossRef637
Tanja X. Pedersen, Susanne Bro, Mikkel H. Andersen, Michael Etzerodt, Matti Jauhiainen, Søren Moestrup, Lars B. Nielsen. (2009) Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipoprotein-E deficient mice. Atherosclerosis 202:2, 372-381
CrossRef638
Ishwarlal Jialal, Mandeep Bajaj. (2009) Therapy and clinical trials: management of diabetic dyslipidemia. Current Opinion in Lipidology 20:1, 85-86
CrossRef639
Bengt Fellström, Hallvard Holdaas, Alan G. Jardine, Maria K. Svensson, Mattis Gottlow, Roland E. Schmieder, Faiez Zannad. (2009) Cardiovascular disease in patients with renal disease: the role of statins. Current Medical Research and Opinion 25:1, 271-285
CrossRef640
Csaba P. Kovesdy, Kamyar Kalantar-Zadeh. (2009) Why Is Protein–Energy Wasting Associated With Mortality in Chronic Kidney Disease?. Seminars in Nephrology 29:1, 3-14
CrossRef641
Sadollah Abedini, Ingar Holme, Bengt Fellström, Alan Jardine, Edward Cole, Bart Maes, Hallvard Holdaas. (2009) Cerebrovascular Events in Renal Transplant Recipients. Transplantation 87:1, 112-117
CrossRef642
Megumi Tsushima, Chikako Tsutaya, Kanemitsu Yamaya, Yuriko Terayama, Hisao Saitoh, Tomihisa Funyu. (2009) Usefulness of high molecular weight adiponectin-leptin ratio as a predictor of all-cause mortality in dialysis patients. Nihon Toseki Igakkai Zasshi 42:11, 847-856
CrossRef643
P. Wei, P. R. Grimm, D. C. Settles, C. R. Balwanz, B. J. Padanilam, S. C. Sansom. (2009) Simvastatin Reverses Podocyte Injury but not Mesangial Expansion in Early Stage Type 2 Diabetes Mellitus. Renal Failure 31:6, 503-513
CrossRef644
Christoph Wanner. (2009) Prevention of Cardiovascular Disease in Chronic Kidney Disease Patients. Seminars in Nephrology 29:1, 24-29
CrossRef645
James E. Novak, Lynda A. Szczech. (2009) Phosphate Binders in Chronic Kidney Disease and End-Stage Renal Disease: A Patient-Centered Approach. Seminars in Dialysis 22:1, 56-63
CrossRef646
Kumar Sharma. RENAL INSUFFICIENCY. In: Pharmacology and Therapeutics. Elsevier, 2009:435-444.
CrossRef647
Tomohito Hamazaki. (2009) Are the upper limits for serum cholesterol levels necessary?. Journal of Lipid Nutrition 18:1, 33-50
CrossRef648
David M Charytan, Richard E Kuntz, Michael Garshick, Susana Candia, M Faisal Khan, Laura Mauri. (2009) Location of acute coronary artery thromboses in patients with and without chronic kidney disease. Kidney International 75:1, 80-87
CrossRef649
Jean-Paul Kovalik, Eugene C. Kovalik. Endocrine and Neurologic Manifestations of Chronic Kidney Disease. In: Primer on Kidney Diseases. Elsevier, 2009:514-524.
CrossRef650
Michael Clearfield. (2009) Clinical trials report. Current Atherosclerosis Reports 11:1, 3-8
CrossRef651
Srinivasan Beddhu. Outcome of End-Stage Renal Disease Therapies. In: Primer on Kidney Diseases. Elsevier, 2009:472-477.
CrossRef652
Anton F.H. Stalenhoef. (2009) The benefit of statins in non-cardiac vascular surgery patients. Journal of Vascular Surgery 49:1, 260-265
CrossRef653
Brian Radbill, Barbara Murphy, Derek LeRoith. (2008) Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease. Mayo Clinic Proceedings 83:12, 1373-1381
CrossRef654
Christoph Wanner, Eberhard Ritz. (2008) Reducing lipids for CV protection in CKD patients—current evidence. Kidney International 74, S24-S28
CrossRef655
David J. A. Goldsmith, Adrian Covic. (2008) Calcium and the saga of the binders: accumulating controversy, or building consensus?. International Urology and Nephrology 40:4, 1009-1014
CrossRef656
Jose M Valdivielso, Juan C Ayus. (2008) Role of vitamin D receptor activators on cardiovascular risk. Kidney International 74, S44-S49
CrossRef657
Vera Krane, Karl Winkler, Christiane Drechsler, Jürgen Lilienthal, Winfried März, Christoph Wanner. (2008) Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International 74:11, 1461-1467
CrossRef658
Nicola C. Edwards, Asle Hirth, Charles J. Ferro, John N. Townend, Richard P. Steeds. (2008) Subclinical Abnormalities of Left Ventricular Myocardial Deformation in Early-Stage Chronic Kidney Disease: The Precursor of Uremic Cardiomyopathy?. Journal of the American Society of Echocardiography 21:12, 1293-1298
CrossRef659
Charles F. Harper, Terry A. Jacobson. (2008) Reply. Journal of the American College of Cardiology 52:20, 1680
CrossRef660
S. Seiler, A. Schlitt, X.-C. Jiang, C. Ulrich, S. Blankenberg, K. J. Lackner, M. Girndt, K. Werdan, M. Buerke, D. Fliser, G. H. Heine. (2008) Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V. Nephrology Dialysis Transplantation 23:11, 3599-3604
CrossRef661
M. Tepel, W. Hopfenmueller, A. Scholze, A. Maier, W. Zidek. (2008) Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation 23:11, 3605-3612
CrossRef662
David G. Martinez. (2008) Binder Wars. American Journal of Kidney Diseases 52:5, 1024
CrossRef663
Wajeh Qunibi, Larry R. Muenz, Jose A. Diaz-Buxo. (2008) In Reply to ‘Hyperphosphatemia in the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study’ and ‘Binder Wars’. American Journal of Kidney Diseases 52:5, 1025
CrossRef664
Wajeh Qunibi, Larry R. Muenz. (2008) Progression of Calcification in the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study. American Journal of Kidney Diseases 52:5, 1022-1023
CrossRef665
Edward J. Mills, Beth Rachlis, Ping Wu, Philip J. Devereaux, Paul Arora, Dan Perri. (2008) Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments. Journal of the American College of Cardiology 52:22, 1769-1781
CrossRef666
Rulan S Parekh, Laura C Plantinga, W H Linda Kao, Lucy A Meoni, Bernard G Jaar, Nancy E Fink, Neil R Powe, Josef Coresh, Michael J Klag. (2008) The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney International 74:10, 1335-1342
CrossRef667
James E Novak, Jula K Inrig, Uptal D Patel, Robert M Califf, Lynda A Szczech. (2008) Negative trials in nephrology: what can we learn?. Kidney International 74:9, 1121-1127
CrossRef668
Peter A. McCullough, Leslie R. Rocher, Ravi Nistala, Adam Whaley-Connell. (2008) Chronic kidney disease as a cardiovascular risk state and considerations for the use of statins. Journal of Clinical Lipidology 2:5, 318-327
CrossRef669
Gurushankar Govindarajan, Georges Saab, Adam Whaley-Connell. (2008) Outcomes of Carotid Revascularization in Patients With Chronic Kidney Disease. Advances in Chronic Kidney Disease 15:4, 347-354
CrossRef670
Jaana Kuoppala, Anne Lamminpää, Eero Pukkala. (2008) Statins and cancer: A systematic review and meta-analysis. European Journal of Cancer 44:15, 2122-2132
CrossRef671
Sami L. Khella. (2008) New Insights Into Stroke in Chronic Kidney Disease. Advances in Chronic Kidney Disease 15:4, 338-346
CrossRef672
D. G. Haider, H. Fuhrmann, J. Kovarik, S. Heiss, H. Graf, M. Auinger, F. Mittermayer, M. Wolzt, W. H. Hörl. (2008) Postprandial intradialytic dysglycaemia and diabetes in maintenance haemodialysis patients. European Journal of Clinical Investigation 38:10, 721-727
CrossRef673
Nicola Marangon, Bengt Lindholm, Peter Stenvinkel. (2008) Nonphosphate-Binding Effects of Sevelamer-Are They of Clinical Relevance?. Seminars in Dialysis 21:5, 385-389
CrossRef674
Roberto R. Giraldez, Robert P. Giugliano, Satishkumar Mohanavelu, Sabina A. Murphy, Carolyn H. McCabe, Christopher P. Cannon, Eugene Braunwald. (2008) Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy. Journal of the American College of Cardiology 52:11, 914-920
CrossRef675
Yolanda E Bogaert, Michel Chonchol. (2008) Assessing the benefits and harms of statin treatment in patients with chronic kidney disease. Nature Clinical Practice Nephrology 4:9, 470-471
CrossRef676
Manish P. Ponda, Irina Barash. (2008) Lipid Metabolism in Dialysis Patients-The Story Gets More Complicated. Seminars in Dialysis 21:5, 390-394
CrossRef677
Kitty J Jager, Paul C van Dijk, Carmine Zoccali, Friedo W Dekker. (2008) The analysis of survival data: the Kaplan–Meier method. Kidney International 74:5, 560-565
CrossRef678
Robert D. Toto. (2008) Improving Outcomes in Hemodialysis Patients: The Need for Well-Designed Clinical Trials. American Journal of Kidney Diseases 52:3, 400-402
CrossRef679
C. A. Herzog. (2008) Kidney disease in cardiology. Nephrology Dialysis Transplantation 24:1, 34-37
CrossRef680
Pieter Evenepoel. (2008) Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney International 74:3, 265-275
CrossRef681
James Shepherd, John J.P. Kastelein, Vera A. Bittner, Rafael Carmena, Prakash C. Deedwania, Andrei Breazna, Stephen Dobson, Daniel J. Wilson, Andrea L. Zuckerman, Nanette K. Wenger. (2008) Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Artery Disease, Diabetes, and Chronic Kidney Disease. Mayo Clinic Proceedings 83:8, 870-879
CrossRef682
Pascal Meier, Rachel Meier, Edouard Blanc. (2008) Influence of CD4 + /CD25 + regulatory T cells on atherogenesis in patients with end-stage kidney disease. Expert Review of Cardiovascular Therapy 6:7, 987-997
CrossRef683
K. Winkler, C. Wanner, C. Drechsler, J. Lilienthal, W. Marz, V. Krane, . (2008) Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. European Heart Journal 29:17, 2092-2099
CrossRef684
Mehdi Rambod, Csaba P Kovesdy, Kamyar Kalantar-Zadeh. (2008) Malnutrition–Inflammation Score for risk stratification of patients with CKD: is it the promised gold standard?. Nature Clinical Practice Nephrology 4:7, 354-355
CrossRef685
Xilin Yang, Wing-Yee So, Ronald C. Ma, Gary T. Ko, Alice P. Kong, Chung-Shun Ho, Christopher W. Lam, Risa Ozaki, Clive S. Cockram, Peter C. Tong, Vivian Wong, Juliana C. Chan. (2008) Thresholds of risk factors for ischemic stroke in type 2 diabetic patients with and without albuminuria—A non-linear approach. Clinical Neurology and Neurosurgery 110:7, 701-709
CrossRef686
Sameer Bansilal, Michael E. Farkouh, Valentin Fuster. (2008) Optimal treatment of the diabetic patient with multivessel disease. Current Cardiology Reports 10:4, 272-284
CrossRef687
Rebecca Pellicano, Kevan R. Polkinghorne, Peter G. Kerr. (2008) Reduction in β2-Microglobulin With Super-flux Versus High-flux Dialysis Membranes: Results of a 6-Week, Randomized, Double-blind, Crossover Trial. American Journal of Kidney Diseases 52:1, 93-101
CrossRef688
Andrew Remppis, Eberhard Ritz. (2008) NON-CORONARY HEART DISEASE IN DIALYSIS PATIENTS: Cardiac Problems in the Dialysis Patient: Beyond Coronary Disease. Seminars in Dialysis 21:4, 319-325
CrossRef689
Charles A. Herzog, J. Michael Mangrum, Rod Passman. (2008) NON-CORONARY HEART DISEASE IN DIALYSIS PATIENTS: Sudden Cardiac Death and Dialysis Patients. Seminars in Dialysis 21:4, 300-307
CrossRef690
C.E. Angermann, S. Nitschmann. (2008) Statintherapie bei Herzinsuffizienz. Der Internist 49:7, 884-886
CrossRef691
Peter F. Wilson. Statins. In: Wiley Encyclopedia of Clinical Trials. John Wiley & Sons, Inc., 2008.
CrossRef692
P. K.-T. Li, B. C.-H. Kwan, C. C. Szeto, G. T.-C. Ko. (2008) Metabolic syndrome in peritoneal dialysis patients. NDT Plus 1:4, 206-214
CrossRef693
Bryan Kestenbaum. (2008) Calcification in CKD: No Closer to the Cure. American Journal of Kidney Diseases 51:6, 877-879
CrossRef694
Wajeh Qunibi, Moustafa Moustafa, Larry R. Muenz, David Y. He, Paul D. Kessler, Jose A. Diaz-Buxo, Mathew Budoff. (2008) A 1-Year Randomized Trial of Calcium Acetate Versus Sevelamer on Progression of Coronary Artery Calcification in Hemodialysis Patients With Comparable Lipid Control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) Study. American Journal of Kidney Diseases 51:6, 952-965
CrossRef695
Charles R. Harper, Terry A. Jacobson. (2008) Managing Dyslipidemia in Chronic Kidney Disease. Journal of the American College of Cardiology 51:25, 2375-2384
CrossRef696
C P Kovesdy, K Kalantar-Zadeh. (2008) Vitamin D receptor activation and survival in chronic kidney disease. Kidney International 73:12, 1355-1363
CrossRef697
Robert Thomas, Abbas Kanso, John R. Sedor. (2008) Chronic Kidney Disease and Its Complications. Primary Care: Clinics in Office Practice 35:2, 329-344
CrossRef698
Armin Steinmetz. (2008) Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention. Diabetes/Metabolism Research and Reviews 24:4, 286-293
CrossRef699
Elke Wühl, Franz Schaefer. (2008) Therapeutic strategies to slow chronic kidney disease progression. Pediatric Nephrology 23:5, 705-716
CrossRef700
X. Yang, W. Y. So, R. Ma, G. Ko, A. Kong, C. Lam, C. S. Ho, C. Cockram, C.-C. Chow, P. Tong, J. Chan. (2008) Effects of albuminuria and renal dysfunction on development of dyslipidaemia in type 2 diabetes--the Hong Kong Diabetes Registry. Nephrology Dialysis Transplantation 23:9, 2834-2840
CrossRef701
M. Svensson, E. B. Schmidt, K. A. Jorgensen, J. H. Christensen. (2008) The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study. Nephrology Dialysis Transplantation 23:9, 2918-2924
CrossRef702
W. Van Biesen, F. Verbeke, R. Vanholder. (2008) An infallible recipe? A story of cinnamon, souffle and meta-analysis. Nephrology Dialysis Transplantation 23:9, 2729-2732
CrossRef703
G. Schlieper, M. Hristov, V. Brandenburg, T. Kruger, R. Westenfeld, A. H. Mahnken, E. Yagmur, G. Boecker, N. Heussen, U. Gladziwa, M. Ketteler, C. Weber, J. Floege. (2008) Predictors of low circulating endothelial progenitor cell numbers in haemodialysis patients. Nephrology Dialysis Transplantation 23:8, 2611-2618
CrossRef704
C. A. Herzog, J. W. Strief, A. J. Collins, D. T. Gilbertson. (2008) Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention?. Nephrology Dialysis Transplantation 23:8, 2629-2633
CrossRef705
Gere Sunder-Plassmann, Wolfgang C. Winkelmayer, Manuela Födinger. (2008) Approaching the End of the Homocysteine Hype?. American Journal of Kidney Diseases 51:4, 549-553
CrossRef706
Devasmita Choudhury, Cynthia Luna-Salazar. (2008) Preventive health care in chronic kidney disease and end-stage renal disease. Nature Clinical Practice Nephrology 4:4, 194-206
CrossRef707
Csaba P Kovesdy, Kamyar Kalantar-Zadeh. (2008) Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease. Expert Opinion on Investigational Drugs 17:4, 451-467
CrossRef708
Ognen Ivanovski, Dorota Szumilak, Thao Nguyen-Khoa, Igor G. Nikolov, Nobuhiko Joki, Nadya Mothu, Julien Maizel, Ralf Westenfeld, Marcus Ketteler, Bernard Lacour, Tilman B. Drüeke, Ziad A. Massy. (2008) Effect of Simvastatin in Apolipoprotein E Deficient Mice With Surgically Induced Chronic Renal Failure. The Journal of Urology 179:4, 1631-1636
CrossRef709
Kevin A. Bybee, John H. Lee, James H. O'Keefe. (2008) Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Current Medical Research and Opinion 24:4, 1217-1229
CrossRef710
James Shepherd, John J.P. Kastelein, Vera Bittner, Prakash Deedwania, Andrei Breazna, Stephen Dobson, Daniel J. Wilson, Andrea Zuckerman, Nanette K. Wenger. (2008) Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease. Journal of the American College of Cardiology 51:15, 1448-1454
CrossRef711
M Ostermann. (2008) Cardiac arrests in hemodialysis patients: An ongoing challenge. Kidney International 73:8, 907-908
CrossRef712
Kosmas I. Paraskevas. (2008) Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering. International Urology and Nephrology 40:1, 165-170
CrossRef713
Kunitoshi Iseki. (2008) Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan. Expert Opinion on Pharmacotherapy 9:4, 601-610
CrossRef714
Marc A. Pfeffer. (2008) Critical Missing Data on Erythropoiesis-Stimulating Agents in CKD: First Beat Placebo. American Journal of Kidney Diseases 51:3, 366-369
CrossRef715
Jerrilynn D. Burrowes. (2008) New Recommendations for the Management of Diabetic Kidney Disease. Nutrition Today 43:2, 65-69
CrossRef716
Doris T. Chan, Ashley B. Irish, Gursharan K. Dogra, Gerald F. Watts. (2008) Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 196:2, 823-834
CrossRef717
B. M. Biccard. (2008) A peri-operative statin update for non-cardiac surgery. Part II: Statin therapy for vascular surgery and peri-operative statin trial design. Anaesthesia 63:2, 162-171
CrossRef718
Katherine Wesseling, Sevcan Bakkaloglu, Isidro Salusky. (2008) Chronic kidney disease mineral and bone disorder in children. Pediatric Nephrology 23:2, 195-207
CrossRef719
Juan Jesus Carrero, Mahmut Ilker Yilmaz, Bengt Lindholm, Peter Stenvinkel. (2008) Cytokine Dysregulation in Chronic Kidney Disease: How Can We Treat It?. Blood Purification 26:3, 291-299
CrossRef720
Wadi N. Suki. (2008) Effects of Sevelamer and Calcium-Based Phosphate Binders on Mortality in Hemodialysis Patients: Results of a Randomized Clinical Trial. Journal of Renal Nutrition 18:1, 91-98
CrossRef721
Spencer B. King, Sidney C. Smith, John W. Hirshfeld, Alice K. Jacobs, Douglass A. Morrison, David O. Williams. (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 51:2, 172-209
CrossRef722
Astrid Trion, Cindy Schutte-Bart, Wilhelmina H. Bax, J. Wouter Jukema, Arnoud Laarse. (2008) Modulation of calcification of vascular smooth muscle cells in culture by calcium antagonists, statins, and their combination. Molecular and Cellular Biochemistry 308:1-2, 25-33
CrossRef723
Steven D. WEISBORD, Paul L. KIMMEL. (2008) Health-related quality of life in the era of erythropoietin. Hemodialysis International 12:1, 6-15
CrossRef724
(2008) 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 71:1, E1-E40
CrossRef725
Elke Wühl, Franz Schaefer. Progression of Chronic Kidney Disease and Renoprotective Therapy in Children. In: Comprehensive Pediatric Nephrology. Elsevier, 2008:695-708.
CrossRef726
Jeffrey Giullian, Anthony Langone. End-Stage Renal Failure in the Diabetic Patient. In: Handbook of Dialysis Therapy. Elsevier, 2008:1061-1075.
CrossRef727
Robert D. Toto, Gloria Lena Vega, Scott M. Grundy. Cholesterol Management in Patients with Chronic Kidney Disease. In: Therapy in Nephrology & Hypertension. Elsevier, 2008:715-724.
CrossRef728
Uwe Querfeld, Mark Mitsnefes. Cardiovascular Disease in Pediatric Chronic Kidney Disease. In: Comprehensive Pediatric Nephrology. Elsevier, 2008:793-810.
CrossRef729
Joanne M. Bargman. (2008) Opinion: What Are the Problems with Using the Peritoneal Membrane for Long-Term Dialysis?. Seminars in Dialysis 21:1, 11-13
CrossRef730
Eberhard Ritz, Christoph Wanner. Cardiovascular Complications of End-Stage Renal Disease. In: Therapy in Nephrology & Hypertension. Elsevier, 2008:773-782.
CrossRef731
Bertram L. Kasiske, Ajay K. Israni. Cardiovascular Complications after Renal Transplantation. In: Kidney Transplantation. Elsevier, 2008:469-491.
CrossRef732
Bo-Kyung Son, Masahiro Akishita, Katsuya Iijima, Masato Eto, Yasuyoshi Ouchi. (2008) Mechanism of Pi-induced Vascular Calcification - Regulation of Growth Arrest-Specific Gene 6 (Gas6)-Mediated Survival Pathway. Journal of Atherosclerosis and Thrombosis 15:2, 63-68
CrossRef733
Christopher O’Regan, Ping Wu, Paul Arora, Dan Perri, Edward J. Mills. (2008) Statin Therapy in Stroke Prevention: A Meta-analysis Involving 121,000 Patients. The American Journal of Medicine 121:1, 24-33
CrossRef734
Ziad A. Massy, William F. Keane. Management of Hyperlipidemia in Chronic Dialysis Patients. In: Handbook of Dialysis Therapy. Elsevier, 2008:905-911.
CrossRef735
Arif Mutwali, Liam G Glynn, Donal Reddan. (2008) Management of Ischemic Heart Disease in Patients with Chronic Kidney Disease. American Journal of Cardiovascular Drugs 8:4, 219-231
CrossRef736
Jan Galle, Kai Lopau. Chronische Niereninsuffizienz. In: Facharzt Nephrologie. Elsevier, 2008:563-630.
CrossRef737
J CLELAND, A COLETTA, A ABDELLAH, D CULLINGTON, A CLARK, A RIGBY. (2008) Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy. European Journal of Heart Failure 10:1, 102-108
CrossRef738
Bernard MY Cheung. (2008) Statins for people with diabetes. The Lancet 371:9607, 94-95
CrossRef739
(2008) Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet 371:9607, 117-125
CrossRef740
Peter A. McCullough, Leslie R. Rocher. (2007) Statin therapy in renal disease: Harmful or protective?. Current Diabetes Reports 7:6, 467-473
CrossRef741
A. M. Borzecki, A. Lee, S. W. Wang, L. Brenner, L. E. Kazis. (2007) Survival in end stage renal disease: calcium carbonate vs. sevelamer. Journal of Clinical Pharmacy and Therapeutics 32:6, 617-624
CrossRef742
Giacomo Levantesi, Marco Scarano, RosaMaria Marfisi, Giovanna Borrelli, Anne W.S. Rutjes, Maria Giuseppina Silletta, Gianni Tognoni, Roberto Marchioli. (2007) Meta-Analysis of Effect of Statin Treatment on Risk of Sudden Death. The American Journal of Cardiology 100:11, 1644-1650
CrossRef743
Ivan Tkáč. (2007) Treatment of dyslipidemia in patients with type 2 diabetes: Overview and meta-analysis of randomized trials. Diabetes Research and Clinical Practice 78:3, S23-S28
CrossRef744
Carl Mogensen. Renal Dysfunction and Hypertension. In: Type 2 Diabetes. CRC Press, 2007:263-276.
CrossRef745
R. Agarwal. (2007) Effects of Statins on Renal Function. Mayo Clinic Proceedings 82:11, 1381-1390
CrossRef746
K Kalantar-Zadeh, J D Kopple, N Kamranpour, A M Fogelman, M Navab. (2007) HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney International 72:9, 1149-1156
CrossRef747
Pierre Amarenco. (2007) Atorvastatin in prevention of stroke and transient ischaemic attack. Expert Opinion on Pharmacotherapy 8:16, 2789-2797
CrossRef748
W N Suki, R Zabaneh, J L Cangiano, J Reed, D Fischer, L Garrett, B N Ling, S Chasan-Taber, M A Dillon, A T Blair, S K Burke. (2007) Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney International 72:9, 1130-1137
CrossRef749
Colin Baigent, Martin J. Landray, David C. Wheeler. (2007) CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Misleading Associations between Cholesterol and Vascular Outcomes in Dialysis Patients: The Need for Randomized Trials. Seminars in Dialysis 20:6, 498-503
CrossRef750
Christoph Wanner. (2007) On Statin Treatment to Prevent Sepsis in Dialysis Patients. American Journal of Kidney Diseases 50:5, 700-702
CrossRef751
Ray K. Wan, Patrick B. Mark, Alan G. Jardine. (2007) CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: The Cholesterol Paradox Is Flawed; Cholesterol Must Be Lowered in Dialysis Patients. Seminars in Dialysis 20:6, 504-509
CrossRef752
G WELTEN, M CHONCHOL, S HOEKS, O SCHOUTEN, M DUNKELGRUN, Y VANGESTEL, D GOEI, J BAX, R VANDOMBURG, D POLDERMANS. (2007) Statin therapy is associated with improved outcomes in vascular surgery patients with renal impairment. American Heart Journal 154:5, 954-961
CrossRef753
Csaba P. Kovesdy, John E. Anderson. (2007) CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Reverse Epidemiology in Patients with Chronic Kidney Disease Who Are Not Yet on Dialysis. Seminars in Dialysis 20:6, 566-569
CrossRef754
Florian Kronenberg, Katsunori Ikewaki, Juergen R. Schaefer, Paul König, Hans Dieplinger. (2007) CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Kinetic Studies of Atherogenic Lipoproteins in Hemodialysis Patients: Do They Tell Us More about Their Pathology?. Seminars in Dialysis 20:6, 554-560
CrossRef755
Nathan W. Levin, Garry J. Handelman, Josef Coresh, Friedrich K. Port, George A. Kaysen. (2007) Reverse Epidemiology: A Confusing, Confounding, and Inaccurate Term. Seminars in Dialysis 20:6, 586-592
CrossRef756
Robert P. Pauly, Christopher T. Chan. (2007) CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Reversing the Risk Factor Paradox: Is Daily Nocturnal Hemodialysis the Solution?. Seminars in Dialysis 20:6, 539-543
CrossRef757
Alexander S. Goldfarb-Rumyantzev, Arsalan N. Habib, Bradley C. Baird, Lev L. Barenbaum, Alfred K. Cheung. (2007) The Association of Lipid-Modifying Medications With Mortality in Patients on Long-Term Peritoneal Dialysis. American Journal of Kidney Diseases 50:5, 791-802
CrossRef758
Kamyar Kalantar-Zadeh. (2007) CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: What Is So Bad about Reverse Epidemiology Anyway?. Seminars in Dialysis 20:6, 593-601
CrossRef759
K Iseki, K Kohagura. (2007) Anemia as a risk factor for chronic kidney disease. Kidney International 72, S4-S9
CrossRef760
Jane Armitage. (2007) The safety of statins in clinical practice. The Lancet 370:9601, 1781-1790
CrossRef761
Allan Goody, Nicole Monserrate, Anu Bodetti. End-Stage Renal Disease. In: Comprehensive Handbook of Clinical Health Psychology. John Wiley & Sons, Inc., 2007:301-317.
CrossRef762
Eberhard Ritz, Lars Christian Rump. (2007) Do β-blockers combined with RAS inhibitors make sense after all to protect against renal injury?. Current Hypertension Reports 9:5, 409-414
CrossRef763
G A Kaysen. (2007) Dialysis removes apolipoprotein C-I, improving very low-density lipoprotein clearance. Kidney International 72:7, 779-781
CrossRef764
NIGEL D TOUSSAINT, PETER G KERR. (2007) Vascular calcification and arterial stiffness in chronic kidney disease: Implications and management. Nephrology 12:5, 500-509
CrossRef765
M Wolf, A Shah, O Gutierrez, E Ankers, M Monroy, H Tamez, D Steele, Y Chang, C A Camargo, M Tonelli, R Thadhani. (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney International 72:8, 1004-1013
CrossRef766
Rachel M Holden, Sarah L Booth. (2007) Vascular calcification in chronic kidney disease: the role of vitamin K. Nature Clinical Practice Nephrology 3:10, 522-523
CrossRef767
Richard Haynes, Jane Armitage. (2007) Fluvastatin for reduction of cardiovascular risk in patients with moderate to severe renal insufficiency. Nature Clinical Practice Nephrology 3:10, 530-531
CrossRef768
David C. WHEELER. (2007) Which issues should trials address in hemodialysis?. Hemodialysis International 11:s2, S44-S47
CrossRef769
José Pedro L. Nunes, Maria do Sameiro Faria, J. M. Mota Garcia, Francisco Rocha Gonçalves. (2007) Glomerular Filtration Rate and Coronary Artery Disease Burden in Patients with Acute Coronary Syndrome. Clinical Cardiology 30:9, 464-468
CrossRef770
V S Stel, K J Jager, C Zoccali, C Wanner, F W Dekker. (2007) The randomized clinical trial: An unbeatable standard in clinical research?. Kidney International 72:5, 539-542
CrossRef771
Fadi G. Hage, Stuart Smalheiser, Gilbert J. Zoghbi, Gilbert J. Perry, Mark Deierhoi, David Warnock, Ami E. Iskandrian, Angelo M. de Mattos, Raed A. Aqel. (2007) Predictors of Survival in Patients With End-Stage Renal Disease Evaluated for Kidney Transplantation. The American Journal of Cardiology 100:6, 1020-1025
CrossRef772
Montserrat Bosch, Imma Danés. (2007) Prevención primaria con estatinas en diabéticos. Medicina Clínica 129:8, 314-316
CrossRef773
Kamyar Kalantar-Zadeh, Csaba P Kovesdy, Stephen F Derose, Tamara B Horwich, Gregg C Fonarow. (2007) Racial and survival paradoxes in chronic kidney disease. Nature Clinical Practice Nephrology 3:9, 493-506
CrossRef774
Kevin C. Abbott, Robert T. Neff, Erin M. Bohen, Rajeev Narayan. (2007) Anticoagulation for Chronic Atrial Fibrillation in Hemodialysis Patients: Which Fruit From the Decision Tree?. American Journal of Kidney Diseases 50:3, 345-348
CrossRef775
Jeffrey M. Saland, Henry N. Ginsberg. (2007) Lipoprotein metabolism in chronic renal insufficiency. Pediatric Nephrology 22:8, 1095-1112
CrossRef776
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef777
STEPHANIE E REUTER, RANDALL J FAULL, ALLAN M EVANS. (2007) L-carnitine supplementation in the dialysis population: Are Australian patients missing out?. Nephrology 0:0, 070712161837003-???
CrossRef778
Helen M. Colhoun. (2007) Lipid goals in metabolic syndrome and diabetes. Current Atherosclerosis Reports 9:4, 286-295
CrossRef779
Kamyar Kalantar-Zadeh, Tamara B Horwich, Antigone Oreopoulos, Csaba P Kovesdy, Houman Younessi, Stefan D Anker, John E Morley. (2007) Risk factor paradox in wasting diseases. Current Opinion in Clinical Nutrition and Metabolic Care 10:4, 433-442
CrossRef780
Bernd Genser, Winfried März. (2007) Low density lipoprotein cholesterol, statins and cardiovascular events: a meta–analysis. Clinical Research in Cardiology 96:7, 526-526
CrossRef781
PG Kerr, AP Guerin. (2007) ARTERIAL CALCIFICATION AND STIFFNESS IN CHRONIC KIDNEY DISEASE. Clinical and Experimental Pharmacology and Physiology 34:7, 683-687
CrossRef782
C. Hasslacher. (2007) Protektion der Nierenfunktion bei Diabetikern. Der Internist 48:7, 686-697
CrossRef783
Tanya Knickerbocker, Jiunn R Chen, Ravi Thadhani, Gavin MacBeath. (2007) An integrated approach to prognosis using protein microarrays and nonparametric methods. Molecular Systems Biology 3,
CrossRef784
Jens Jordan, Guido Grassi. (2007) Adrenergic overdrive: a ???not-so-sympathetic??? risk factor in renal failure patients. Journal of Hypertension 25:6, 1197-1199
CrossRef785
V M Campese, J Park. (2007) HMG-CoA reductase inhibitors and the kidney. Kidney International 71:12, 1215-1222
CrossRef786
C.E. Mogensen. (2007) Microalbuminuria, renal disease, metabolic syndrome and risks in diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 1:2, 127-133
CrossRef787
Gursharan Dogra, Ashley Irish, Dick Chan, Gerald Watts. (2007) A Randomized Trial of the Effect of Statin and Fibrate Therapy on Arterial Function in CKD. American Journal of Kidney Diseases 49:6, 776-785
CrossRef788
Kamyar Kalantar-Zadeh, Eric S. Daar, Viktor E. Eysselein, Loren G. Miller. (2007) Hepatitis C inflection in dialysis patients: a link to poor clinical outcome?. International Urology and Nephrology 39:1, 247-259
CrossRef789
Usman Baber, Robert D. Toto, James A. de Lemos. (2007) Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. American Heart Journal 153:4, 471-477
CrossRef790
Dhrubo J. Rakhit, Xiaohong H. Zhang, Rodel Leano, Kirsten A. Armstrong, Nicole M. Isbel, Thomas H. Marwick. (2007) Prognostic role of subclinical left ventricular abnormalities and impact of transplantation in chronic kidney disease. American Heart Journal 153:4, 656-664
CrossRef791
Hallvard Holdaas, Christoph Wanner, Claudia Abletshauser, Claudio Gimpelewicz, Jonathan Isaacsohn. (2007) The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: A pooled analysis of double-blind, randomized trials. International Journal of Cardiology 117:1, 64-74
CrossRef792
Vinicius Daher Alvares Delfino, Areuza Célia de Andrade Vianna, Altair Jacob Mocelin, Décio Sabbatini Barbosa, Rosana Aiko Mise, Tiemi Matsuo. (2007) Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients. Nutrition 23:3, 242-247
CrossRef793
P Evenepoel. (2007) Control of hyperphosphatemia beyond phosphate. Kidney International 71:5, 376-379
CrossRef794
Gerald F. Fletcher, Vincent Bufalino, Fernando Costa, Larry B. Goldstein, Dan Jones, Lynn Smaha, Sidney C. Smith, Neil Stone. (2007) Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke. The American Journal of Cardiology 99:6, S1-S35
CrossRef795
Daniel E. Weiner, Mark J. Sarnak. (2007) Chronic kidney disease and cardiovascular disease: A bi-directional relationship?. Dialysis & Transplantation 36:3, 113-120
CrossRef796
G A Block, P Raggi, A Bellasi, L Kooienga, D M Spiegel. (2007) Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International 71:5, 438-441
CrossRef797
Myles Wolf, Ravi Thadhani. (2007) Vitamin D in patients with renal failure: A summary of observational mortality studies and steps moving forward. The Journal of Steroid Biochemistry and Molecular Biology 103:3-5, 487-490
CrossRef798
György Jermendy, Piero Ruggenenti. (2007) Preventing microalbuminuria in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews 23:2, 100-110
CrossRef799
(2007) References. American Journal of Kidney Diseases 49:2, S160-S179
CrossRef800
C A White, J Jaffey, P Magner. (2007) Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney International 71:4, 312-317
CrossRef801
Marcello Tonelli, Marc A. Pfeffer. (2007) Kidney Disease and Cardiovascular Risk. Annual Review of Medicine 58:1, 123-139
CrossRef802
Vera Krane, Detlef H. Krieter, Manfred Olschewski, Winfried März, Johannes F.E. Mann, Eberhard Ritz, Christoph Wanner. (2007) Dialyzer Membrane Characteristics and Outcome of Patients With Type 2 Diabetes on Maintenance Hemodialysis. American Journal of Kidney Diseases 49:2, 267-275
CrossRef803
Marius Terblanche, Yaniv Almog, Robert S Rosenson, Daniel G Hackam. (2007) Statins and sepsis: panacea or Pandora's box? – Authors' reply. The Lancet Infectious Diseases 7:2, 80-81
CrossRef804
Yoko Kato, Miho Okada, Gakuro Yoshida, Haruko Yokoyama, Hiroshi Oda, Michiya Ohno, Hiroshige Ohashi. (2007) Efficacy and pleiotropic effects of a new HMG-CoA reductase inhibitor, Rosuvastatin, in peritoneal dialysis patients with dyslipidemia. Nihon Toseki Igakkai Zasshi 40:9, 781-787
CrossRef805
Paul Gusbeth-Tatomir, Adrian Covic. (2007) Causes and Consequences of Increased Arterial Stiffness in Chronic Kidney Disease Patients. Kidney and Blood Pressure Research 30:2, 97-107
CrossRef806
Gillian M Keating, Katherine F Croom. (2007) Fenofibrate. Drugs 67:1, 121-153
CrossRef807
Grace H. Lee, Deborah Benner, Deborah L. Regidor, Kamyar Kalantar-Zadeh. (2007) Impact of Kidney Bone Disease and Its Management on Survival of Patients on Dialysis. Journal of Renal Nutrition 17:1, 38-44
CrossRef808
A. Covic, P. Gusbeth-Tatomir. (2007) To what extent can coronary calcification and arterial stiffness be influenced by the nephrologist?. Clinical Research in Cardiology Supplements 2:S1, S15-S21
CrossRef809
C. J. F. Holubarsch. (2007) Kardiovaskuläre Erkrankungen bei Patienten mit Nierenerkrankungen. Clinical Research in Cardiology Supplements 2:S1, S9-S14
CrossRef810
Peter A. McCullough, Leslie R. Rocher. (2007) Statin therapy in renal disease: Harmful or protective?. Current Atherosclerosis Reports 9:1, 18-24
CrossRef811
Bengt Fellström, Hallvard Holdaas, Alan G. Jardine, Helen Rose, Roland Schmieder, Wim Wilpshaar, Faiez Zannad. (2007) Effect of Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Baseline Data from the AURORA Study. Kidney and Blood Pressure Research 30:5, 314-322
CrossRef812
Christoph Wanner, Christiane Drechsler, Vera Krane. (2007) Lipid Metabolism in Chronic Kidney Disease: The Role of Statins in Cardiovascular Risk. Journal of Renal Nutrition 17:1, 75-78
CrossRef813
Danelle Cayea, Cynthia Boyd, Samuel C Durso. (2007) Individualising Therapy for Older Adults with Diabetes Mellitus. Drugs & Aging 24:10, 851-863
CrossRef814
Chris Isles. Proteinuria. In: Comprehensive Hypertension. Elsevier, 2007:793-800.
CrossRef815
George A. Kaysen. (2007) Disorders in High-Density Metabolism With Insulin Resistance and Chronic Kidney Disease. Journal of Renal Nutrition 17:1, 4-8
CrossRef816
Amanda D. Hyre, Caroline S. Fox, Brad C. Astor, Andrew J. Cohen, Paul Muntner. (2007) The Impact of Reclassifying Moderate CKD as a Coronary Heart Disease Risk Equivalent on the Number of US Adults Recommended Lipid-Lowering Treatment. American Journal of Kidney Diseases 49:1, 37-45
CrossRef817
David W. JOHNSON, Ann-Maree CRAVEN, Nicole Maree ISBEL. (2007) Modification of cardiovascular risk in hemodialysis patients: An evidence-based review. Hemodialysis International 11:1,
CrossRef818
C. Presne, M. Biard, I. Shahapuni, K. Rahmouni, M. Monge, J.F. Bonne, R. Makdassi, H. Mazouz, P.F. Westeel, A. Remond, T. Bernasconi, M. Caminzuli, M.-A. Sevestre, I. El Esper, N. El Esper, Z. Massy, J.-D. Lalau, G. Choukroun, A. Fournier. (2007) Hypertension associée aux sténoses de l'artère rénale et aux atteintes rénales parenchymateuses. EMC - Cardiologie 2:1, 1-28
CrossRef819
, G. Breithardt. (2006) Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. Clinical Research in Cardiology Supplements 1:2, 103-117
CrossRef820
G A Kaysen. (2006) Dyslipidemia in chronic kidney disease: Causes and consequences. Kidney International 70, S55-S58
CrossRef821
I G Nikolov, N Joki, J Maizel, B Lacour, T B Drüeke, Z A Massy. (2006) Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney International 70, S16-S23
CrossRef822
M Ketteler, C Giachelli. (2006) Novel insights into vascular calcification. Kidney International 70, S5-S9
CrossRef823
T Drüeke, R N Foley. (2006) Introduction: Improving outcomes in chronic kidney disease. Kidney International 70, S1-S4
CrossRef824
Gursharan Dogra, Ashley Irish, Dick Chan, Gerald Watts. (2006) Insulin Resistance, Inflammation, and Blood Pressure Determine Vascular Dysfunction in CKD. American Journal of Kidney Diseases 48:6, 926-934
CrossRef825
Sharon M Moe. (2006) Treatment of Chronic Kidney Disease?Mineral Bone Disorder and Vascular Complications. Therapeutic Apheresis and Dialysis 10:s1, S2-S15
CrossRef826
Riza C Ozsoy, Sander I van Leuven, John JP Kastelein, Lambertus Arisz, Marion G Koopman. (2006) The dyslipidemia of chronic renal disease: effects of statin therapy. Current Opinion in Lipidology 17:6, 659-666
CrossRef827
Singh , Ajay K. , Szczech , Lynda , Tang , Kezhen L. , Barnhart , Huiman , Sapp , Shelly , Wolfson , Marsha , Reddan , Donal , . (2006) Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. New England Journal of Medicine 355:20, 2085-2098
Free Full Text828
Marcello Tonelli. (2006) The effect of statins on preservation of kidney function in patients with coronary artery disease. Current Opinion in Cardiology 21:6, 608-612
CrossRef829
S S Prichard. (2006) Management of hyperlipidemia in patients on peritoneal dialysis: Current approaches. Kidney International 70, S115-S117
CrossRef830
Rey F. Rosario, Sharma Prabhakar. (2006) Lipids and diabetic nephropathy. Current Diabetes Reports 6:6, 455-462
CrossRef831
Vera Krane, Christiane Drechsler, Christoph Wanner. (2006) Dyslipidemia, inflammation and dialysis outcomes: what we know now. Current Opinion in Nephrology and Hypertension 15:6, 566-570
CrossRef832
Edoardo Casiglia, Mario Saugo, Laura Schiavon, Valérie Tikhonoff, Giulio Rigoni, Giancarlo Basso, Alberto Mazza, Enzo Rizzato, Francesco Guglielmi, Bortolo Martini, Anna Bascelli, Sandro Caffi, Achille C. Pessina. (2006) Reduction of cardiovascular risk and mortality: A population-based approach. Advances in Therapy 23:6, 905-920
CrossRef833
Rajnish Mehrotra, Sharon Adler. (2006) Strong association of carotid plaques with mortality and cardiovascular morbidity in hemodialysis patients. Nature Clinical Practice Nephrology 2:11, 620-621
CrossRef834
S Aslam, T Santha, A Leone, C Wilcox. (2006) Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney International
CrossRef835
D Charytan, R E Kuntz. (2006) The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney International
CrossRef836
F Zannad, M Kessler, P Lehert, J P Grünfeld, C Thuilliez, A Leizorovicz, P Lechat. (2006) Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney International 70:7, 1318-1324
CrossRef837
M E Williams, E Lacson, M Teng, N Ofsthun, J M Lazarus. (2006) Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney International 70:8, 1503-1509
CrossRef838
Kamyar KALANTAR-ZADEH, Vaidyanathapuram S. BALAKRISHNAN. (2006) The kidney disease wasting: Inflammation, oxidative stress, and diet-gene interaction. Hemodialysis International 10:4, 315-325
CrossRef839
B Feldt-Rasmussen. (2006) Is there a need to optimize glycemic control in hemodialyzed diabetic patients?. Kidney International 70:8, 1392-1394
CrossRef840
B S Dixon. (2006) Why don't fistulas mature?. Kidney International 70:8, 1413-1422
CrossRef841
David Saltissi, Justin Westhuyzen, Colleen Morgan, Helen Healy. (2006) Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure. Clinical and Experimental Nephrology 10:3, 201-209
CrossRef842
Daniel Sollinger, Markus G. Mohaupt, Albina Wilhelm, Dominik Uehlinger, Felix J. Frey, Ute Eisenberger. (2006) Arterial Stiffness Assessed by Digital Volume Pulse Correlates With Comorbidity in Patients With ESRD. American Journal of Kidney Diseases 48:3, 456-463
CrossRef843
Jia Liu, Kambiz Kalantarinia, Mitchell H. Rosner. (2006) Endocrinology and Dialysis: Management of Lipid Abnormalities Associated with End-Stage Renal Disease. Seminars in Dialysis 19:5, 391-401
CrossRef844
, G. Breithardt. (2006) Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. Clinical Research in Cardiology Supplements 1:1, 8-30
CrossRef845
C. P. Schmitt. (2006) Biochemische und klinische Wirkungen von Calcimimetika. Der Nephrologe 1:3, 189-190
CrossRef846
Luc Frimat. (2006) Épidémiologie génétique et maladies rénales. Commission d'épidémiologie de la Société de néphrologie. Néphrologie & Thérapeutique 2:4, 208-212
CrossRef847
Christina M. Gullion, Douglas S. Keith, Gregory A. Nichols, David H. Smith. (2006) Impact of Comorbidities on Mortality in Managed Care Patients With CKD. American Journal of Kidney Diseases 48:2, 212-220
CrossRef848
O. M. Steinmetz, U. Panzer, R. A. K. Stahl, U. O. Wenzel. (2006) Statin therapy in patients with chronic kidney disease: to use or not to use. European Journal of Clinical Investigation 36:8, 519-527
CrossRef849
Patricia M Kearney, Colin Baigent. (2006) Statins: are any questions unanswered?. Current Opinion in Lipidology 17:4, 418-425
CrossRef850
Tetsuo Shoji, Yoshiki Nishizawa. (2006) Plasma Lipoprotein Abnormalities in Hemodialysis Patients—Clinical Implications and Therapeutic Guidelines. Therapeutic Apheresis and Dialysis 10:4, 305-315
CrossRef851
Kerstin Amann, Jürgen Hofstetter, Valentina Câmpean, Andreas Koch, Marie-Luise Gross, Roland Veelken, Eberhard Ritz. (2006) Nonhypotensive dose of β-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure. Virchows Archiv 449:2, 207-214
CrossRef852
Bernd Genser, Winfried März. (2006) Low density lipoprotein cholesterol, statins and cardiovascular events: a meta–analysis. Clinical Research in Cardiology 95:8, 393-404
CrossRef853
C Zoccali. (2006) Traditional and emerging cardiovascular and renal risk factors: An epidemiologic perspective. Kidney International 70:1, 26-33
CrossRef854
Carmelo J. Panetta, Charles A. Herzog, Timothy D. Henry. (2006) Acute coronary syndromes in patients with renal disease: What are the issues?. Current Cardiology Reports 8:4, 296-300
CrossRef855
Lisa M. Miller, Wilma M. Hopman, Jocelyn S. Garland, Karen E. Yeates, Rachel M. Pilkey. (2006) Cardioprotective medication use in hemodialysis patients. Canadian Journal of Cardiology 22:9, 755-760
CrossRef856
Christian S. Shinaberger, Ryan D. Kilpatrick, Deborah L. Regidor, Charles J. McAllister, Sander Greenland, Joel D. Kopple, Kamyar Kalantar-Zadeh. (2006) Longitudinal Associations Between Dietary Protein Intake and Survival in Hemodialysis Patients. American Journal of Kidney Diseases 48:1, 37-49
CrossRef857
Patricia Painter, Kirsten L. Johansen. (2006) Improving Physical Functioning: Time to Be a Part of Routine Care. American Journal of Kidney Diseases 48:1, 167-170
CrossRef858
Bryce A Kiberd. (2006) Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease. Nature Clinical Practice Nephrology 2:7, 354-355
CrossRef859
A J Bleyer, J Hartman, P C Brannon, A Reeves-Daniel, S G Satko, G Russell. (2006) Characteristics of sudden death in hemodialysis patients. Kidney International 69:12, 2268-2273
CrossRef860
Giovanni F.M. Strippoli, Suetonia Palmer, Allison Tong, Grahame Elder, Piergiorgio Messa, Jonathan C. Craig. (2006) Meta-Analysis of Biochemical and Patient-Level Effects of Calcimimetic Therapy. American Journal of Kidney Diseases 47:5, 715-726
CrossRef861
P Alaupovic, P-O Attman, C Knight-Gibson, H Mulec, L Weiss, O Samuelsson. (2006) Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency. Kidney International 69:10, 1865-1871
CrossRef862
Micah L. Thorp, Loris Eastman, David H. Smith, Eric S. Johnson. (2006) Managing the Burden of Chronic Kidney Disease. Disease Management 9:2, 115-121
CrossRef863
Khan Pohlel, Parker Grow, Tarek Helmy, Nanette K Wenger. (2006) Treating dyslipidemia in the elderly. Current Opinion in Internal Medicine 5:2, 150-153
CrossRef864
Bertram L. Kasiske, Christoph Wanner, W. Charles O’Neill. (2006) An Assessment of Statin Safety by Nephrologists. The American Journal of Cardiology 97:8, S82-S85
CrossRef865
Harold Bays. (2006) Statin Safety: An Overview and Assessment of the Data—2005. The American Journal of Cardiology 97:8, S6-S26
CrossRef866
Vera Krane, Christoph Wanner. (2006) At which stage of chronic kidney disease should dyslipidemia be treated?. Nature Clinical Practice Nephrology 2:4, 176-177
CrossRef867
Leif R. Erhardt, A. Gotto. (2006) The evolution of European guidelines: Changing the management of cholesterol levels. Atherosclerosis 185:1, 12-20
CrossRef868
Keith C. Ferdinand. (2006) Management of Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus as a Component of the Cardiometabolic Syndrome. Journal of the CardioMetabolic Syndrome 1:2, 133-140
CrossRef869
Kamyar Kalantar-Zadeh, Kevin C. Abbott, Florian Kronenberg, Stefan D. Anker, Tamara B. Horwich, Gregg C. Fonarow. (2006) Epidemiology of Dialysis Patients and Heart Failure Patients. Seminars in Nephrology 26:2, 118-133
CrossRef870
Rajiv Agarwal. (2006) Effects of Statins on Renal Function. The American Journal of Cardiology 97:5, 748-755
CrossRef871
Elke S. Schaeffner, Manuela Födinger, Reinhard Kramar, Ulrich Frei, Walter H. Hörl, Gere Sunder-Plassmann, Wolfgang C. Winkelmayer. (2006) Prognostic Associations Between Lipid Markers and Outcomes in Kidney Transplant Recipients. American Journal of Kidney Diseases 47:3, 509-517
CrossRef872
Bonnie C-H Kwan, Srinivasan Beddhu, Florian Kronenberg, Alfred K Cheung. (2006) Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis?. Nature Clinical Practice Nephrology 2:2, 76-77
CrossRef873
Wolfgang C. Winkelmayer, David M. Charytan, Raisa Levin, Jerry Avorn. (2006) Poor Short-Term Survival and Low Use of Cardiovascular Medications in Elderly Dialysis Patients After Acute Myocardial Infarction. American Journal of Kidney Diseases 47:2, 301-308
CrossRef874
Matthias Briel, Alain J Nordmann, Heiner C Bucher. (2006) Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses. Current Opinion in Internal Medicine 5:1, 29-33
CrossRef875
Susanne B. Schwedler, János G. Filep, Jan Galle, Christoph Wanner, Lawrence A. Potempa. (2006) C-Reactive Protein: A Family of Proteins to Regulate Cardiovascular Function. American Journal of Kidney Diseases 47:2, 212-222
CrossRef876
Marc W Merx, Christian Weber. (2006) Statins: a preventive strike against sepsis in patients with cardiovascular disease?. The Lancet 367:9508, 372-373
CrossRef877
Sankar D. Navaneethan, Francesca Pansini, Giovanni F. M. Strippoli. (2006) Statins in Patients with Chronic Kidney Disease: Evidence from Systematic Reviews and Randomized Clinical Trials. PLoS Medicine 3:5, e123
CrossRef878
RJ Hinchliffe, WJ Jeffcoate, FL Game. (2006) Diabetes, established renal failure and the risk to the lower limb. Practical Diabetes International 23:1, 28-32
CrossRef879
Andrew J Krentz. (2006) Diabetes, the kidney and vascular disease: a complex relationship. Practical Diabetes International 23:1, 1-3
CrossRef880
Karen Warburton, Jeffrey S. Berns. (2006) Opinion: How Should Chronic Medical Therapies be Altered with the Onset of End-Stage Renal Disease and Initiation of Dialysis?. Seminars in Dialysis 19:1, 17-20
CrossRef881
S ADLER. (2006) Atorvastatin in Patients With Type 2 Diabetes Mellitus Undergoing HemodialysisWanner C, for the German Diabetes and Dialysis Study Investigators (Univ of Würzburg, Germany; et al) N Engl J Med 353:238–248, 2005§. Yearbook of Medicine 2006, 218-219
CrossRef882
H. T. Ong. (2006) Evidence-Based Prescribing of Statins: A Developing World Perspective. PLoS Medicine 3:3, e50
CrossRef883
Frank M. van der Sande, Jeroen P. Kooman, Karel M.L. Leunissen. (2006) The Predictive Value of C-Reactive Protein in End-Stage Renal Disease: Is It Clinically Significant?. Blood Purification 24:4, 335-341
CrossRef884
W HOWARD, L KENNEDY. (2006) Atorvastatin in Patients With Type 2 Diabetes Mellitus Undergoing HemodialysisWanner C, for the German Diabetes and Dialysis Study Investigators (Univ of Würzburg, Germany; et al) N Engl J Med 353:238–248, 2005§. Yearbook of Endocrinology 2006, 114-117
CrossRef885
Anup K. Sabharwal, Jeffrey B. Boord. (2006) Low-density lipoprotein reduction: Is the risk worth the benefit?. Current Atherosclerosis Reports 8:1, 19-25
CrossRef886
Sally M Marshall. (2006) Cardiovascular disease in diabetic patients with renal disease. Practical Diabetes International 23:1, 8-9
CrossRef887
Ernst J. Schaefer, Bela F. Asztalos. (2006) The effects of statins on high-density lipoproteins. Current Atherosclerosis Reports 8:1, 41-49
CrossRef888
Richard A. Sherman. (2005) Briefly Noted: Briefly Noted. Seminars in Dialysis 18:6, 569-570
CrossRef889
John Shik, Patrick S Parfrey. (2005) The clinical epidemiology of cardiovascular disease in chronic kidney disease. Current Opinion in Nephrology and Hypertension 14:6, 550-557
CrossRef890
(2005) Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Dialysis. New England Journal of Medicine 353:17, 1858-1860
Free Full Text891
V. Panichi. (2005) In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrology Dialysis Transplantation 21:2, 337-344
CrossRef892
Kamyar Kalantar-Zadeh. (2005) Recent Advances in Understanding the Malnutrition-Inflammation-Cachexia Syndrome in Chronic Kidney Disease Patients: What is Next?. Seminars in Dialysis 18:5, 365-369
CrossRef
- Letters
